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Our Mission
To protect and enhance public and animal health 
through the regulation of medicines, medical devices 
and healthcare products.
Our strategIc gOaLs and BaLanced scOrecard
STAKEHOLDERS 
Enhance healthcare product safety and patient outcomes by effective risk management 
and market surveillance.
Deliver clear, relevant and timely communications to patients, consumers and 
healthcare professionals.
PROCESSES 
Improve service delivery within a high quality, risk-based regulatory framework.
ORGANISATIONAL DEVELOPMENT 
Improve service delivery within a high quality, risk-based regulatory framework.
Influence legislation and policy development at European and international levels for 
the benefit of public and animal health.
HUMAN RESOURCES DEVELOPMENT 
Build future capabilities to meet evolving regulatory requirements, and scientific and 
technological advances.
FINANCIALS/VALUE FOR MONEY 
Build future capabilities to meet evolving regulatory requirements, and scientific and 
technological advances.
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CHAIRMAN’S 
STATEMENT
It gives me great pleasure to present the 2012 
Annual Report of the Irish Medicines Board (IMB). 
This report details the IMB’s activities over the 
past year and it is evident that this was a very busy 
period for the organisation. While fulfilling the 
core remit of protecting public and animal health, 
management and staff also made significant 
progress on the strategic objectives contained in 
the IMB’s Strategic Plan for 2011-2015. 
In last year’s report, which was my first as Chairman 
of the IMB, I noted how impressed I was with the 
positive ethos permeating the organisation and the 
dedication to excellence that underpinned every 
task and decision that was made at all levels of the 
organisation. I continue to be impressed by the 
commitment of everyone at the IMB notwithstanding 
the challenges presented by a busy year and an 
expanding remit. 
The IMB’s core objective of safeguarding public 
and animal health involves regulating healthcare 
products and sectors. In the case of medicines, 
this involves regulating across the entire product 
lifecycle from clinical trials, through manufacturing, 
to marketing and distribution, and end use by 
patients and animal owners. For other products, 
such as medical devices and cosmetics, the IMB has 
responsibility for key stages in the regulatory process 
with a particular focus on monitoring the safe use 
of these products. In 2012, executing this remit led 
to significant work outputs in all divisions across the 
organisation. Additionally, the IMB’s remit grew this 
past year to include responsibility for key aspects 
of the EU Directive on the standards of quality and 
safety of human organs intended for transplant. 
Throughout the year detailed preparations were also 
made towards becoming the competent authority on 
the protection of animals used for scientific purposes 
(in 2013.
Decisions taken by the IMB are done so in the interest 
of public and animal health. They are taken by 
experienced scientists and healthcare professionals 
based on the best available information at national 
and EU level. From time to time, this information can 
lead to the IMB issuing national recommendations 
to ensure safe use of medicine and in 2012 the 
organisation made two such recommendations both 
in respect of children’s medicines. 
The IMB’s has a strong reputation as a robust and 
effective regulator. The respect and regard with which 
it is held in Europe and wider afield is testimony 
to this. Staff, led by the Chief Executive, are heavily 
involved in planning for and implementing new 
legislation and policy at both national and EU level, 
playing an active and highly influential role. The 
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senior positions they hold on many committees and 
the valuable contributions they make ensure that the 
health interests of Irish people are well represented. 
These committee positions are taken in addition to 
their day to day responsibilities and I commend the 
staff involved for their uncompromising commitment 
to their work despite the many demands that are 
made of them.
The pharmaceutical, medical device and broader 
life sciences sector in Ireland exports products 
globally and is a major contributor to our economy. 
The IMB as a robust regulator plays an important 
role in supporting the sector’s continued success. 
Compliance and monitoring of good manufacturing 
practices underpin the sector and a strong and 
effective regulator is a significant asset to Ireland’s 
reputation as major world player in this specialist 
sector. 
It is important that the regulatory decisions taken 
by the IMB, and the policy and legislation behind 
these, are clearly understood. Communicating with 
key stakeholders is important in aiding a better 
understanding of IMB actions as well as how and 
why particular decisions are taken. During the 
last year, there was considerable progress in the 
achievement of a primary strategic goal which 
is to ensure that all stakeholders have access to 
relevant and timely safety, licensing and regulatory 
information. An example of this is the important 
strides made in increasing engagement with key 
stakeholders. The Consultative Panel on the Legal 
Classification of Medicines, for example, is a valuable 
forum for the sharing of views and perspectives 
on the reclassification of medicines while the IMB’s 
information days and seminars which were held 
across a range of issues provided regulatory guidance 
and updates as well as valuable opportunities for two 
way dialogue with the IMB. 
Looking to the future, 2013 marks the mid-way 
point of the organisation’s five year strategic plan 
and as such is an important milestone as efforts 
continue to build and enhance organisational 
capabilities in response to ongoing scientific, 
technological and regulatory changes. It will also see 
the organisation begin preparations for a significant 
brand transformation as the current Irish Medicines 
Board will give way to the Health Products Regulatory 
Authority (HPRA) early the following year. The hard 
work and effort put in during 2012 has meant we 
are well placed for the work ahead in 2013 as we 
continue this transformational progress.
The IMB plays and will continue to play a critical 
role at EU level where new legislation is developed 
that protects our citizens in relation to healthcare 
products. The organisation will be an active 
contributor in this area with its objective being to 
ensure that a strong patient centric regulatory system 
for human and veterinary products is maintained and 
enhanced. This will be particularly evident in the first 
half of 2013 as Ireland holds the EU Presidency. 
I would like to thank again the Chief Executive, 
management and staff of the IMB for their 
unwavering dedication to best practice across all 
aspects of the organisation and their contribution 
to the significant progress that was made across the 
year in pursuit of core strategic goals. 
I would also like to thank my fellow Board members 
for their commitment, time and support across the 
year. My thanks also to the chairs and members of the 
IMB advisory committees and sub-committees who 
make such a significant contribution to the regulatory 
process. 
Finally, on behalf of the Board, I thank the Minister 
for Health and the Minister for Agriculture, Food and 
the Marine as well as their executives and staff. Their 
continued support of the IMB and its activities is 
greatly valued and of significant importance to us as 
we strive to fulfill our remit and safeguard public and 
animal health now and into the future.
Michael D. Hayes
Chairman
BOARD MEMBERS
The Board of the IMB is appointed by the Minister for 
Health in accordance with the powers conferred by 
subsection 2 of section 7 of the Irish Medicines Board 
Act, 1995. There were nine Board members as of 31 
December 2012.
Mr. Michael D. Hayes 
(Chairman)
Engineering Consultant
Professor Caitriona O’Driscoll
Professor of Pharmaceutics, 
University College Cork
Mr. Noel O’Donoghue
Veterinary Surgeon
Mr. Brendan McLaughlin
Farmer and Elected Board 
Director in the Management 
Committee of ICSA
Ms. Anne Horan
Chief Executive, Ryan Academy 
for Entrepreneurship, Dublin  
City University
Mr. Wilfred Higgins
Former Principal Engineering 
Advisor, Health Service Executive
Professor Mary Horgan 
Associate Professor of Medicine, 
University College Cork
Dr. Elizabeth Keane 
Adjunct Professor of 
Epidemiology and Public Health, 
University College Cork
Mr. Pat Brangan
Former Senior Veterinary 
Inspector, Department of 
Agriculture, Food and the Marine
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Mr. Pat O’Mahony
Chief  Executive
Mr. John Lynch 
Director of  Compliance
Dr. Gabriel Beechinor
Director of  Veterinary Sciences
Dr. J.M. Morris 
Director of  Scientific Affairs
Ms. Suzanne McDonald 
Director of Information 
Technology and Change 
Management
Ms. Ann O’Connor
Director of Human Products 
Authorisation and Registration 
Ms. Rita Purcell
Director of Finance  
and Corporate Affairs 
Dr. Joan Gilvarry 
Director of Human Products  
Monitoring
Ms. Frances Lynch
Director of  Human Resources
MANAGEMENT COMMITTEE
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CHIEF 
EXECUTIVE’S 
REPORT
I am very pleased to submit our 2012 annual 
report in accordance with Section 19 of the Irish 
Medicines Board Act, 1995. The report outlines the 
significant efforts made across the organisation 
during the year in review and the progress made 
towards achieving our strategic objectives as 
set out in the five-year Strategic Plan for 2011 to 
2015.  
The report also details the addition of further 
functions which were effectively and efficiently 
merged with the existing activities under our remit. 
Despite the ongoing challenges faced by the public 
sector, my colleagues across the Irish Medicines 
Board (IMB) again responded with diligence and 
professionalism in delivering on our absolute 
commitment to the protection of public and animal 
health.
STRATegIc goAlS 
The IMB’s five high-level strategic goals are:
1. Enhance healthcare product safety and patient 
outcomes by effective risk management and 
market surveillance.
2. Deliver clear, relevant and timely 
communications to patients, consumers and 
healthcare professionals.
3. Improve service delivery within a high quality, 
risk-based regulatory framework.
4. Influence legislation and policy development at 
European and international levels for the benefit 
of public and animal health.
5. Build future capabilities to meet evolving 
regulatory requirements, and scientific and 
technological advances.
The layout of the annual report for 2012 is structured 
to ensure that the main chapters are closely aligned 
with the goals set out above.
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AuThoRISATIon, RegISTRATIon And 
lIcenSIng AcTIvITIeS  
The pre-market authorisation and registration of 
healthcare products, as well as the licensing of 
manufacturing, wholesaling and related activities, is 
a core regulatory function of the IMB. By operating an 
efficient regulatory framework we play an important 
role in ensuring patients have timely access to 
appropriate treatments. The following activities were 
of particular note during 2012: 
•	 In	respect	of	human	medicines,	there	was	an	
11% increase in variations applications to 17,153 
for products authorised through the national 
or mutual recognition (MR) procedures. The 
number of new product applications assessed by 
the IMB in 2012 was 1,372 down from 1,977 the 
previous year. This decrease was mainly due to a 
40% fall in the number of new parallel product 
authorisations applications. 
•	 In	2012,	we	assessed	and	approved	144	new	
product applications for veterinary products, a 
total that has remained broadly constant over the 
last number of years. There were 1,242 variations 
to authorisations granted through the national, 
MR or centralised procedures.
•	 The	IMB	continued	to	actively	contribute	to	the	
European licensing system throughout 2012. 
For human medicines, we were allocated as lead 
assessor (rapporteur) or joint lead assessor (co-
rapporteur) for 10 new marketing authorisations 
at the European Medicines Agency. The IMB also 
completed 12 new marketing authorisations 
via the MR procedure with Ireland as the 
reference member state. As regards veterinary 
medicines, the IMB acted as the rapporteur or 
co-rapporteur for 16 centralised procedures 
(including extension applications) and issued 42 
new marketing authorisations as the reference 
member state.
•	 During	2012,	the	IMB	processed	388	notifications	
to the medical device register. These related 
to class I, in-vitro diagnostic and custom made 
medical devices and to system and procedure 
packs.
•	 There	were	110	site	manufacturing	licences	
in place at year end for human and veterinary 
medicines. This figure has remained broadly 
stable in recent years. In addition, the IMB 
operates a register of new medical device 
organisations including manufacturers. The 
number of organisations registered during 2012 
was 48, up from 32 the previous year.
SAfeTy And coMPlIAnce MonIToRIng 
Post-market surveillance, which involves monitoring 
the safety and quality of medicines, medical devices 
and other healthcare products that have been 
authorised, licensed or registered for use in Ireland, 
is a primary function of the IMB. Our decisions in 
this area are always evidence based and are decided 
ultimately by the benefit / risk balance.  
•	 Under	our	national	pharmacovigilance	
programme, the IMB monitors adverse reaction 
reports to look for new types, or increased 
numbers, of adverse reactions. During the past 
year, the IMB received a total of 2,757 suspected 
adverse reaction reports in association with the 
use of human medicines, consistent with the 
reporting rates seen in 2011.
•	 Periodic	safety	update	reports	(PSURs)	are	a	tool	
to monitor the ongoing safety of medicines. 
In 2012, the total output for PSURs was 3,372. 
This includes PSURs for national authorisations, 
mutual recognition, centralised and PSUR 
work-sharing procedures. The IMB continues to 
actively participate in the Heads of Medicines 
Agencies (HMA) PSUR work-sharing project and 
is ranked in the top eight of national competent 
authorities in Europe.
•	 The	IMB	also	monitors	the	safety	of	veterinary	
medicines on an ongoing basis. There were 244 
reports of suspected adverse events associated 
with the use of veterinary products received in 
2012, an increase of 7% from 2011. PSURs for a 
total of 805 products were assessed. 
•	 The	IMB’s	reporting	system	for	medical	devices	
is intended to protect the health and safety of 
patients and other users of medical devices by 
monitoring adverse incident and correcting 
product problems. A total of 2,225 medical 
device vigilance reports were received and 
assessed in 2012. This figure represents a 25% 
increase on the previous 12 months. A total of 
725 compliance cases were investigated in 2012.
  
Where necessary, the IMB will also implement or 
issue national recommendations to ensure the 
continued safe use of medicines. During 2012, two 
such recommendations were announced in respect of 
children’s medicines. 
•	 New	dosage	instructions	for	liquid	paracetamol	
medicines for paediatric use were announced by 
the IMB in March 2012. The updated instructions 
provide more precise age and dosage bands so 
that children receive the most effective amount 
of medicine for their needs. 
•	 In	August,	the	IMB	advised	that	children’s	herbal	
products containing Echinacea should not be 
used for children under 12 years of age due to a 
lack of scientific data to support their use. 
The IMB is committed to ensuring industry 
compliance with relevant standards and legislation. 
Healthcare products manufactured or distributed in 
Ireland must meet essential quality standards and 
they must be advertised appropriately.
•	 A	total	of	289	national	inspections	and	audits	
were carried out in comparison with 271 in 2011. 
A further 26 foreign inspections and audits were 
performed.
•	 During	the	past	12	months,	741	quality	defects	
were reported to, or identified by, the IMB. This 
19% annual decrease was the first year-on-year 
reduction in the number of quality defects 
recorded.
•	 In	certain	cases,	so	as	to	protect	the	health	
and safety of patients, it may be necessary to 
withdraw, or recall, products from the Irish 
market. During 2012, there were 141 medicine 
recalls of which 136 related to human medicines 
and five related to veterinary products. 
•	 Where	necessary,	the	IMB	will	take	legal	
proceedings against those who breach medicinal 
product and medical device legislation. We 
initiated, or were party to, 11 prosecutions and 
court proceedings during the 12 months under 
review.
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legISlATIve And RegulAToRy 
develoPMenTS
The remit and role of our organisation continues to 
change and expand due to changes in our operating 
environment, such as new national and European 
legislation, and in response to the addition of further 
competencies.
Legislative Changes
Colleagues from across the IMB were heavily 
involved in implementing, or preparing for the 
implementation of, new and updated European and 
national legislation. Such developments can have a 
significant impact on the functions and workload of 
our organisation. 
•	 Throughout	2012,	the	IMB	continued	to	work	
with a wide range of stakeholders in planning for 
and implementing provisions contained in the 
new European Union (EU) pharmacovigilance 
legislation. The aim of the new legislation is to 
enhance public health by strengthening the 
current European safety monitoring system for 
medicines. 
•	 The	European	falsified	medicines	directive	aims	
to strengthen the protection of patients and 
consumers by preventing falsified (counterfeit) 
medicines entering the legal supply chain. 
Preparations continued during 2012 for the 
introduction of parts of this directive which 
must be transposed nationally by January 2013. 
The remaining measures will be transposed at 
defined times thereafter. 
•	 The	Health	(Pricing	and	Supply	of	Medical	
Goods) Bill 2012, which is due to be enacted and 
commenced in the first half of 2013, outlines 
the circumstances under which medicines are 
considered interchangeable (also often referred 
to as generic substitution) and where they 
are not considered interchangeable. Under 
the legislation, the IMB will be charged with 
responsibility for the establishment, consultation, 
publication and subsequent maintenance of 
a List of Interchangeable Medicinal Products. 
During 2012, the IMB actively supported the 
Department of Health in preparation for the 
implementation of this legislation. An internal 
project group was also established to plan for 
this additional IMB responsibility.
•	 The	European	Commission	adopted	proposals	in	
2012 to introduce two Regulations to strengthen 
the EU medical devices regulatory system and to 
standardise the application of rules throughout 
the EU. During 2012, the IMB continued to 
contribute to working groups and subgroups 
in the development of technical aspects of the 
regulatory system which may be reflected in the 
new legislative proposals. 
•	 The	European	Directive	on	standards	of	quality	
and safety of human organs intended for 
transplantation (Directive 2010/53/EC) was 
transposed into Irish legislation in August 2012 
and resulted in the appointment of the IMB 
and the HSE as the responsible Competent 
Authorities for the implementation of different 
aspects of the Directive. At the IMB, we are 
responsible for the inspection and authorisation 
of organ procurement and transplant centres and 
for the development of a system for reporting 
of serious adverse reactions and events. During 
the year, an internal multidisciplinary group 
continued to review the requirements of the 
directive from an IMB perspective and developed 
appropriate internal systems and procedures for 
implementation of these requirements. 
•	 The	IMB	implemented	a	range	of	activities	during	
2012 in advance of becoming the competent 
authority responsible for the implementation 
of Directive 2010/63/EU on the protection of 
animals used for scientific purposes from 1 
January 2013. This is significant and complex 
legislation intended to improve the welfare 
of animals used for scientific purposes and to 
promote the principles of the 3Rs (replacement, 
refinement and reduction). Among the primary 
functions of the IMB in respect of this legislation 
is the authorisation of establishments and the 
monitoring of animal welfare at establishments 
where animals used for scientific purposes are 
kept. Authorisations will also be required at 
project level and at individual level. 
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Participation in the European and International 
Regulatory Systems
The products regulated by the IMB are part of an 
ever-changing and developing international industry. 
Healthcare products manufactured here are used 
around the world while products manufactured 
elsewhere are used by Irish patients and consumers. 
As a result, the IMB is committed to playing its part 
in the global regulatory network to ensure that we 
represent and protect the interests of Irish patients 
and consumers.
Throughout 2012, our participation across the 
European medicines regulatory system continued 
to be significant. IMB scientific and technical staff 
again contributed to a broad range of committees 
and working parties at the European Medicines 
Agency, the European Commission, the Heads 
of Medicines Agencies (HMA) and via other 
platforms. The IMB also worked closely with relevant 
international organisations as necessary. Among the 
significant contributions and achievements from 
an IMB perspective during the past year include the 
following: 
•	 In	respect	of	human	medicines,	the	Irish	
delegate to the European Medicines Agency’s 
Pharmacovigilance Risk Assessment Committee 
(PRAC) was elected to the position of Vice-
Chair of the committee for a 3-year period. The 
establishment of the PRAC was one of the main 
provisions of the new EU pharmacovigilance 
legislation which was transposed into Irish law 
in July 2012. IMB experts were also significantly 
involved in a joint project team, involving 
representatives from Member States and the 
European Medicines Agency, to support the 
implementation of the this new legislation. 
•	 The	IMB	is	a	significant	contributor	to	the	
Benchmarking of European Medicines Agencies 
(BEMA) steering group of the HMA of which I am 
co-chair. During 2012, we continued to lead the 
steering group as preparations for the third cycle 
were finalised and the first visits began.
•	 The	IMB	Pharmacovigilance	Manager	(human	
medicines) continued to represent the World 
Health Organization (WHO) as a member of the 
Board of the Uppsala Monitoring Centre (UMC) 
and WHO Collaborating Centre for International 
Drug Monitoring.
•	 At	the	start	of	the	year,	the	IMB	Inspection	
Manager took up her appointment to the 
Executive Bureau (management group) of the 
Pharmaceutical Inspection Co-operation Scheme 
(PIC/S).
•	 With	regard	to	the	proposed	new	legislation	for	
veterinary medicinal products, the IMB was an 
active contributor to the preparatory workshops 
which were held by the European Commission 
during the summer of 2012. 
•	 The	IMB	welcomed	the	establishment	in	2012	by	
the European Commission of maximum residue 
limits (MRLs) for certain flukicidal veterinary 
medicines used in milk producing animals. This 
action followed a specific request from the IMB 
to the European Medicines Agency to provide 
a more suitable reference level for residue 
monitoring purposes.
•	 In	early	2012,	the	European	Commissioner	for	
Health and Consumers wrote to all European 
Ministers for Health outlining a ‘joint plan of 
immediate actions’ focused on reinforcing the 
existing regulatory system for medical devices. 
The plan outlined actions for Member States and 
the Commission in respect of the functioning 
of notified bodies, market surveillance, 
coordination, communication and transparency. 
The most significant work items arising from 
the joint plan during 2012 for the IMB included 
a review of class III notified bodies for medical 
devices, and analysis and communication 
of resource and activities relevant to market 
surveillance of medical devices. In addition, 
significant input was provided to the preparation 
of an implementing Regulation and a 
Commission recommendation on notified bodies 
for medical devices in advance of the plan’s 
deadline.
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•	 The	IMB	continued	to	engage	actively	during	
2012 in discussions with other European 
competent authorities, the European 
Commission and relevant stakeholders on 
how to optimise resourcing of the network for 
medical device regulation in Europe. The IMB also 
continued to promote discussions during the 
year on enhancing cooperation and partnership 
between the HMA and the Competent 
Authorities for Medical Devices (CAMD).
STAkeholdeR engAgeMenT And 
coMMunIcATIonS
A core strategic goal of the IMB is to ensure that all 
our stakeholders have access to relevant and timely 
safety, licensing and regulatory information. As well 
as our regular meetings and ongoing publication 
of safety and regulatory updates, newsletters and 
guidance documents, a number of additional 
engagement and communications initiatives were 
progressed during 2012.
Consultative Panel on the Legal Classification of 
Human Medicines
Established in 2011, the Consultative Panel 
on the Legal Classification of medicines held 
quarterly meetings during the past year. The aim 
of the independently chaired panel is to assist in 
developing the debate on policies in the area of 
legal classification of human medicines. It consists of 
external representatives drawn from a wide range of 
interested stakeholders including patients, healthcare 
professionals, the Department of Health and 
relevant government agencies. During 2012, each 
representative was invited to present their views and 
perspectives to the panel. The final meeting of the 
panel was planned for early 2013 and it is anticipated 
that a report on its deliberations will be finalised later 
in the year.
Events
•	 IMB	information	days	and	seminars	provide	
regulatory guidance and updates to a range of 
stakeholders. These events also afford attendees 
the opportunity to submit questions, seek 
clarifications and network with colleagues. In late 
September 2012, a GMP / market compliance 
information day and a wholesale distribution 
information day were both held. A clinical trials 
information seminar for academic sponsors 
and investigators was also held in June 2012. 
Additionally, a training seminar for distributors of 
cosmetic products was held in March. 
•	 In	October	2012,	the	IMB	co-hosted	The	
Organisation for Professionals in Regulatory 
Affairs (TOPRA) annual symposium which was 
held in University College Dublin. The event 
brought together over 600 representatives of 
regulatory agencies, industry and the European 
Commission to review and discuss current 
regulatory issues and to debate future planned 
developments. 
•	 The	IMB	and	the	Parenteral	Drug	Association	
(PDA) Ireland Chapter hosted a major two day 
scientific gathering entitled Making Gene and 
Cell Therapy Medicines a Reality in July 2012. The 
two day event was organised as a satellite event 
to the EuroScience Open Forum (ESOF2012). 
•	 For	the	third	year	in	succession,	thousands	
of students as well as teachers, parents and 
members of the general public from all over 
Ireland visited the IMB’s exhibition stand at the 
BT Young Scientist Exhibition in mid-January in 
the RDS. 
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Drug Safety Newsletter: 50th Edition
The IMB’s Drug Safety Newsletter provides safety 
updates to doctors, dentists and pharmacists. 
A special 50th edition, which highlighted the 
changes arising from the revised pharmacovigilance 
legislation, was published in November. Additionally, 
an information leaflet for patients and consumers on 
the safety monitoring of medicines in the context of 
the revised legislative framework was also distributed 
to patient organisations and published on the IMB 
website. 
Website
The IMB website outlines the primary functions and 
activities of the IMB and facilitates the dissemination 
of information to a wide variety of audiences 
including patients and consumers, healthcare 
professionals and industry personnel. More 171,000 
unique visitors accessed the website during the past 
twelve months representing an annual increase of 
36%. 
Media Relations 
We continued to progress our proactive media 
communications programme to highlight important 
safety messages and to build awareness of the role 
of the IMB. In total, we issued 38 press releases 
concerning safety and regulatory issues and 
responded to 532 queries from different media 
sources during the year.
develoPIng oRgAnISATIonAl 
cAPABIlITy
It is essential that the IMB continues to build our 
organisational capabilities in response to scientific, 
technological and regulatory changes. In particular, 
we are committed to ensuring that we have the 
necessary structures, systems and supports in place 
to deliver on our public health remit. 
Staff Developments 
It is vitally important that the IMB has the human 
resources in place to fulfil all our functions for the 
benefit of our many stakeholders.   
While recognising the constraints on public sector 
employment numbers, during 2011 we submitted 
a proposal as a predominantly self-funded agency 
on future staffing requirements to the Department 
of Health. This proposal focused on obligations 
arising from new responsibilities being assigned to 
the IMB by the Department as well as the impact of 
the introduction of a range of legislative changes 
between now and 2015. Following consideration of 
the report by the Department, I am pleased to report 
that in 2012 we were able to successfully recruit 
new specialist staff for those areas of additional 
competencies.
Also during the year, we continued with the 
operation of the IMB’s first leadership development 
programme. The eight participants in the programme 
engaged in a range of activities throughout the year 
and this initial course will conclude early in 2013. 
The feedback from the participants, their managers 
and all others involved in the programme has been 
hugely positive. I am delighted to report that the 
quality of the programme has also been recognised 
externally with accreditation from the Institute of 
Leadership and Management (ILM) achieved in late 
2012.
 
Information Technology and Change 
Management
Work progressed during the past year on the delivery 
of the IMB’s IT Strategy (2011 to 2015) which focuses 
on the delivery of a range of technologies to support 
the management of core IMB activities. The range 
of new and enhanced requirements identified in 
the strategy highlight the growing dependence on 
information technology in delivering services to 
stakeholders. 
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Also during 2012, as part of the IMB’s contribution 
to the wider European regulatory network, we 
continued our development of the Common 
European Submission Portal (CESP). Our lead role in 
this project now means that multiple Member States 
are utilising the services of the IMB to manage the 
secure delivery of medicines data. During the Irish EU 
Presidency, over 20 Member States are scheduled to 
formally agree a three year contract with the IMB in 
respect of CESP usage. 
The IMB has a long held commitment to change 
management and continuous improvement. This 
was further evidenced by the establishment of an 
organisational project management office (PMO) 
in 2012 to support project prioritisation, ensure 
consistency with organisational objectives and to 
develop consistent control mechanisms. The PMO 
is already supporting a range of key IMB regulatory, 
organisational and technology programmes.
Financial Performance
The IMB is committed to the highest standards of 
independence and governance so as to ensure 
quality of service combined with value for money. 
We continued in 2012 to successfully manage the 
affairs of the IMB in line with our statutory obligation 
that income at least meets costs. The IMB is largely 
self-funded by a system of fees which are approved 
annually by the Minister for Health following an 
annual public consultation process. This approach to 
funding is similar to the model employed by other 
healthcare products regulators globally.
THE FuTuRE
It is clear that 2013 will be another busy year for 
the IMB and will present both challenges and 
opportunities. Our focus will remain the promotion 
and protection of public and animal health. We will 
continue to enhance both our pre and post market 
activities for all products under our remit. We will 
respond to regulatory developments, communicate 
openly with stakeholders, and further progress our 
vision of a modern and efficient organisation. 
A significant event in 2013 for the IMB will be Ireland’s 
Presidency of the Council of European Union. We 
will have the honour of hosting over 20 informal 
meetings of our regulatory peers from across the 
member states, European Medicines Agency and 
European Commission in the various areas we 
regulate. We intend making substantial progress in 
the organisation of the medical devices competent 
authorities, indeed the regulation of medical devices 
will receive enhanced input as we respond to the 
joint plan of immediate actions and to the real need 
to improve this system for the benefit of patients 
and consumers. We also plan to host the first joint 
meeting of the CHMP, CMDh and PRAC with a view 
to enhancing understanding of their respective roles 
and how they must collaborate to the benefit of 
patients.  
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AUTHORISATION, REGISTRATION 
AND LICENSING ACTIVITIES  
The authorisation and registration of healthcare products is 
a core public health function of the IMB. Often referred to 
as ‘pre market’ activities, these are the regulatory functions 
carried out by the IMB which happen before a healthcare 
product can be marketed and supplied in Ireland. Ensuring 
timely approval of new products applications in particular, 
following a positive assessment of their safety, quality and 
effectiveness, gives patients and users access to a range of 
appropriate treatments.
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The IMB is responsible for the authorisation of 
medicines and clinical trials and for the registration of 
medical devices and cosmetics. The IMB licenses the 
manufacturers and wholesalers of human medicines 
and the manufacturers of veterinary medicines. The 
IMB also licenses blood and tissue establishments 
and, since August 2012, is a competent authority in 
respect of the quality and safety of human organs 
intended for transplantation. In addition, the IMB 
is responsible for issuing export certificates and we 
provide a borderline product classification service.
HuMAN MEDICINES
BoRdeRlIne PRoducT clASSIfIcATIon
The IMB provides a service to stakeholders to assist 
in clarifying which products should be categorised 
as human medicinal products, veterinary medicinal 
products and medical devices. Such products 
fall under the remit of the IMB from a regulatory 
perspective and are distinct from other products 
which are outside the IMB’s remit.
For products for human use, a classification service 
is operated for products which are on the borderline 
between human medicines and other products 
such as food supplements, cosmetics and medical 
devices. Requests for classification, whether external 
or internal, are presented to an internal, multi-
disciplinary, human medicinal product Classification 
Committee.
The Committee, which met 11 times in 2012, consists 
of appropriately experienced IMB staff from across 
the organisation and is chaired by the Director of 
Scientific Affairs. During the past 12 months, a total of 
144 new products were considered consisting of 127 
internal applications and 17 external applications. 
In addition, there were 22 products revisited from 
pre-2012.
The accompanying table outlines the numbers 
of classification queries for 2012 compared with 
previous years. Queries are generally evaluated 
within the normal 28 day timeframe and written 
explanations of the outcome are provided.
The Committee has a close working relationship with 
the Food Safety Authority of Ireland while it also 
engages in regular dialogue with the Department of 
Health and other national regulatory authorities.
number of Applications Received 2009 2010 2011 2012
Source Internal 114 72 132 127
 External 17 33 21 17
Classification Outcome Medicinal Product 88 63 88 91
 Medical Device 4 4 9 6
 Food Product 13 24 36 26
 Cosmetic Product 3 6 4 10
 Biocide    2 1
 Pending 21 7 12 6
 Other 2 1 2 4
 Total 131 105 153 144
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clInIcAl TRIAlS
The role of the IMB is to assess applications from 
sponsors to conduct clinical trials in Ireland. Sponsors 
include pharmaceutical companies and / or research 
institutions. The IMB approves the clinical trial 
protocols which describe in detail how each trial is 
to be conducted and outlines the steps that will be 
taken to protect the health of volunteers or patients.
In 2012, 77 new clinical trials were approved to 
commence in Ireland representing a 13% increase 
compared to 2011. While this increase is encouraging, 
overall there continues to be a general decline in 
clinical trial activity across the European Union. As 
in previous years, the majority of clinical trials were 
authorised for the treatment of cancer (38%) and 
haematology indications (21%).
The European Commission is proposing new 
legislation in an effort to increase the number of 
clinical trials being carried out in Europe. The IMB 
contributed to the consultation process surrounding 
these new proposals during 2012.
 clinical Trials Approved 2008 - 2012
Voluntary Harmonisation Procedures 
The IMB participated in five voluntary harmonisation 
procedures (VHP) during 2012 and acted as 
Rapporteur, or the lead Member State, for the 
assessment of the clinical trial application in one 
of these procedures. A VHP is a co-ordinated work 
sharing assessment procedure for multinational 
clinical trials. This procedure was established by the 
Clinical Trials Facilitation Group of the HMA. 
neW MARkeTIng AuThoRISATIon 
APPlIcATIonS 
Before a new medicine can be placed on the Irish 
market, it must be firstly assessed and authorised, 
or licensed, by the IMB or the European Medicines 
Agency. Licences granted by the IMB result 
from companies submitting either new national 
applications or applications via the mutual 
recognition procedure (MRP) and the decentralised 
procedure (DCP). Both MRP and DCP applications 
involve the input of a number of national European 
competent authorities with one country acting as the 
reference member state while the other countries 
involved are known as the concerned member states. 
Details of the IMB’s contribution to this process as a 
RMS are outlined on page 19.
During 2012, the IMB continued to assess all new 
product applications received with regard to safety 
and efficacy. Where the IMB assessment team 
establish that a medicines public health benefits 
outweigh its known risks, it is granted a marketing 
authorisation. 
The number of new product applications assessed 
by the IMB in 2012 was 1,372. This included 279 new 
national applications, including both parallel product 
authorisations and dual pack import registrations, as 
well as 92 new MRP and 532 new DCP applications. 
There were 184 new centralised applications and 285 
transfer applications.
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Total output for new Applications 2008 - 2012
 
The number of submissions of new parallel product 
authorisations applications has been declining since 
its peak in 2009. There was almost a 40% drop in 
these applications in 2012 compared to the previous 
12 month period. In addition, there was a 21% 
decrease in new decentralised procedures reflecting 
the known trend in Europe.
vARIATIonS 
After a medicine has been authorised, the terms of 
the marketing authorisation may subsequently be 
varied. Examples of variations include the addition of 
a new indication or potential side effect, or updates 
to the company’s manufacturing or contact details. 
In the past year, the IMB issued 17,153 variations to 
marketing authorisations for products authorised 
through the national or MR procedures. The 11% 
annual increase in variations applications was mostly 
in the Type IA notifications (those not requiring 
immediate notification).
ReneWAlS
In 2012, 650 renewals to marketing authorisations 
for products authorised through the national or 
MR procedures were processed. This reduction of 
15% compared to 2011 reflects the lifecycle of the 
products in question as marketing authorisations 
are valid for five years from the date of first issue. For 
the authorisation to remain valid, it must then be 
renewed at the end of this five year period.
IMB AS RAPPoRTeuR/co-RAPPoRTeuR 
The IMB was allocated as lead assessor (Rapporteur) 
or joint lead assessor (Co-Rapporteur) for 10 new 
marketing authorisations by the Committee for 
Medicinal Products for Human use (CHMP) at the 
European Medicines Agency. These applications, 
referred to as centralised procedures, allow a 
successful applicant to market its product in all 
member states. The application types included 
respiratory, radiocontrast agent (ECHO), treatment 
of inborn errors of bile acid metabolism, alcohol 
dependence, IVF media and lysosomal storage 
disease.   
Companies may also seek scientific advice from the 
CHMP. During 2012, the IMB acted as Rapporteur 
for 26 scientific advice procedures for medicines 
proposed for the treatment of a broad range of 
conditions. Areas of focus included respiratory 
medicine, diabetes mellitus and musculo-skeletal 
conditions.
IMB AS RefeRence MeMBeR STATe
In certain circumstances, companies can apply for the 
simultaneous authorisation of a medicine in more 
than one EU country. As outlined, such applications 
require one country to be the reference member state 
(RMS) while the other countries involved are known 
as the concerned member states (CMS).
The IMB continued to actively contribute to the 
European licensing system throughout 2012 and 
completed 12 new marketing authorisations via the 
MR procedure with Ireland as the RMS.
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TRAdITIonAl heRBAl MedIcInAl 
PRoducTS 
To protect the health of consumers, the EU 
introduced the Traditional Herbal Medicinal Products 
Directive in 2004 to allow for the regulation of 
traditional herbal medicinal products (THMPs). 
This directive was transposed into Irish law on 23 
July 2007 with the IMB designated as the national 
Competent Authority for the implementation of the 
legislation. On this basis, the IMB established the 
traditional herbal medicinal products registration 
scheme. The registration is a simplified procedure 
which takes into account the “traditional use” of these 
products. 
At national level, registration requirements have 
applied to new products coming onto the market 
since 2007. With the ending of a transitional 
protection period in April 2011, registration 
requirements now apply to all products on the 
marketplace. Since then, the number of applications 
received by IMB has remained disappointingly low. 
In total, 61 applications had been received under 
the scheme by the end of 2012 and 10 products had 
been registered by the IMB. During the past year, 
the IMB focus was on progressing assessment of the 
applications received thus far. As a result, a significant 
number were progressed to an advanced stage of 
assessment with completed registration expect 
during 2013.
hoMeoPAThIc MedIcIneS
There are two registration schemes which apply 
to homeopathic medicines. The Simplified Rules 
Scheme (SRS) applies to products marketed without 
indications. The National Rules Scheme (NRS) applies 
to products marketed with indications.
In 2012, the three new applications received under 
the Simplified Rules Scheme were completed 
and registrations issued. During this period, two 
homeopathic variations, the first under scheme, were 
received and processed. In total, 80 homeopathic 
medicinal products have been registered under the 
Simplified Rules Scheme to date.
A legislative deadline of 31 May was put in place 
for receipt of applications under the National Rules 
Scheme enabling products to remain on the Irish 
market as long as an application under the NRS was 
submitted to the IMB. In total, nine applications were 
received and assessment is on-going.
conTRolled dRugS lIcenSIng 
Import, export and holding of controlled drugs (for 
legitimate purposes) are subject to licensing. The 
Department of Health is the licensing authority while 
the IMB handles the administrative aspects of the 
application and licensing process.
During the past 12 months, licensing activity 
increased marginally as outlined in the following 
table.
controlled drugs licensing Activity 2008 - 2012
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VETERINARy MEDICINES
In the conduct of its veterinary medicines licensing 
activities, the IMB is committed to protecting the 
welfare of treated animals, including fish, poultry, 
bees and domestic animals, as well as ensuring the 
safety of foodstuffs obtained from animals treated 
with veterinary medicines. The assessment of 
veterinary products also includes an evaluation of any 
possible risks to the user as well as the elaboration 
of risk-management measures to control any risks. 
Finally, we also evaluate the potential impact of new 
veterinary medicines on the environment.
PRoducT clASSIfIcATIon RequeSTS 
The IMB provides a service to stakeholders to assist in 
clarifying whether a product falls within the scope of 
medicines legislation and thus should be categorised 
as a veterinary medicinal product. Such products fall 
under the remit of the IMB and are distinct from other 
products which may be regulated by the Department 
of Agriculture, Food and the Marine such as biocides 
and feeding stuffs. 
During 2012, 74 product classification queries were 
received in respect of veterinary medicines. There 
were 70 responses issued which related to queries 
received both during, and prior to, 2012.
clInIcAl TRIAlS
The IMB is regularly consulted by the Department of 
Agriculture, Food and the Marine prior to the granting 
of an approval for a clinical trial in animals. The 
Department is the Competent Authority for licensing 
of these trials. On receipt of a valid application from 
the Department, the IMB reviews the information 
based on an assessment of the expected risks to the 
animal, the user, the consumer and the environment. 
The IMB also considers the design and conduct of the 
proposed study.
During 2012, three clinical trial applications were 
received by the IMB and issued to the Department. 
All were assessed and issued within clinical trial set 
timelines.
neW APPlIcATIonS
Before a new veterinary medicine can be placed 
on the Irish market, it must be firstly assessed and 
authorised by the IMB or the European Medicines 
Agency. The decision on whether a medicine is 
authorised centrally in Europe or at a national level, 
is generally dependent on the type of product 
in question and/or the choice of the marketing 
authorisation holder. 
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When a company seeks approval from the IMB for 
a new medicine, it submits a dossier that includes 
critical summary reports, details of the product 
information, such as the leaflet and label, as well as 
quality, safety and efficacy data. An IMB assessment 
team of veterinary practitioners, pharmacists and 
other scientists will then review the dossier to 
establish if the medicine’s benefits, including animal 
and public health where relevant, outweigh its 
known risks.
During 2012, the number of new product applications 
received by the IMB was 185 of which 18 were purely 
national applications. This equates to a 20% increase 
in new products received for assessment compared 
to 2011. We assessed and approved 144 applications, 
including 11 new national licences. This figure has 
remained constant over the last number of years. 
The number of MRP and DCP licenses issued was 107 
while 127 such applications were received. The MRP 
and DCP figures included both applications where 
Ireland was the reference member state as well as 
those where it was a concerned member state. (See 
also ‘IMB as Reference Member State’ below).
Total output for new Applicants 2008-2012
vARIATIonS
After a medicine has been authorised, the terms of 
the marketing authorisation may subsequently be 
varied. Examples of variations include the addition of 
a new indication or potential side effect, or updates 
to the company’s manufacturing or contact details. 
During the year in review, the IMB approved 1,242 
variations to authorisations granted through the 
national, MR or centralised procedures while 1,251 
variations applications were received. These figures 
were broadly similar to the previous 12 month period.
ReneWAlS
New marketing authorisations are valid for five years 
from the date of first issue. For the authorisation 
to remain valid, it must be renewed at the end of 
this five-year period. Following this renewal, the 
authorisation remains valid for an indefinite period 
unless a further renewal is deemed necessary by the 
IMB on animal/public safety grounds.
In 2012, 58 renewals to marketing authorisations for 
veterinary medicinal products authorised through 
the national or MR procedures were received while 
66 were issued. This issued figure is a 47% decrease 
compared to 2011. The continuous decrease 
can be explained by the change in legislation 
where normally only one renewal of a marketing 
authorisation is now required after five years instead 
of one every five years.
IMB AS RAPPoRTeuR/co-RAPPoRTeuR 
In the ‘centralised’ or ‘Community’ procedure, the 
Committee for Medicinal Products for Veterinary 
Use (CVMP) of the European Medicines Agency is 
responsible for conducting the initial assessment of 
veterinary medicines for which an EU-wide marketing 
authorisation is sought. Under this procedure, the 
CVMP appoints members from two different EU 
countries to assess the application and these are 
known as the rapporteur and co-rapporteur. 
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During 2012, the IMB acted as the rapporteur or co-
rapporteur for 16 centralised procedures (including 
extension applications) up from nine in 2011. These 
assessments were complex and involved extensive 
discussion with EU colleagues. 
IMB AS RefeRence MeMBeR STATe
The IMB continued to actively contribute to the 
European veterinary licensing system and issued 
42 new marketing authorisations as the reference 
member state, 41 of these through the decentralised 
procedure.
WoRk-In-PRogReSS APPlIcATIonS
The overall work-in-progress at the end of the year 
was 831 units (made up of various application types).
MEDICAL DEVICES
clASSIfIcATIon RequeSTS
European legislation provides for the categorisation 
of medical devices into four different classes ranging 
from low risk to high risk. In addition, in certain cases 
it may not be clear if a product falls under the medical 
device legislation or whether, for example, it should 
be classified as a medicine or a cosmetic product.
The IMB received 56 applications for the classification 
of medical devices or products queried as medical 
devices. Of these queries, 55% were received 
from other medical device competent authorities 
in Europe and related to complex classification 
questions or where a consensus was sought on the 
classification of a particular product. Of the remaining 
queries, 2% were received from notified bodies, 18% 
were received from other external stakeholders, such 
as medical device manufacturers or distributors, and 
25% were received by other departments within IMB. 
clInIcAl InveSTIgATIon APPlIcATIonS
When clinical investigations are to be carried out 
in Ireland, it is necessary to make an application to 
the IMB. Typically, applications are submitted to us 
by commercial sponsors such as medical device 
manufacturers. 
The IMB received one application for a clinical 
investigation of a novel medical device to be 
conducted in Ireland in 2012. In addition, one 
amendment to an ongoing clinical investigation was 
received.
The number of clinical investigations of medical 
devices ongoing in Ireland remains at a very low 
level. The last revision of the European medical 
devices legislation, Directive 2007/47/EC, put greater 
emphasis on the conduct of clinical investigations. 
However, the anticipated increase in clinical 
investigation activity has not been seen in Ireland. 
Several European authorities, including the IMB, 
have suggested that further analysis be conducted at 
European level to review recent legislative revisions.
The IMB continues to raise awareness of clinical 
investigation processes and requirements at relevant 
national and international conferences, meetings 
and directly with interested stakeholders. It is worth 
noting that the medical device legislation in Europe 
only requires application/notification to the IMB 
of pre-market clinical investigations from medical 
device manufacturers. Other types of clinical research 
involving medical devices are not required to be 
notified under national or European legislation, so the 
number of research applications received by IMB may 
not necessarily be indicative of the clinical research of 
medical devices in Ireland.
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deSIgnATIon And MonIToRIng of IRISh 
noTIfIed BodIeS 
Manufacturers of certain medical devices require a 
notified body to carry out a compliance assessment 
of those products before they can be placed on the 
market. In Ireland, the notified body is the National 
Standards Authority of Ireland (NSAI). It is the role 
of the IMB, as the national Competent Authority for 
medical devices, to monitor the performance of the 
NSAI as a notified body.
There was significant attention at European level 
on medical device notified bodies during 2012. 
The European Commission’s joint action plan for 
immediate actions compiled in February required all 
European competent authorities to review notified 
bodies for class III medical devices based in their 
territory. 
Therefore, in addition to our normal designation and 
monitoring activities, the IMB completed a review in 
September 2012 of the NSAI as a notified body for 
class III medical devices. 
Normal scheduled designation and monitoring 
activities were realigned during the year as a result of 
the additional requirements of the joint action plan. 
As part of its normal surveillance activities, the IMB 
conducted a surveillance audit of the NSAI’s Dublin 
headquarters in October 2012.
The IMB received 148 certification notifications, 
including certificate issuance, modification and 
withdrawal, during 2012 which were then uploaded 
to the European database (EUDAMED) as required.
PRoducT RegISTRATIonS
The IMB received 388 notifications of medical devices 
to the medical device register during the past year. 
These relate to class I, in-vitro diagnostic and custom 
made medical devices and to system and procedure 
packs. Registration of these devices in the Member 
State in which the manufacturer or their authorised 
representative is based is required by legislation and 
there is a self-declaration of conformity made by the 
manufacturer. During the 12 months under review, 48 
organisations registered with the IMB as Irish based 
manufacturers or authorised representatives of these 
types of medical devices. 
The IMB completed a review of registered 
organisations in 2012 to ensure that registered details 
were correct and up-to-date. Of the organisations 
registered with the IMB, 32% required amendment 
or update to their registration details while 22% of 
organisations withdrew or were removed from the 
register. A further 14% require further follow up 
surveillance.
A new IMB extranet registration system became 
operational in August 2012. The update to this system 
was in response to the European Commission’s 
further development of EUDAMED which captures 
registration information from national competent 
authorities.
COSMETIC PRODuCTS
PRoducT noTIfIcATIonS
Manufacturers, importers and persons acting on their 
behalf who have responsibility for placing cosmetic 
products onto the EU market are required to notify 
such placement. This can be done either nationally, to 
the IMB and counterparts in other member states or, 
since January 2012, via the European Commission’s 
Cosmetic Product Notification Portal (CPNP). This 
centralised portal will replace national notification 
requirements from July 2013.
In 2012, the IMB received 1,050 cosmetic product 
notifications. The three most common notification 
categories were: 
•	 Make-up	products	and	make-up	(21%);
•	 Lip	products	(21%);
•	 Creams,	emulsions,	lotions,	gels	and	oils	(18%).							
24 IMB ANNUAL REPORT 2012
AuTHORISATION/LICENSING OF SITES 
AND FACILITIES
The IMB is responsible for the regulation of 
manufacturers of human and veterinary medicines, 
of wholesalers of human medicines and of blood and 
tissue establishments. We are also responsible for the 
approval of contract laboratories.
Such sites and facilities are required to be authorised 
or licensed by the IMB for the activities which they 
carry out. The authorisation is based on satisfactory 
outcomes to IMB inspections (see also the Safety 
Monitoring and Surveillance section of this report) 
during which adherence to relevant European 
guidance is evaluated.
The total number of authorisations/licences in force 
at year end is presented below by category. The 
figures for 2012 remained broadly stable. 
EXPORT CERTIFICATES 
Export certificates are required by health authorities 
in many third country markets as an indication that a 
product registered, authorised and/or manufactured 
in the country of origin is of appropriate quality. As 
Ireland is a large exporter of medicines and medical 
devices, companies exporting from here request a 
large number of certificates. Export certificates are 
also required in many third countries to facilitate the 
registration of cosmetic products. The inspection and 
authorisation/registration programmes operated 
by the IMB form the basis on which certificates 
are issued. Where possible, certificate formats as 
published by the World Health Organization are used.
There was an output of 3,646 export certificates in 
2012 as set out in the accompanying table:
Total number of licences/Authorisations (Sites) 2008 2009 2010 2011 2012
Manufacturers of Medicines for Human Use 86 85 86 88 87
Manufacturers of Veterinary Medicines 26 25 27 24 23
Investigational Medicinal Products for Human Use 45 50 51 50 47
Wholesalers of Medicines for Human use 214 209 220 243 258
Blood Establishments 6 5 4 4 3
Tissue Establishments 6 13 16 22 21
Laboratory Approvals 11 13 16 16 17
Total 394 400 420 447 456
Product certification Activity  2008 2009 2010 2011 2012
Certification of Documents 266 235 234 239 272
Certificates of Good Manufacturing Practice  254 269 255 272 276 
for Active Substance & Finished Product     
Manufacturers 
Certificates for Medicinal Products 1295 964 1200 1416 1350
Medical Device Free Sale Certificates 434 977 2142 1780 1522
Cosmetic Products Free Sale Certificates N/A N/A 174* 388 210
Other 61 56 28 51 16
Total 2310 2501 4033 4146 3646
*2011 was the first full year that the IMB was responsible for issuing certificates for cosmetics.
25IMB ANNUAL REPORT 2012
SAFETY AND COMPLIANCE  
MONITORING 
Post-market surveillance, which refers to the safety 
monitoring of medicines, medical devices and other 
healthcare products that have been authorised, licensed or 
registered for use in Ireland, is a primary function of  
the IMB. 
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Assessing reports of suspected adverse events/
incidents and reactions (also known as side effects), 
conducting scheduled safety reviews, monitoring 
field safety corrective actions to medical devices 
and evaluating new and emerging data from trials 
and studies are among the tools used to monitor 
the safety of healthcare products on an ongoing 
basis. Quality issues concerning how a product is 
manufactured, packaged, labelled, distributed or 
stored may also arise at the post-market stage. In 
a small number of cases, where it is established 
that the risks of a particular product outweigh the 
benefits for those using it, the manufacturer and/
or the IMB may decide that it is necessary to remove 
or recall that product from the market. In such 
circumstances, we will work with all stakeholders 
impacted to ensure such recalls are managed in a 
timely and effective manner.
HuMAN MEDICINES
PhARMAcovIgIlAnce 
Pharmacovigilance is defined as the science and 
activities relating to the detection, assessment, 
understanding and prevention of adverse reactions, 
or side effects, associated with the use of medicines. 
Key to its effectiveness is an active reporting 
culture. The majority of adverse reaction reports 
are notified to the IMB by the pharmaceutical 
companies marketing the medicines, also known 
as the marketing authorisation holder (MAH). Most 
of these reports will have been initiated by doctors, 
pharmacists and other healthcare professionals who 
may also report directly to the IMB. We also receive 
reports of adverse reactions directly from patients 
and members of the public.
The IMB monitors adverse reaction reports to look 
for new types, or increased numbers, of adverse 
reactions. We assess such reports and trends in 
co-operation with pharmacovigilance professionals 
across Europe and further afield. Where the overall 
benefit/risk profile of a medicine appears to be 
impacted, consideration is given as to how any new 
risks should best be managed and communicated to 
healthcare professionals and patients.
During 2012, the IMB received a total of 2,757 
suspected adverse reaction reports in association 
with the use of human medicines, consistent with the 
reporting rates seen in 2011.
Individual case reports were followed up by the IMB, 
with feedback information provided to reporters 
as appropriate. Serious, suspected cases notified 
directly to the IMB by healthcare professionals were 
appropriately forwarded to relevant stakeholders, 
including the European Medicines Agency and 
marketing authorisation holders within the agreed 
timeframes and formats.
Source of Suspected Adverse   
Reaction Reports %
Marketing Pharmaceutical Company 69
Community Care Doctor 8
Hospital Doctor 5
General Practitioner 5
Hospital Pharmacist 4
Community Pharmacist 4
Hospital Nurse 2
Patient/Consumer 2
Community Nurse 1
Haemovigilance Officer <1
Health Sector - Other <1
 
In addition to the initial reports outlined earlier, the 
IMB also received and processed some 2,744 follow 
up reports during the year. 
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Online Reporting 
The online reporting system, available to healthcare 
professionals, patients and other members of the 
public, accounted for 12% (335) of all reports received 
during 2012. Access to the online reporting system is 
available through the IMB website at www.imb.ie.  
By the end of the year, some 324 companies were 
operational with electronic reporting to the IMB, 
an increase on the 288 companies reporting 
electronically in 2011. 
During 2012, the IMB continued to report all 
suspected serious adverse reactions occurring in 
Ireland electronically via EudraVigilance to the 
European Medicines Agency.
Monitoring Compliance with Pharmacovigilance 
Obligations 
Company/sponsor compliance with 
pharmacovigilance obligations is monitored on an 
ongoing basis through:
•	 Review	of	the	timeliness	and	quality	of	individual	
adverse	reaction	reports;
•	 Evaluation	of	follow-up	information	provided	for	
individual	reports;	and	
•	 Assessment	of	responses	to	IMB	requests	for	
pharmacovigilance data. 
Issues identified in relation to compliance were 
followed up with the companies concerned through 
correspondence, meetings and teleconferences. The 
IMB also reviewed and gave feedback on corrective 
action plans developed to address the issues raised. 
The pharmacovigilance inspection programme 
continued in 2012, jointly carried out by IMB 
pharmacovigilance and compliance colleagues. 
The pharmacovigilance team participated in two 
inspections during the year.
At a European level, the IMB continued to contribute 
to the Pharmacovigilance Inspectors Working 
Group in relation to the revised pharmacovigilance 
legislation and to the development of Good Vigilance 
Practice (GVP) guidance for pharmacovigilance 
systems requirements and inspections.
vIgIlAnce ASSeSSMenT
Vigilance assessment activities encompass particular 
aspects of benefit-risk management of medicines 
throughout the product lifecycle and include the 
evaluation of periodic safety update reports (PSURs), 
risk management plans (RMPs) and protocols and 
results relating to post-authorisation safety studies. 
Post market evaluations undertaken also include 
referrals on issues of safety or benefit-risk balance 
to the European Medicines Agency, assessment 
and approval of Direct Healthcare Professional 
Communications issued by MAHs, and signal 
management. 
During 2012, the IMB worked with a wide range 
of stakeholders including the European Medicines 
Agency and other national competent authorities 
to ensure the successful and timely implementation 
of new and updated assessment procedures 
introduced under the legal framework of the new 
pharmacovigilance legislation which came into effect 
throughout the EU in July 2012 (see page 51 for 
further information). 
Pharmacovigilance Working Party Assessments
During the first half of 2012, the IMB provided active 
representation to the CHMP Pharmacovigilance 
Working Party and its drafting groups at the 
European Medicines Agency. During this period, the 
working party provided advice to the CHMP and also 
the CMDh (the HMA’s co-ordination group for MRPs 
and DCPs) for centrally authorised and nationally 
authorised products respectively. The working 
party held its final meeting in July 2012 following 
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the establishment of the Pharmacovigilance Risk 
Assessment Committee (PRAC). Dr. Almath Spooner, 
the IMB delegate to the PRAC, was elected vice-
chairperson of the committee for a three year period 
at its first meeting.
During 2012, 468 safety variations were assessed and 
concluded by the IMB and these included variations 
to implement the following CHMP Pharmacovigilance 
Working Party recommendations for nationally 
authorised products:
•	 Risedronate	and	the	risk	of	oesophageal	cancer;
•	 Levodopa,	dopamine	agonist	and	COMT	inhibitor	
products and risk of impulse control disorders 
(ICDs);
•	 Risk	of	allopurinol-induced	serious	cutaneous	
adverse reactions – association in patients who 
are	carriers	of	the	HLA-B*5801	allele;
•	 Tramadol	and	the	risk	of	convulsion,	serotonin	
syndrome, suicide and posology in the elderly 
and	in	patients	with	renal	or	hepatic	impairment;
•	 Inconsistency	in	product	information	of	
prazepam-containing medicinal products 
regarding	contra-indication	in	glaucoma;
•	 Association	of	oxcarbazepine	with	risk	of	
hypersensitivity adverse drug reactions 
potentially	associated	with	HLA-A*3101	allele;	
•	 Risk	of	carbamazepine-induced	cutaneous	
reactions – association with HLA-A*3101 allele 
in European and Japanese patients and update 
of recommendation on testing for HLA-B*1502 
allele	in	some	Asian	populations;
•	 Paracetamol,	solution	for	infusion	(MRP	Perfalgan	
(FR) and generic products) and risk of accidental 
overdosing of neonates and infants, due to 
medication errors following confusion between 
mg	and	ml,	and	underweight	adults;
•	 Fluoroquinolones	and	risk	of	QT-interval	
prolongation;
•	 Selective	serotonin	reuptake	inhibitors	(SSRIs)	
(fluvoxamine, citalopram, escitalopram, 
fluoxetine and sertraline, paroxetine) and 
possible risk of male infertility due to sperm 
impairment.
Periodic Safety update Reports
Periodic safety update reports (PSURs) are intended 
to provide an update of the worldwide safety 
experience of a medicine to competent authorities 
at defined time points following the authorisation of 
the medicine and are a tool to monitor the ongoing 
safety of medicines. PSURs are evaluated either by the 
IMB or by other EU medicines agencies operating a 
work-sharing system.
As a result of the new EU pharmacovigilance 
legislation, the format and content of PSURs are 
changing and the extent of the evaluation will 
integrate cumulative information on both the 
benefits and risks. The link to risk management 
is also strengthened. The assessment procedure 
involving the Pharmacovigilance Risk Assessment 
Committee (PRAC) at the European Medicines Agency 
commenced for PSURs for centrally authorised 
products during 2012 and may result in automatic 
regulatory action such as variation, suspension or 
revocation.
During 2012, the total output for PSURs was 3,372. 
This includes PSURs for national authorisations, 
mutual recognition, centralised and PSUR work-
sharing procedures. Since July, a PSUR submission has 
been based on a risk based approach and submission 
is no longer routinely required for certain types of 
medicinal products such as the majority of products 
authorised as generics.
The IMB continues to actively participate in the HMA 
PSUR work-sharing project and is ranked in the top 
seven of national competent authorities in Europe in 
terms of lead MS assessment responsibilities. 
29IMB ANNUAL REPORT 2012
P-RMS allocation
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Risk Management Plans 
The Risk Management Plan (RMP) describes what 
is known and not known about the side effects 
of a medicine and states how these risks may be 
prevented or minimised in patients. It also includes 
plans for studies and other activities to gain more 
knowledge about the safety of the medicine and 
the risk factors for developing side effects. RMPs are 
continually modified and updated throughout the 
lifetime of the medicine as new information becomes 
available.
Since July 2012, all new marketing authorisation 
applications require an RMP as part of the initial 
submission for approval. New guidance documents 
regarding the format and content of RMPs were 
published during the year.
The total number of RMPs assessed during 2012 was 
331 which consisted of both incoming and outgoing 
centralised applications. There were also 32 follow-
up measures which included assessment of the 
results of post authorisation safety studies. Some 
34 Direct Healthcare Professional Communications, 
which provided new safety information or risk 
minimisation advice, were approved. In addition, 
50 risk minimisation plans were assessed including 
risk minimisation tools for healthcare professionals 
and patients to support the safe and effective use of 
particular medicines.
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Signal Management
A safety signal is information on a new or 
incompletely documented adverse event that is 
potentially caused by a medicine and that warrants 
further investigation. Signals are generated from 
several sources such as spontaneous reports, 
clinical studies and the scientific literature. Signal 
management is the process whereby new risks 
associated with a medicine or significant changes to 
known risks can be detected, confirmed, analysed 
and prioritised for review. This process may ultimately 
lead to a recommendation for regulatory action at a 
European level. 
During 2012, the IMB implemented new procedures 
and processes for signal detection and management 
including work-sharing for signal detection within 
the EU. The IMB provides the lead in management of 
signals for 59 active substances which are nationally 
authorised within the EU and also assesses signals for 
21 centrally authorised products for which Ireland is 
rapporteur.
BLOOD, TISSuES AND CELLS
hAeMovIgIlAnce
The IMB is the Competent Authority for legislation 
concerning blood and blood components.
Haemovigilance refers to a set of organised 
surveillance procedures relating to serious adverse 
or unexpected events or reactions in donors or 
recipients and the epidemiological follow-up of 
donors.
The IMB continued its interaction with the National 
Haemovigilance Office (NHO) during 2012 and 
discussed issues of mutual interest and concern at 
regular meetings throughout the year. Key items 
discussed at these meetings included: 
•	 Review	and	discussion	of	national	experience	
with	haemovigilance	reactions	and	events;
•	 Updates	to	guidance	on	haemovigilance	
reporting;	
•	 Options	to	facilitate	simultaneous,	dual	
submission of mandatory reports to NHO and  
the	IMB;
•	 Further	developments	to	support	monitoring	
activities and ensure compliance with EU and 
national legislative provisions.
Following collaboration with the NHO, the IMB 
submitted an annual report on serious adverse 
reactions and events to the EU Commission during 
2012. The report reflected information received from 
January to December 2011 and included information 
on 129 serious adverse reactions and 157 serious 
adverse events which met the mandatory legislative 
reporting requirements. These figures represent a 
decrease of approximately 15% for serious adverse 
reaction reports and an increase of approximately 
30% for serious adverse event reports when 
compared with the previous year. These trends were 
not unexpected and are consistent with the impact of 
changes to agreed EU reporting criteria. 
The European Commission continued to progress 
harmonisation initiatives to develop a common 
approach to the provision of data by member states 
through a Working Group on Haemovigilance first 
convened in 2007. During 2012, the IMB attended 
a meeting of this group and, in collaboration with 
colleagues from the NHO, actively contributed to the 
development of updated guidance.
TISSue And cell vIgIlAnce
The IMB is the Competent Authority in Ireland for the 
purposes of the EU tissues and cells legislation. The 
legislation focuses on standards of quality and safety 
for donations, procurement, testing, processing, 
preservation, storage and distribution of human 
tissue and cells.
Tissue and cell vigilance activities progressed during 
2012 and included the three year project co-funded 
by the EU Public Health group on Substances of 
Human Origin Vigilance and Surveillance (SOHOV&S). 
The primary aim of the project is to support the 
establishment of effective vigilance and surveillance 
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systems for tissues and cells used in transplantation 
and in assisted reproduction. The IMB continued 
its participation as a partner in the various working 
groups of this project and was the lead partner for 
one of the work packages, with responsibility for 
organising training courses on the investigation and 
management of vigilance and surveillance for tissues 
and cells. In 2012, this training was provided in the 
form of two training courses with each comprising a 
four week e-learning module followed by a two-day 
interactive residential module. 
In line with the legislative requirements, the IMB 
submitted an annual report on serious adverse 
reactions and events associated with tissues and 
cells to the EU Commission during 2012. The report 
reflected information received from January to 
December 2011 and consisted of some 47 reports 
associated with use of tissues and cells, 43 of which 
met the legislative reporting requirements. These 43 
reports included six serious adverse reactions (three 
in 2011) and 37 serious adverse events (24 in 2011). 
The remaining four donor reaction reports, while not 
fulfilling the mandatory reporting requirements, were 
included on a voluntary basis as requested by the 
Commission.   
The EU Commission continued to progress 
harmonisation initiatives to develop a common 
approach to the provision of data by member 
states through a working group on tissues and 
cells vigilance. During 2012, the IMB continued to 
participate in the development of guidance for 
reporting which was further updated during the year.
VETERINARy MEDICINES
PhARMAcovIgIlAnce
Effective reporting is central to a successful and 
robust pharmacovigilance scheme. During 2012, 
there were 244 reports of suspected adverse events 
associated with the use of veterinary medicinal 
products received by the IMB. This represents an 
increase of 7% compared to the number of reports 
received in 2011. 
The breakdown of the 244 reports is as follows:
•	 117	related	to	suspected	adverse	reactions	in	
treated	animals;
•	 116	related	to	suspected	lack	of	expected	
efficacy;
•	 10	involved	suspected	adverse	reactions	
in individual users following exposure to a 
veterinary	medicinal	product;
•	 1	related	to	a	violation	of	an	approved	residue	
limit in foodstuffs of animal origin.
Periodic Safety update Reports
PSURs are intended to provide an update of the 
worldwide safety experience of a medicine. In 2012, 
PSURs for a total of 805 products were assessed. This 
represents a 44% increase on the number of PSURs 
assessed in 2011.
Inspections of Pharmacovigilance Systems
The IMB conducted one inspection of a 
pharmacovigilance system at a marketing 
authorisation holder’s premises during 2012. In 
addition, we participated in one inspection in another 
EU member state in respect of centrally-authorised 
products for which the IMB was the rapporteur. 
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uSE OF VETERINARy ANTIMICROBIALS IN 
IRELAND
In accordance with EU policy to help underpin 
effective strategies to control the spread of 
antimicrobial resistance in animals and in humans, 
the IMB gathered information on the usage of 
veterinary antimicrobials in Ireland. The total 
consumption in 2011 was 88.4 tonnes. This figure 
compares favourably with 93.2 tonnes in 2010 and 
91.1 tonnes in 2009.
MARKET COMPLIANCE – HuMAN AND 
VETERINARy MEDICINES
The IMB is responsible for a number of risk-based 
market surveillance programmes. These include 
proactive activities such as the sampling and 
analysis programme and the advertising compliance 
programme, and reactive activities such as the quality 
defect and recall programme. 
The IMB also operates an exempt medicinal products 
notification scheme designed to monitor the 
importation and supply of unauthorised medicinal 
products. In addition, we carry out a programme of 
regulatory compliance inspections at the premises 
of marketing authorisation holders. The latter is 
designed to assess the level of compliance against 
national legislation relating to the placing on the 
market and advertising of medicines.
quAlITy defecTS And RecAllS
The quality defect and recall programme investigates, 
on the basis of risk to public and animal health, 
reports of suspected quality defects in both human 
and veterinary medicines and in their related active 
substances. Recalls from the Irish market are also co-
ordinated under this programme.
Number and Type of Quality Defects 
During the past 12 months, 741 quality defects were 
reported to, or identified by, the IMB. This represents 
a 19% decrease on the 2011 figure. This first annual 
reduction in the number of quality defects was 
likely due to the fact that there were fewer multiple 
product defect investigations. 
Human medicines accounted for 703 quality defects 
with 38 relating to veterinary medicines. Of the 
total number of defects, 74% were determined to 
affect Ireland. In these cases, the defective batch or 
batches were either on the Irish market and/or were 
manufactured in Ireland. 
The type and quantity of quality defects received is 
provided in the accompanying table.
33IMB ANNUAL REPORT 2012
Comparisons with the quality defect data from 2011 
show that:
•	 Good	Manufacturing	Practice	(GMP)	non-
compliances increased by 54%. This was in 
part due to individual non-compliance issues 
identified at manufacturing facilities in Italy and 
India;
•	 Of	the	83	cases	pertaining	to	marketing	
authorisation non-compliances, 47 (57%) 
related to the non-implementation of variations 
within the agreed timeframe. Other MA non-
compliances included assignment of erroneous 
expiry dates, sourcing of active substances from 
non-registered suppliers and non-compliances 
with	Braille	requirements;
•	 Cold	chain	issues	decreased	significantly	by	
95%. A single significant issue had affected 65 
products	in	2011;	
•	 Damaged	product	issues	decreased	by	75%.	A	
single significant issue had affected 38 products 
in	2011;
•	 There	was	a	decrease	of	51%	in	reports	related	to	
non-printed packaging components.
Types of quality defects human quality defects veterinary quality defects
Stability 88 14
Non-Compliance with MA 80 3
Contamination Issue 74 2
SPC/Carton/Label/Leaflet 73 3
Non-Compliance with Spec 62 8
Other 49 1
Other Packaging Component 48 0
Undeclared Active 39 0
Non-compliance with GMP 36 1
Product Prep / Admin Issue 34 0
Product Mix-Up 28 0
Unlicensed Product  20 0
Damaged Product 16 0
Falsified Medicine Issue 16 0
Lack of Sterility Assurance 14 3
Erroneous Distribution 8 1
Adverse Reaction  / Change in Risk - Benefit 8 1
Lack of Efficacy 6 1
Cold Chain Issue 4 0
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The below table illustrates the breakdown of quality defects by classification over the past five years. 
Type of defect  2008 2009 2010 2011 2012
Minor Quality Defects 105 147 241 314 236
Major Quality Defects 299 345 332 364 303
Critical Quality Defects 127 105 173 231 189
Number of Quality Defect Reports Not Justified 23 17 5 8 13 
Total Number of Quality Defects  554 614 751 917 741
Source  human Medicines veterinary Medicines  
 Reports Reports 
Companies (Manufacturers, Distributors 398 16 
and/or MA Holders) 
Other Competent Authorities 199 17
Hospital Pharmacists 35 
IMB Staff Members 35 3
Community Pharmacists 28 
Community Pharmacists 28 
Patients and/or Members of the Public 7 
Physicians and Nurses 1 
Department of Agriculture, Food and the Marine                                     1
Veterinary Practitioners                                                                      1
Critical quality defects, which are those defects 
defined as potentially life-threatening or a serious 
risk to health, accounted for 189 of the total defects 
recorded. Of these, 59 were determined to affect 
Ireland.
A breakdown of the Irish market data shows that 
23 defects related to an unlabelled unit which was 
unaccounted for during a compounding campaign at 
an Irish facility. A further nine defects were associated 
with falsified medicines. While the genuine products 
were manufactured in Ireland in eight of these cases, 
none of the related falsified products were identified 
on the Irish market. The remaining case related to the 
presence of a possible falsified product within the 
Irish distribution chain. However, IMB investigations 
concluded that the product was genuine. Other 
critical quality defect cases included product mix-
up, breaches of cold chain, non-compliance with 
specifications and damaged products. 
Sources of Quality Defect Reports 
While as in previous years, companies accounted for 
the majority of reports of quality defects received 
(54%), there was a year-on-year reduction of 22% in 
the number of reports from this source. The reduction 
in this reporting category can be partly attributed 
to a revision of the IMB Guide to Reporting Quality 
Defects which provided further guidance for industry 
stakeholders on which types of quality defects are 
reportable / non-reportable. 
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Recalls of Human and Veterinary Medicinal 
Products 
In order to protect the health and safety of patients, 
it is deemed necessary in certain cases to withdraw, 
or recall, products from the Irish market. During 
2012, there were 141 medicine recalls of which 136 
related to human medicines and five related to 
veterinary products. The recall of a batch (or batches) 
of medicines occurred in approximately 19% of all 
quality defect cases investigated during the year, 
compared to 28% in 2011. This reduction was mainly 
due to the number of multiple product recalls which 
occurred during 2011.
cause of Recalls - human Medicines 2011 2012
Contamination Issue 24 21
Stability 13 15
Unauthorised Product on the Irish Market 8 14
Non-compliance with Marketing Authorisation 2 11
Printed Packaging Component Issue 17 11
Non-compliance with Specifications 28 6
Product Mix-Up 2 6
Erroneous Distribution 3 5
Lack of Sterility Assurance 7 5
Adverse Event / Change in Benefit/Risk Ratio 4 4
Non-printed Packaging Component Issue 5 4
Lack of Therapeutic Efficacy 2 3
Undeclared Active Substance 5 2
Damaged product 38 1
Product Preparation / Administration Issue 9 1
Non-adherence to Cold Chain 67 0
Falsified Medicine Issue 0 0
Non-compliance with GMP 0 0
Other 6 27
Total 240 136
cause of Recalls - veterinary Medicines 2011 2012
Non-compliance with Specifications 0 2
Stability 1 1
Contamination Issue 0 1
Printed Packaging Component Issue 0 1
Non-adherence to Cold Chain 3 0
Damaged Product 8 0
Unauthorised Product on the Irish Market 1 0
Total 13 5
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Of the 141 recalls, 8% involved products which were 
recalled to patient / user level, 55% to pharmacy / 
retail level and 37% to wholesale level. While there 
was a 41% annual decrease in patient / user level 
recalls, this corresponded with a 41% decrease in 
critical quality defects impacting Ireland. 
Other findings from the recall programme include 
the following:
•	 Exempt	medicinal	products	accounted	for	18	
(13%) of human medicinal product recalls.
•	 Compounded	products	for	human	use,	
accounted for 29 (21%) of all recalls. As already 
outlined, 23 of the recalls related to one issue at 
an Irish compounding facility.
•	 Of	the	products	recalled	from	the	Irish	market,	 
45 (32%) were manufactured at an Irish facility.
SAMPlIng And AnAlySIS PRogRAMMe
The IMB’s sampling and analysis programme for 
medicines for human and veterinary use contributes 
to our monitoring of the quality and safety of 
medicines on the Irish marketplace as well as to the 
identification of borderline medicinal/non-medicinal 
products that may be present.
This is achieved through the analytical testing 
and/or examination of packaging and labelling of 
active substances, medicinal products, borderline 
medicinal/non-medicinal products and enforcement-
related samples. 
A total of 435 product samples were sent for 
analytical testing and/or examination in 2012.
Analytical Testing 
There were 287 medicines and other product 
samples tested during the year in review. Of these, 
273 were obtained from the Irish marketplace and 
14 originated from other EU marketplaces as part 
of IMB’s involvement in EU-wide work-sharing 
programmes.
Approximately 39% of the analytical work carried out 
related to enforcement and borderline medicinal/
non-medicinal product samples while the remainder 
related to medicinal products within the legal supply 
chain. 
Product categories selected for Analytical Testing in 2012 number of Samples Analysed
Enforcement-related and borderline products 121
Human medicinal products (nationally and centrally authorised,  
parallel imports, biological, export only) 158
Veterinary medicinal products (nationally authorised including biologicals 8
Total 287
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Examination of Packaging and Labelling 
During 2012, 190 medicinal and other products on 
the Irish marketplace were examined. 
A significant element of this programme was directed 
towards examining the adequacy of safety-related 
information on package leaflets. This work resulted 
in the identification of significant non-compliance 
issues, each of which required further follow-up 
activity.
Participation in Eu Co-ordinated Market 
Surveillance Activities
The IMB is an active participant in EU programmes, 
co-ordinated through the Official Medicines Control 
Laboratories (OMCL) Network, that involve the 
sampling and analysis of medicinal products on 
behalf of the European Medicines Agency.
We participated in the sampling of 13 and the 
analysis of 17 centrally authorised medicinal 
products, while 13 MRP/DCP products from the Irish 
market were analysed at OMCLs in other countries.
Additional work sharing activity included:
•	 The	analysis	of	nine	borderline	products	by	the	
UK’s	OMCL	at	the	request	of	the	IMB;	
•	 The	analysis	of	12	Irish	market	medicinal	
products at the UK’s OMCL as part of an ongoing 
falsified medicine detection project running in 
conjunction	with	the	UK	regulator,	the	MHRA;
•	 The	microbiological	analysis	of	26	samples	for	the	
IMB at the Finnish and Czech OMCLs.
Principal Findings
The laboratory analysis findings included five out-
of-specification results and 24 deficiencies in the 
analytical methods for a total of nine products. Each 
non-compliance was followed-up with the relevant 
companies until the issues could be closed.  
The packaging and labelling findings consisted of 26 
non-compliances which included issues relating to 
product information details, the application of Braille 
on product packaging, incorrect/out-of-date package 
leaflets and SPCs, and the over-labelling of parallel 
imported products.
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description of products examined number of samples examined
Medicinal products subjected to general compliance monitoring for  155 
packaging and labelling attributes 
Medicinal products subjected to Braille-compliance checks 28
Product usability checks 3
Borderline Medicinal / Non-medicinal products associated with  
IMB Classification Committee work 4
Total 190
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RETAIL SALES MONITORING 
Exempt Medicinal Products Programme
Registered doctors and dentists are permitted to 
prescribe unauthorised medicines for individual 
patients under their direct responsibility in order 
to fulfil the special needs of those patients. Such 
products are defined as ‘exempt medicinal products’.
In accordance with the Medicinal Products 
Regulations of 2007-2012, wholesalers and 
manufacturers of medicinal products are obliged to 
provide certain information to the IMB in relation to 
any exempt products that they source. This is done by 
submitting electronic notification to an IMB database. 
The main purpose of receiving such information is to 
facilitate, when required, the effective recall of any 
defective exempt medicinal products from the Irish 
market. 
The total number of packs of exempt medicinal 
products notified was 1,661,483, an increase of 13% 
on 2011. The IMB continues to work with stakeholders 
in several areas to identify and develop solutions 
aimed at limiting the use of exempt products in 
Ireland.
A number of non-compliances were identified 
with the supply of exempt products and the IMB 
monitored the implementation of corrective actions 
at the companies concerned.
General Retail Sale Investigations
We operate both a proactive and reactive risk based 
monitoring programme that encompasses retail 
outlets such as grocery shops, health food shops and, 
where necessary, pharmacies.  
This retail monitoring programme checks for:
•	 Medicines	that	have	not	authorised	for	
placement	on	the	Irish	market;	
•	 Pharmacy	confined	medicines	that	are	being	sold	
in	non-pharmacy	outlets;	
•	 Traditional	herbal	medicinal	products	(THMPs)	
and products containing herbal substances 
that require a THMP registration or marketing 
authorisation, respectively, before being placed 
on the Irish market.
 
The main findings and subsequent actions from the 
2012 programme included:
•	 The	recall	of	nine	unregistered	THMPs	(without	
transitional	protection);
•	 The	recall	of	two	unauthorised	products	
containing herbal substances that require a 
marketing authorisation before being placed on 
the	Irish	market;
•	 A	number	of	actions	arising	from	the	completion	
of 12 proactive inspections of retail outlets 
encompassing both health food shops and 
pharmacies during the fourth quarter of 2012. 
Certain issues arising from these inspections 
were	ongoing	at	year	end;
•	 The	identification	and	recall	of	a	total	of	59	
different unauthorised medicinal products from 
the Irish market. These included two products 
that were subject to prescription control and 
eight pharmacy-only products all of which were 
identified in non-pharmacy retailers.
Regulatory Compliance Inspections 
These inspections are carried out at the premises of 
marketing authorisation holders and are risk-based. 
The programme of inspections enables the IMB to 
inspect key areas of activity relating to the marketing 
and advertising of medicinal products in Ireland so 
as to determine the level of compliance with the 
relevant legal requirements. Areas of activity that 
have a high potential to impact upon the quality, 
safety and the safe use of medicinal products are the 
main focus of these inspections.  
Two such inspections were carried out and a number 
of significant non-compliances were identified. 
Monitoring and follow-up of these compliance issues 
were continuing at year end.  
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Human Medicines Advertising Compliance 
Programme
It is the role of the IMB to monitor and review 
advertising and promotion activities by the 
industry for compliance with the requirements of 
the Medicinal Products (Control of Advertising) 
Regulations, 2007. 
Overall, 464 individual advertisements were 
reviewed for compliance during 2012 through the 
IMB’s advertising compliance programme. The 
main findings, categorised under the four main 
components of the programme, were as follows:
•	 Proactive	Monitoring
-  There were 352 advertisements across several 
different media reviewed. Of these, 77% were 
reviewed as part of risk based pre-planned 
proactive surveillance projects with the 
remainder selected on a random basis. 
- Arising from the pre-planned activity, 22 
advertisements were found to be non-
compliant while 23 were found to be non-
compliant during random surveillance work. 
•	 Inspection	of	Company	Advertising	Programmes	
and Related Activities
- As previously outlined, two regulatory 
compliance inspections were carried out at 
the offices of marketing authorisation holders. 
- During one of these inspections, the 
advertising programmes and activities were 
reviewed in detail and one major deficiency 
was identified.   
•		 Advertising-related	Complaints
- A total of 18 advertising-related complaints 
were received primarily from healthcare 
professionals, companies, the general public 
and IMB staff. As part of the investigation of 
these complaints, 76 advertisements were 
reviewed. 
- Of the complaints received, 7 complaints were 
upheld concerning approximately 59 non-
complaint advertisements. Three complaints 
were carried into 2013. 
•	 Advertising-related	Queries
- There were 89 advertising-related queries 
received from a range of interested parties 
resulting in the review of 36 advertisements. 
Of those, eight were considered to be non-
compliant.  
 Total Advertisements non-compliances   
  Reviewed Identified
Proactive Monitoring: Pre-planned Projects 9 271* 22 individual advertisements were  
   non-compliant
Proactive Monitoring: Randomly 13 82* 24 individual advertisements  
Selected Projects    were non-compliant
MAH Inspections Performed 2 Multiple 1 major deficiency identified
Complaints Received 18 76* 59 advertisements were found to be  
   non-compliant
Queries Received 89 36* 8 advertisements were found to be  
   non-compliant
*Note: Some of these figures include website advertisements, and each page of a website is counted as one   
 advertisement, because multiple pages can have multiple advertisements.  
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A breakdown of advertisements reviewed by product 
type is provided in the accompanying table. Of the 
346 advertisements promoting prescription-only 
products, 54 (16%) were found to be non-compliant. 
In respect of advertisements promoting over-the-
counter medicines, 23 (25%) were deemed non-
compliant.
In all cases of non-compliance identified by the 
different elements of the programme, the IMB 
supervised the adoption of the necessary corrective 
and/or preventative actions by the marketing 
authorisation holder. In a small number of cases, this 
follow-up was ongoing at year end.
Advertisements Reviewed in 2012 by Product Type
POM Medicine
OTC Medicine
Borderline Medicine
Borderline Food supplement
Exempt
Borderline Food
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MEDICAL DEVICES
vIgIlAnce 
Post-market surveillance and vigilance is a key 
element in protecting the health and safety of those 
who use medical devices and is a core function of the 
IMB.
The medical devices vigilance system was established 
under the European medical device directives (93/42/
EEC, 90/385/EEC and 98/79/EC). Together with the 
Guidelines on a Medical Devices Vigilance System 
(MedDev 2.12-1), the directives detail the reporting 
requirements for medical devices manufacturers to 
national competent authorities such as the IMB. The 
MedDev guidelines also outline the obligations on 
competent authorities to share information reported 
to them with each other and with the European 
Commission. The vigilance system refers to the 
process of notification and evaluation of vigilance 
reports. 
The IMB’s reporting system for medical devices is 
intended to protect the health and safety of patients, 
users and others by reducing the likelihood of the 
same type of incident occurring elsewhere and to 
correct product problems.
2012 Reports
A total of 2,225 medical device vigilance reports were 
received and assessed representing a 25% increase 
on 2011. As can be seen from the accompanying 
graph, there has been a consistent upward trend 
in the number of vigilance cases received annually. 
This is a result of greater clarity on reporting criteria, 
communication of issues among Member States and 
the IMB encouraging reporting on an ongoing basis.   
Manufacturers accounted for 53% of all vigilance 
reports received in 2012 while 34% were received 
from competent authorities. Users accounted for 12% 
of reports, up from 7% in 2011. In total, 45% of the 
reports received were as a result of an incident on the 
Irish market.
Concerning the regulatory response to the reports 
received, 51% resulted in an action being taken in 
Europe. In Ireland, the IMB published online 441 
manufacturer’s field safety notices directly affecting 
the local market. These notices are intended to 
inform users of safety issues relating to medical 
devices. In addition, there were 204 product removals 
conducted in Ireland in 2012. Safety information was 
also highlighted to the public through IMB safety 
notices. There were 19 such notices sent to the 
relevant interest groups and published on the IMB 
website. During the year in review, the IMB issued 81 
national competent authority reports. 
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2012 Reports by Product Type
Orthopaedic implants, surgical equipment, and 
infusion and transfusion devices accounted for 
a large proportion of vigilance reports received. 
A number of field actions relating to automated 
external defibrillators were also received. The 
continued reporting of revision procedures 
associated with the ASR Articular Surface 
Replacement and ASR XL Acetabular system 
manufactured by DePuy contributed to the majority 
of orthopaedic implant reports received. In addition, 
vigilance reports following the explanation of breast 
implants manufactured by Poly Implant Prothese 
following a global recall in 2010 continued to be 
submitted to the IMB. There have been a number of 
reported revision surgeries in relation to implanted 
defibrillation leads.
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In the area of in-vitro diagnostic (IVD) devices, the 
largest number of vigilance reports received related 
to clinical biochemistry. Field safety corrective 
actions relating to clinical biochemistry reagents and 
analysers continued to have a high impact on the 
number of IVD vigilance cases.
coMPlIAnce
Medical device compliance activities ensure that 
medical devices on the Irish market comply with 
the relevant European directives. All potential safety 
and non-compliance issues identified are subject to 
investigation and follow up. In 2012, a total of 725 
compliance cases were investigated. A significant 
amount of proactive compliance work was focused 
in the area of self-test IVDs. Similar to previous years, 
issues identified in 2012 and investigated as part 
of compliance cases included labelling problems, 
missing or incorrectly attached CE marking and 
classification issues. Of the total cases notified to the 
IMB, 86% were from other competent authorities 
and mainly related to notified body certificate 
withdrawals.
MARKET COMPLIANCE OF COSMETICS
MARkeT SuRveIllAnce
Post market surveillance activity relating to cosmetics 
involves close co-operation between the IMB and the 
HSE. In this context, the HSE Environmental Health 
Service and the three Public Analysts’ Laboratories 
based in Cork, Dublin and Galway were involved in 
the preparation of the market surveillance schedule 
and the subsequent sampling and analysis of 
cosmetic products on the Irish market. 
Reactive surveillance included investigation of 
quality related complaints (compliance cases) and 
reports of undesirable effects relating to the use of 
cosmetics (vigilance cases). Compliance cases were 
initiated and these accounted for the vast majority 
of investigations. A total of 16 vigilance cases were 
investigated. 
There were also six recalls of cosmetic products in 
response to public health concerns.
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RAPEX Alerts
Reactive surveillance of cosmetic products also 
includes investigation of in-coming RAPEX Alerts 
(EU safety alerts for cosmetic and other consumer 
products). The National Consumer Agency (NCA) is 
the national contact point for receipt and circulation 
of these alerts. In conjunction with the HSE, the IMB 
investigated 105 RAPEX Alerts during 2012. In respect 
of the subsequent five products found on the Irish 
market, a reaction report was submitted to the NCA 
outlining the market actions taken.
INSPECTIONS AND AuDITS 
As part of our regulatory role, the IMB is focused on 
ensuring industry compliance with relevant standards 
and legislation. Our inspections and audits work 
programme includes:
•	 Regular	inspections	of	manufacturers	and	
wholesalers of medicines to check for compliance 
to EU guidelines on Good Manufacturing Practice 
(GMP) and Good Distribution Practice (GDP), 
respectively. 
•	 Inspection	of	clinical	trial	sites	for	compliance	
with EU and International Conference on 
Harmonisation (ICH) guidelines on Good Clinical 
Practice (GCP). 
•	 Inspection	for	compliance	with	Good	
Pharmacovigilance Practice of the systems put 
in place by marketing authorisation holders 
for dealing with reports of adverse reactions to 
medicines.
•	 Regular	audit	of	the	NSAI,	the	notified	body	for	
medical devices that is designated by the IMB. 
•	 Proactive	audit	of	manufacturers	of	Class	I	
devices and ‘for cause’ audits as required, for 
example, as part of the follow-up to a defect.
•	 Inspection	of	blood	and	tissue	establishments	
for compliance with applicable EU guidelines on 
the quality and safety of blood, blood products, 
tissues and cells. 
•	 Inspection,	often	in	conjunction	with	the	
National Drugs Unit of An Garda Síochána, of 
manufacturers and wholesalers of medicines 
containing controlled drugs (CD) and of 
precursors (chemicals that can be used in the 
preparation of illicit drugs). 
oveRvIeW of The 2012 InSPecTIon 
PRogRAMMe
During 2012, there was a total of 289 national 
inspections and audits performed compared to 271 
in 2011. A further 26 foreign inspections and audits 
were performed in the past 12 months. The average 
number of days required to close-out the inspections 
and audits was 76. 
Performance Results and Statistics   2008 2009 2010 2011 2012
No. of national inspections and audits  228 238 293 271 289
No. of foreign inspections and audits  27 28 30 29 26
% inspections and audits closed on time (≤ 90 days) 67 58 62 66 61
Average time for close-out (days) 89 112 194 79 76
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During the 12 months under review:
•	 102	GMP	inspections	were	performed.	These	
included 25 inspections in non-EEA countries, 
five of which were carried out at the request of 
the European Medicines Agency and related to 
centrally-authorised products.
•	 147	inspections	were	conducted	to	assess	
compliance with GDP and CD requirements. Of 
these inspections, five specifically related to the 
assessment of compliance with THMP legislation. 
•	 19	GCP	inspections	were	completed	all	of	which	
were carried out at investigator sites in Ireland.  
•	 4	pharmacovigilance	inspections	were	
completed. Three of these inspections were 
at the facilities of Irish based marketing 
authorisation holders while one foreign 
inspection for centrally-authorised veterinary 
medicinal products was conducted at the request 
of the European Medicines Agency.
•	 6	audits	were	conducted	of	authorised	
representatives of medical device manufacturers 
while 13 audits were conducted of manufacturers 
of custom made medical devices. Audits of 
medical device manufacturers included proactive 
surveillance audits.  
•	 1	surveillance	audit	of	the	NSAI,	the	notified	body	
for medical devices in Ireland, was conducted. 
This took place at the NSAI’s offices and also via 
observation of NSAI staff performing audits at 
device manufacturers’ premises. 
•	 7	blood	establishment	inspections	were	
completed, including inspection of facilities 
maintained by the Irish Blood Transfusion Service 
(IBTS).
•	 13	tissue	establishment	inspections	were	
carried out including an inspection related to 
an application for a new tissue establishment 
authorisation.
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ENFORCEMENT 
Illegal activity involving the manufacture, supply 
and sale of medicines or medical devices can 
potentially have consequences for public health. 
It is the role of the IMB to investigate potential 
breaches of human medicinal product and medical 
device legislation. Where necessary, we will take the 
appropriate corrective action including possible legal 
proceedings.
enfoRceMenT cASeS
During 2012, 3,911 enforcement cases were initiated, 
down 14% on 2011 (4,549). The reduction represents 
a decrease in the number of importations by mail 
order of prescription only medicinal products that 
were detected. There were 3,925 cases closed.
deTAIned MedIcIneS
The quantity of medicinal products detained 
reduced marginally in 2012 to a total of 758,276 
dosage units. This represents a slight decrease 
when compared to 2011. These detained products 
included 153,042 dosage units indicated for weight-
loss products and containing the active substance 
sibutramine. Sibutramine is not permitted in any 
authorised medicinal product in the EU. In addition, 
52,089 dosage units detained related to Erectile 
Dysfunction products. Other products contained 
diazepam, zopiclone, melatonin, Tribulus terrestris, 
Corticosteroids and anabolic steroids. The majority of 
these unauthorised medicinal products supplied into 
Ireland originated from India and China.
Medicinal products destroyed during the year, in 
compliance with the Waste Management Acts 1996 
and 2003, amounted to 1,065 kilograms.
A summary of the IMB enforcement data is provided 
in the accompanying table.
InTeR-Agency co-oPeRATIon And 
PAngeA v
The IMB liaises with other enforcement agencies, 
both nationally and internationally, to stem the 
unauthorised flow of illegal medicinal products, 
medical devices and cosmetic products into and 
out of the State. During 2012, officers from the IMB, 
Revenue’s Customs Service and An Garda Síochána 
carried out a number of joint operations. These 
included joint activities under Operation Pangea 
V in September and October. This global initiative, 
co-ordinated by INTERPOL to identify and act against 
illegal websites supplying counterfeit and illegal 
medicinal products, involved 180 agencies from 
100 countries worldwide. This operation led to the 
detention in Ireland of 121,026 tablets, capsules and 
creams with an estimated value in excess of €375,000.
year 2008 2009 2010 2011 2012
Product detained 393,067  494,502  822,484  762,641  758,276  
 Dosage Units Dosage Units Dosage Units Dosage Units Dosage Units
Cases opened 3,037 3,729 3,936 4,549 3,911
Prosecutions 2 2 5 9 9
Product destroyed 1,902kg 2,601kg 1,400kg 4,519kg 1,065kg
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date court defendant outcome fines / costs
20/02/2012  Dublin District IMB v John Nolan Guilty on 13 charges pertaining  IMB awarded €3,000 costs 
 Court  to supply without a prescription /  and destruction order 
   no marketing authorisation.  for products detained. 
    
   Nine month custodial sentence  
   suspended for 2 years. 
20/02/2012 Dublin District  IMB v Yu (Eric) Gou Mr. Gou pleaded guilty to 15  IMB awarded €2,500 costs 
 Court  charges pertaining to no  and destruction order 
   manufacturer’s authorisation,  for products detained. 
   wholesaler’s authorisation or    
   marketing authorisation.  
    
   Nine month custodial sentence  
   suspended for 2 years. 
27/02/2012 Circuit Criminal DPP v James  Mr. Bellamy pleaded guilty to  Mr. Bellamy fined 
and Court Bellamy one charge of importation and  €100,000. 
20/04/2012   two charges of wholesale.  
  DPP v Harmony  
  Products Ltd Harmony Products Limited  Harmony Products 
   pleaded guilty to three charges. Limited fined €150,000. 
    
   Mr. Bellamy sentenced to three   
   years imprisonment with last   
   year suspended and also fined.
03/04/2012 Dublin District  IMB v Cosmic  Mr. Murphy pleaded guilty to two  Cosmic Closet Limited 
	 Court	 Closet	Limited;	 charges	supplying	unauthorised		 fined	€1,000	and	costs	of 
   medicinal products & received  €2,550 awarded to IMB. 
  IMB v Gary the Probation Act. 
  Murphy 
   Cosmic Closet Limited pleaded 
   guilty to four charges.
06/07/2012 Supreme Court Applicant:  Mr. Carmody commenced Judicial    
  Paschal Carmody.  Review proceedings in 2006  
   Judicial Review to quash convictions imposed 
  Appeal in 2005. The relief sought was 
   refused by the High Court on  
   28 January 2010. Mr. Carmody  
   appealed to the Supreme Court  
   (3 March 2010). The appeal was  
   struck out on 6 July 2012.
PRoSecuTIonS / JudIcIAl RevIeWS 2012
The IMB initiated, or were party to, 11 prosecutions and court proceedings during the course of 2012.
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date court defendant outcome fines / costs
19/07/2012  Balbriggan IMB v David Power Mr. Power and Green EcoTech  Mr. Power was fined   
 District Court IMB v Green Limited both pleaded guilty to 11  €1,250 and Green 
  EcoTech Limited counts of the supply of medicinal  EcoTech Limited 
   products without a prescription  was fined €1,750. 
   and without having a Marketing  The Court awarded costs 
   Authorisation. to the IMB of €3,550.
23/07/2012 High Court  District Justice   The President of the High Court  
  Kilrane respondent granted the Judicial Review to the 
  in the Judicial IMB in relation to a ruling  
  Review regarding Section 33, Irish    
   Medicines Board Acts 1995-2006
11/10/2012 Midleton IMB v Brian Mr. Buckley pleaded guilty to six  Mr. Buckley was fined 
 District Court Buckley charges of supply of prescription  fined €6,000 and the 
   only medicinal products without  Court awarded €3,000 
   a prescription and by mail order costs to the IMB.
24/10/2012 Bray District  IMB v Li Tao Li Tao pleaded guilty to the retrial  Probation Act applied  
 Court  supply of unauthorised prescription  and donation to charity 
   only medicinal products. of €2,000 (and costs 
    of €2,000 awarded 
    to the IMB).
24/10/2012 Bray District  IMB v Fei Tan The Judge dismissed this case.  Detained products 
 Court  He ordered that the prescription  ordered into possession 
   only medicinal products detained  of IMB for destruction. 
   not be released to Fei Tan.  
06/12/2012 Dun Laoghaire  IMB v John Furlong This case related to the importation  Tanning Warehouse 
 District Court IMB v Tanning of 14,400 slimming capsules  Limited fined €750. 
  Warehouse Limited containing sibutramine.  The Probation Act 
   Both parties pleaded guilty. applied to Mr. Furlong   
    and costs of €2,250  
    awarded to the IMB.
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LEGISLATIVE AND REGULATORY 
DEVELOPMENTS
The legislative and regulatory environment in which the IMB 
operates is constantly evolving. As a result, the remit and 
role of our organisation continues to change and expand in 
line with national and European legislative changes and in 
response to the addition of further competencies. 
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This section of our annual report outlines the most 
significant legislative and regulatory developments 
during 2012 for each of the healthcare products we 
regulate, how these changes influenced the work of 
the IMB and, where relevant, the associated impact 
on stakeholders.
HuMAN MEDICINES
neW eu PhARMAcovIgIlAnce 
legISlATIon
New European Union (EU) pharmacovigilance 
legislation came into effect and was transposed into 
Irish law in July 2012. The aim of the new legislation 
is to further protect public health by strengthening 
the current European-wide system for monitoring the 
safety of medicines. In particular, the new legislation 
aims to improve the pharmacovigilance system in the 
EU, enhancing the scope of adverse drug reaction 
reporting and introducing special provisions for 
medicines that need additional monitoring. The 
legislation also aims to ensure that members of the 
public become better informed about the benefits 
and risks of taking medicines.
Many of the new provisions contained in the 
legislation have been effective since July 2012. These 
include:
•	 The	publication	of	guidance	documents	for	
stakeholders;
•	 The	establishment	of	the	Pharmacovigilance	Risk	
Assessment	Committee	(PRAC);	
•	 Increased	transparency	such	as	the	publication	of	
PRAC agendas and minutes. 
The implementation of additional provisions, such as 
the collection of key information on medicines and 
enhanced analysis and understanding of data and 
information, will continue beyond 2012.
Throughout the year in review, the IMB continued 
to work with a wide range of stakeholders including 
the European Medicines Agency and other national 
regulators in planning for and implementing 
provisions contained in the new legislation. Patients, 
the pharmaceutical industry and healthcare 
professionals were also consulted by the regulatory 
authorities to ensure effective implementation. 
The IMB actively contributed to the drafting of 
the first wave of Good Vigilance Practice modules. 
Additionally, further information and guidance was 
made available to stakeholders via a dedicated 
section of the IMB website. The PRAC agenda, 
the meeting highlights and minutes are also now 
published on the website following each PRAC 
meeting. Within the IMB, new business processes 
were established and a number of existing business 
processes were revised. 
ongoIng IMPleMenTATIon of The 
TRAdITIonAl heRBAl MedIcInAl 
PRoducTS dIRecTIve
As outlined earlier in this report, the number 
of applications received by IMB has remained 
disappointingly low. Given that the registration 
process is a new regulatory requirement, progress 
in assessing applications has been in line with 
expectation. The IMB has been working closely with 
applicants, in providing the necessary guidance 
and support to ensure that appropriate standards 
of quality, safety and efficacy for registration of 
products are reached, and also to encourage 
applications through the registration scheme. 
Meetings were held with a number of industry and 
company representatives and a total of 123 queries 
specifically relating to traditional herbal medicines 
were received and processed by IMB during 2012. 
Other initiatives included the provision of up-to-date 
guidance materials to relevant stakeholders.
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fAlSIfIed MedIcIneS dIRecTIve
In July 2011, the EU adopted new legislation 
(Directive 2011/62/EU, amending Directive 2001/83/
EC) on falsified medicines for human use. The 
directive aims to strengthen the protection of 
patients and consumers by preventing falsified 
(counterfeit) medicines entering the legal supply 
chain. Preparations continued during 2012 for the 
introduction of elements of this directive which are 
required to be transposed nationally by January 
2013. The remaining measures will be transposed at 
defined times thereafter.
One of the important changes in the Directive, to 
apply from 2 July 2013, concerns the new rules on 
importing active substances into the Europe. The IMB 
led an information gathering initiative by conducting 
a survey of medicinal product manufacturers in 
Ireland that use active substances produced outside 
of the European Economic Area (EEA). The methods 
used by the IMB were adopted by a HMA falsified 
medicines task force to determine the number of 
non-EEA active substance sites (and their locations) 
supplying finished product manufacturers into 
Europe. 
Concerns have been raised that the new rules under 
this Directive could lead to shortages of medicines. 
However, this area was evolving rapidly at year end 
and the IMB continues to monitor developments 
closely.
decenTRAlISed PRoceduReS WIndoW 
The IMB actively participates in this European 
approval system and a ‘window’ for requests for 
Ireland to act as RMS for DCP applications was first 
introduced in 2010. In 2012, this window closed on 
18 July. All 18 requests received were considered 
and the five successful applicants were allocated a 
dedicated slot for assessment.
clInIcAl TRIAlS RegulATIon 
In July 2012, the European Commission published 
a proposal on a Regulation to revise the EU clinical 
trial legislation. IMB staff actively participated in the 
consultation and development stages of the draft 
Regulation.
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conTRIBuTIng To The euRoPeAn And 
gloBAl RegulAToRy neTWoRk 
europe
Throughout 2012, we continued to actively 
participate in the European medicines regulatory 
system. IMB scientific and technical staff contributed 
to a broad range of committees and working parties, 
preparing papers as appropriate, at the European 
Medicines Agency, the European Commission, the 
HMA, and at other fora. This broad and significant 
involvement of IMB staff at European meetings is 
outlined in Appendix 4.
In addition to our regular participation at a European 
level, highlights from the past year included the 
following: 
•	 The	Irish	delegate	to	the	PRAC	was	elected	as	
Vice-Chair of the committee for a 3-year period. 
•	 The	Irish	Delegate	to	the	PRAC	represented	
the EU at the ICH E2C (R2) Expert Working 
Group tasked with evaluating the ICH 
pharmacovigilance documentation, conducting  
a gap and potential improvement analysis and 
drafting a new ICH Guideline covering periodic 
benefit risk evaluation reporting. This process 
reached Stage 4 in November 2012. The concept 
paper highlights the fact that the technology and 
science of pharmacovigilance has progressed 
significantly and the associated documentation 
has not kept pace. In order to address this and 
to ensure that regulatory and industry resources 
are more productively linked to public health 
protection and promotion, the E2C guideline has 
been revised.
•	 IMB	experts	were	significantly	involved	in	a	joint	
project team, involving representatives from 
Member States and the European Medicines 
Agency, to support the implementation of 
the new EU pharmacovigilance legislation. In 
addition, the IMB was represented in the project 
coordination group and at project oversight 
level as a member of the HMA European Risk 
Management Strategy Facilitation Group. Key 
deliverables included input to the drafting of 
the technical contribution on the European 
Commission’s Implementing Measures and the 
first wave of Good Vigilance Practice Modules.
World Health Organization 
The IMB Pharmacovigilance Manager continued to 
represent the World Health Organization (WHO) as 
a member of the Board of the Uppsala Monitoring 
Centre (UMC) and WHO Collaborating Centre 
for International Drug Monitoring during 2012. 
In addition, IMB staff participated at the annual 
meeting of national centres participating in the 
WHO international drug monitoring programme 
and continued to provide details of reports 
received nationally to the WHO for inclusion on its 
international database. 
The volume of adverse reaction reports from Ireland 
continued to fall within the highest reporting rates 
among participating countries (111 full country 
members as of February 2012). As can be seen from 
the accompanying graph, Ireland ranked as the ninth 
highest reporter for the year during 2012. 
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Pharmaceutical Inspection Co-operation  
Scheme (PIC/S)
At the beginning of the year the Inspection Manager 
took up her appointment to the Executive Bureau 
(management group) of the PIC/S.
In January, the IMB hosted a training seminar for 
new inspectors under the auspices of the PIC/S. 
The seminar was developed to provide a thorough 
grounding to new GMP inspectors on the conduct 
of inspections of manufacturers and was a further 
contribution to the harmonisation of global 
inspection standards. Subsequently in October, we 
also conducted a training seminar for new GMP 
inspectors from the Commonwealth of Independent 
States region organised by the State Administration 
of Ukraine on Medicinal Products (SAUMP).
Also in 2012:
•	 Two	IMB	trainers	presented	talks	and	hosted	
workshops at the PIC/S annual seminar in Kiev 
on the subject of ‘Qualification and Validation – 
Today and Tomorrow’.
•	 Active	substance	inspectors	from	IMB	
participated in the steering group tasked with 
developing the PIC/S International API Inspector 
Training Programme and two inspectors 
contributed to advanced training for inspectors 
from a number of countries in Washington DC, 
USA.
•	 An	IMB	inspector	presented	at	the	PIC/S	Expert	
Circle on Quality Risk Management.  
International Pharmaceutical Federation (FIP)
FIP is the global federation representing pharmacists 
and pharmaceutical scientists worldwide. The IMB’s 
Director of Scientific Affairs is a member of the 
FIP special interest group on dissolution testing. 
Dissolution testing is considered an important tool in 
both drug development and quality control. 
During 2012, the Director of Scientific Affairs 
contributed actively to the activities and 
deliberations of the group. This included a 
presentation to the FIP annual (centennial) 
conference held in Amsterdam in October and a 
contribution to a workshop on dissolution testing 
held in June in Romania.
CONTRIBuTING TO NATIONAL HEALTH 
INITIATIVES
Memorandum of understanding with the Irish 
Sports Council
In May, the IMB and the Irish Sports Council signed 
a Memorandum of Understanding to formalise the 
sharing of information and intelligence in an effort 
to protect Irish athletes and to combat the illegal use 
of medicinal products. In recent years, the two state 
agencies have co-operated and shared intelligence 
in the area of anti-doping. This Memorandum of 
Understanding places this relationship on a formal 
basis and signals that it will have a more prominent 
role in the general battle against doping in sport. 
 
Consumer Warning on Health Dangers of Illegal 
Stimulant (DMAA)
In July, the IMB and the Food Safety Authority of 
Ireland issued a joint precautionary message for 
consumers on the health dangers of taking food 
supplements or products containing the substance 
DMAA (1,3-dimethylamylamine). The warning came 
after a number of adverse reactions internationally 
related to products containing DMAA.
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HEALTH (PRICING AND SuPPLy OF 
MEDICAL GOODS) BILL 2012
The Health (Pricing and Supply of Medical Goods) Bill 
2012, which is due to be enacted and commenced in 
the first half of 2013, outlines the circumstances under 
which medicines are considered interchangeable 
(also often referred to as generic substitution) and 
where they are not considered interchangeable. The 
purpose of the legislation is to provide for generic 
substitution of medicines that are considered 
interchangeable so that a pharmacist can dispense 
a less expensive medicine than the one prescribed. 
Once enacted, the IMB will be charged with 
responsibility for the establishment, consultation, 
publication and subsequent maintenance of a List 
of Interchangeable Medicinal Products, which will 
be grouped together under their respective active 
substance, strength and pharmaceutical form(s). 
During 2012, the IMB has actively supported 
the Department of Health in preparation for the 
implementation of this legislation. This included IMB 
contributions to a series of stakeholder meetings 
held in November. An internal project group was 
also established for purposes of developing internal 
procedures to enable the generation and publication 
of the lists of interchangeable medicinal products.
NEW DOSAGE INSTRuCTIONS FOR 
CHILDREN’S LIQuID PARACETAMOL 
MEDICINES
New dosage instructions for liquid paracetamol 
medicines for paediatric use were announced by the 
IMB in March 2012. The updated instructions include 
more precise age and dosage bands to ensure that 
children get the most effective amount of medicine 
for their needs whilst making it easier for parents and 
carers to know how much paracetamol they should 
give their children. The changes were highlighted 
by broadcast and print media while the product 
information (package leaflets and labels) for these 
products was subsequently updated to reflect these 
new recommendations. 
RECOMMENDATION THAT ECHINACEA-
CONTAINING HERBAL PRODuCTS 
SHOuLD NOT BE uSED IN CHILDREN 
In August, the IMB advised that children’s herbal 
products containing Echinacea should not be 
used for children under 12 years of age due to a 
lack of scientific data to support their use. The IMB 
communicated with retailers and others within the 
supply chain to inform them of this recommendation 
and to request that children’s echinacea-containing 
products were removed from sale. The action was 
further highlighted via the media.  
ADVERTISING COMPLIANCE 
PROGRAMME
The IMB participated in the first meeting of a 
new regulatory network known as the Forum on 
Advertising of Medicines (FOAM), hosted by the 
UK’s Medicines and Healthcare Products Regulatory 
Agency (MHRA) in London in November. This forum 
is under the auspices of the HMA and comprises 
advertising regulators from 30 countries (all 27 
EU Member States as well as Norway, Iceland and 
Croatia). The forum aims to provide a platform for the 
exchange of information about regulatory practice / 
challenges and advertising cases with cross-border 
relevance.   
There was one meeting of the Advertising Technical 
Working Group in 2012. This group is comprised of 
IMB staff members as well as representatives from 
the pharmaceutical industry in Ireland.  It is a forum 
for the communication of advertising-related issues 
between the IMB and the industry representatives 
with a view to the promotion of good practice and 
compliance in this area.  
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ADVISORy COMMITTEE FOR HuMAN 
MEDICINES
The Advisory Committee for Human Medicines, 
which is appointed by the Minister for Health, met 
four times during 2012. The committee assists and 
advises the IMB Board in relation to any matters 
pertaining to the safety, quality or efficacy of 
medicinal products for human use as are referred to 
it by the Board. It also reviews the licenses for human 
medicinal products as approved by the Management 
Committee.
There are also a number of sub-committees 
appointed by the Advisory Committee for Human 
Medicines. 
•	 The	Clinical	Trials	Committee	met	12	times	
during the year. The Committee considered the 
suitability of trials submitted for approval under 
the European Communities (Clinical Trials on 
Medicinal Products for Human Use) Regulations 
2004, (S.I. No. 190 of 2004).
•	 The	Herbal	Medicines	Committee	met	two	
times in 2012. The Committee considered a 
number of matters including the Traditional 
Herbal Medicinal Products Registration Scheme 
and updates from the Committee on Herbal 
Medicinal Products of the European Medicines 
Agency.
VETERINARy MEDICINES
conTRIBuTIng To The euRoPeAn 
RegulAToRy neTWoRk
The IMB continued to be an active participate in the 
European medicines regulatory system for veterinary 
medicines during 2012. The extensive involvement of 
IMB staff members as part of European committees 
and working parties is outlined in Appendix 4. In 
addition to this regular participation at a European 
level, highlights from the past year included the 
following: 
•	 In	respect	of	the	proposed	new	legislation	for	
veterinary medicinal products, preparatory 
workshops were held by the European 
Commission during the summer of 2012. The 
IMB was an active contributor throughout 
this initiative which is expected to assist the 
Commission in developing the new legislative 
framework;
•	 The	IMB	is	a	participant	to	the	European	
Surveillance of Veterinary Antimicrobial 
Consumption (ESVAC). This initiative is part of 
the European response to antibiotic resistance 
through the surveillance of the use of veterinary 
antibiotics in the region. The IMB is committed 
to this annual exercise and publishes the a 
report of the national consumption of veterinary 
antibiotics	on	an	annual	basis;
•	 The	IMB	continued	to	participate	in	both	the	
European Surveillance Strategy group and the 
Antimicrobial Resistance group at the HMA. The 
IMB is a regular contributor to both groups which 
are increasingly making use of teleconferencing 
rather than physical meetings. 
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Maximum Residue Limits for certain Flukicidal 
Medicines
The IMB welcomed the establishment in 2012 by 
the European Commission of maximum residue 
limits (MRLs) for the substances clorsulon, closantel, 
nitroxynil and triclabendazole. This followed a 
request from the IMB to the European Medicines 
Agency to determine MRLs for certain flukicidal 
veterinary medicines used in milk producing animals. 
The establishment of MRLs provides a more suitable 
reference level for residue monitoring purposes and 
is expected to encourage marketing authorisation 
holders to develop appropriate residue studies in 
pregnant or lactating livestock. This is in turn will 
establish appropriate withdrawal periods for milk 
for such animals. A referral procedure to harmonise 
the warnings/withdrawal periods on the labelling 
of products containing flukicidal substances was 
initiated by the Commission during the year. This is 
expected to lead to a harmonised approach to the 
labelling of affected veterinary medicines in 2013.
As a result of this IMB initiated process, consumers 
can have greater confidence in the safety of milk 
and milk products and it removes any uncertainty 
regarding the conditions of use of the affected 
products in pregnant cattle that are intended for milk 
production for human use. 
conTRIBuTIng To nATIonAl heAlTh 
InITIATIveS
The IMB continued to participate to an initiative of 
the Department of Agriculture, Food and the Marine 
to help minimise the development of anthelmintic 
resistance in Irish sheep. New symbols have been 
introduced on certain anthelmintics which will allow 
for more effective use of the medicines concerned. 
The success of the initiative will depend on efforts of 
stakeholders in educating users to the meaning of 
the symbols and in changing existing practices in the 
use of the products concerned.  
ADVISORy COMMITTEE FOR VETERINARy 
MEDICINES 
The Advisory Committee for Veterinary Medicines 
assists and advises the Board in relation to any 
matters pertaining to the safety, quality or efficacy 
of medicinal products for animal use as are referred 
to it by the Board. It also reviews the licenses for 
veterinary medicinal products as approved by the 
Management Committee. The committee met three 
times in 2012.
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MEDICAL DEVICES
RevISIon of euRoPeAn MedIcAl devIceS 
dIRecTIveS
In September 2012, the European Commission 
adopted proposals to introduce two Regulations 
to strengthen the EU medical devices regulatory 
system and to standardise the application of rules 
throughout the EU. The proposed medical device 
Regulation will replace the current directives on 
medical devices and active implantable medical 
devices (Directives 93/42/EEC and 90/385/EEC, 
respectively) and the proposed IVD Regulation 
will replace the in vitro diagnostic medical device 
directive (Directive 98/79/EC).
The IMB has contributed extensively over the past 
number of years to working groups and subgroups 
in the development of technical aspects of the 
regulatory system which may be reflected in the 
new legislative proposals. The IMB will act as an 
advisor to the Department of Health on the medical 
device proposals during relevant discussions at the 
European Council and European Parliament. This 
will include the period of the Irish Presidency of the 
Council of the European Union from January to  
June 2013.
 
CONTRIBuTING TO THE EuROPEAN 
REGuLATORy NETWORK
European Commission’s Joint Plan for Immediate 
Actions on Medical Devices
In early February, the European Commissioner 
for Health and Consumers wrote to all European 
Ministers for Health outlining a ‘joint plan of 
immediate actions’ with the objective of reinforcing 
the existing regulatory system for medical devices. 
The plan outlined actions for Member States and 
the Commission in respect of the functioning of 
notified bodies, market surveillance, coordination, 
communication and transparency. The IMB believe 
that the plan is critical to reinforcing the existing 
regulatory system for medical devices across Europe 
and to ensuring that European consumers are 
appropriately protected in advance of the future 
revision of the medical devices legislation in Europe.
The planning and the practical implementation of 
the joint plan utilised significant resource across the 
IMB. The most significant work items arising from the 
joint plan during 2012 included:
1. Review of class III notified bodies for medical 
devices. This action was completed by the IMB by 
the deadline of September 2012.
2. Analysis and communication of resource and 
activities relevant to market surveillance of 
medical devices which was completed by the 
revised deadline of September 2012.
3. Significant input to the preparation of an 
implementing Regulation and a Commission 
recommendation on notified bodies for medical 
devices in advance of the plan’s deadline.
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European Commission Guidance Documents
During 2012, the IMB chaired the European taskforce 
to revise the guidelines on the medical devices 
vigilance system (MEDDEV 2.12-1) which specifically 
includes in-vitro fertilisation / assistive reproduction 
technologies devices within the scope of the 
vigilance system as well as greater detail regarding 
the reporting requirements for devices which do not 
generally come into contact with patients.
Resourcing the European Medical Devices 
Regulatory Network
The IMB continued to engage actively during 2012 
in discussions with other European competent 
authorities, the European Commission and relevant 
stakeholders on how to optimise resourcing of the 
network for medical device regulation in Europe. 
These discussions, involving significant dialogue with 
the medical device industry associations, included 
examination of potential mechanisms for changing 
the current funding models for regulatory authorities 
to fee-based models. The IMB hosted two related 
workshops.
Co-operation between the HMA and the 
Competent Authorities for Medical Devices 
Networks
The IMB continued to promote discussions during 
2012 on enhancing cooperation and partnership 
between the HMA and the Competent Authorities 
for Medical Devicess (CAMD). The HMA and CAMD 
are the respective regulatory networks of national 
competent authorities for medicines and medical 
devices. Although these networks represent distinct 
regulatory frameworks, there are many aspects 
and technologies that are of common interest. In 
addition, the systems and structures around these 
networks could be developed for mutual benefit.
AdvISoRy coMMITTee foR MedIcAl 
devIceS 
The Advisory Committee for Medical Devices met 
four times in 2012. Regular updates were provided on 
key medical device issues, regulatory developments, 
the revision of the medical devices legislation 
and IMB activities in regulating medical devices. 
The committee also invited a number of external 
stakeholders, such as academic researchers, to make 
presentations to the Committee in respect of their 
activities.
ADVANCED THERAPIES
An advanced therapy medicinal product (ATMP) 
is a biological medicinal product which is a gene 
therapy medicinal product, a somatic cell therapy 
medicinal product or a tissue engineered product. 
This definition is set out in Directive 2001/83/EC, 
as amended to reflect new innovative therapeutic 
products. Given their innovative nature, applications 
for marketing authorisations for advanced therapy 
products proceed through the centralised procedure 
in accordance with Regulation 726/2004/EC.
During 2012, the IMB continued to actively participate 
in the European Medicines Agency’s Committee for 
Advanced Therapies (CAT). The IMB’s internal group 
on biological products and ATMPs also continued to 
meet regularly as a forum for information exchange 
and for discussion of areas of regulatory interest 
as relevant to ATMPs, blood, tissue and biological 
products.
Key developments in the ATMP area during 2012 
included the IMB’s participation in the planning and 
delivery of the ESOF Satellite Conference ‘Making 
Gene and Cell Therapy a Reality’. The IMB also drafted 
a specific guidance document to provide regulatory 
information to hospital-based manufacturers of 
ATMPs. This guide clarifies the IMB’s requirements 
for the manufacture and use of these medicines. The 
guide underwent public consultation during 2012. 
The outcome of consultation was positive and it is 
planned to formally publish the guide in early 2013.
59IMB ANNUAL REPORT 2012
HuMAN ORGANS FOR 
TRANSPLANTATION
This European Directive on standards of quality and 
safety of human organs intended for transplantation 
(Directive 2010/53/EC) was transposed into Irish 
legislation by Statutory Instrument (S.I. No. 325 of 
2012). Signed by the Minister for Health on 27 August 
2012, this legislation resulted in the appointment of 
the IMB and the HSE as the responsible Competent 
Authorities for implementation of different aspects 
of the Directive. In respect of the IMB, we are 
responsible for the inspection and authorisation of 
organ procurement and transplant centres and for 
the development of a system for reporting of serious 
adverse reactions and events.
During 2012, an internal multidisciplinary group 
continued to review the requirements of the directive 
from an IMB perspective and developed appropriate 
internal systems and procedures for implementation 
of these requirements. As part of this process, an 
initial report form for the notification of suspected 
adverse reactions and events associated with 
transplantation was developed and published on  
the IMB website. 
The IMB also engaged with the HSE in respect of 
areas of mutual interest and contributed to the 
relevant competent authority meetings during  
the year. 
COSMETICS
TeeTh WhITenIng PRoducTS dIRecTIve
Directive 2011/84/EU, concerning the use of hydrogen 
peroxide in teeth-whitening/oral care products, was 
transposed into Irish law in October by the European 
Communities (Cosmetic Products) (Amendment) 
Regulation 2012 (S.I. No. 396 of 2012). This permits 
products with less than 0.1% hydrogen peroxide 
(present or released) to be made available directly 
to consumers. However, products having between 
0.1% to 6% hydrogen peroxide (present or released) 
may only be sold to dentists and used in individuals 
over 18 years of age. The IMB was involved in a range 
of activities both in advance of and subsequent to 
the introduction of this legislation. This included the 
publication of a information on its website specific 
to distributors, retailers and consumers. In addition, 
information was provided to regulatory bodies such 
as the Dental Council and the Pharmaceutical Society 
of Ireland.
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SCIENTIFIC ANIMAL PROTECTION
The IMB implemented an extensive programme 
of work during 2012 in advance of becoming 
the competent authority responsible for the 
implementation of Directive 2010/63/EU on the 
protection of animals used for scientific purposes 
from 1 January 2013. The accompanying national 
Regulations are set out in SI No 543 of 2012. This 
authority was transferred from the Department of 
Health which regulated this area until 31 December 
2012.
Directive 2010/63/EU is significant and complex 
legislation intended to improve the welfare of 
animals used for scientific purposes and to promote 
the principles of the 3Rs (replacement, refinement 
and reduction). 
Among the primary functions of the IMB in respect of 
this legislation is the authorisation of establishments 
and monitoring of animal welfare at establishments 
where animals used for scientific purposes are kept. 
In addition to establishments, authorisations will 
also be required at project level and at individual 
level. The Department of Health continues to have 
responsibility for related policy and legislative 
developments.
IMB IMPLEMENTATION PROGRAMME
During 2012, a dedicated section was established 
within the Veterinary Sciences Department to 
advance preparations for the implementation of 
Directive 2010/63/EU. This section will now also be 
responsible for carrying out the assessment and 
inspection duties required. In addition, an internal 
steering committee and a cross-functional project 
team were established. The implementation plan 
included the development of the operational 
processes, authorisation procedures, policies, 
application forms and accompanying guidelines that 
are necessary to implement the requirements of the 
legislation. The project team also met with a broad 
range of stakeholders including representatives 
of the research institutions, the broader research 
community and the animal protection movement. 
In addition, relevant website content was developed 
and published on www.imb.ie. 
Throughout 2012, the IMB worked closely with 
officials from the Department of Health on clarifying 
legal and operational issues arising from the 
implementation of Directive 2010/63/EU and on the 
development of the relevant national Regulations.
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STAKEHOLDER ENGAGEMENT 
AND COMMUNICATIONS 
A core strategic goal of the IMB is to ensure that all our 
stakeholders have timely access to relevant safety, licensing 
and regulatory information. We are committed to enhancing 
our communications and engagement activities and this will 
continue to be an area of focus and development for the 
IMB over the coming years.
Throughout 2012, there were a series of communications 
programmes and initiatives implemented. 
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STAkeholdeR engAgeMenT
Consultative Panel on the Legal Classification  
of Medicines
The Consultative Panel on the Legal Classification of 
medicines held quarterly meetings during 2012. The 
aim of the Panel is to assist in developing the debate 
on policies in the area of legal classification of human 
medicines. It was established following a public 
consultation process which was held during 2011. 
The Panel is independently chaired and consists of 
external representatives drawn from a wide range of 
interested stakeholders including patients, healthcare 
professionals, the Department of Health and relevant 
government agencies. The panel provides advice on 
external socioeconomic and policy issues that should 
be considered when determining the appropriate 
classification of medicines. During 2012, each 
representative was invited to present their views and 
perspectives to the panel. The final meeting of the 
panel was planned for early 2013 and it is anticipated 
that a report on its deliberations will be finalised later 
in the year.
Meetings with Stakeholders – Human Medicines
Two joint meetings were held with the Association 
of Pharmaceutical Manufacturers in Ireland (APMI) 
and the Irish Pharmaceutical Healthcare Association 
(IPHA). Issues of mutual interest are discussed at these 
bi-annual meetings. In 2012, these included labelling, 
electronic submissions, new legislation, shortages of 
medicines and national timelines.
A number of meetings were also held with industry 
and company representatives in respect of the 
ongoing implementation of the Traditional Herbal 
Medicinal Products Directive. These meetings 
provided guidance and direction to stakeholders 
in an effort to improve the number and quality 
of applications received through the registration 
scheme. 
Two meetings were held with the Pharmaceutical 
Distributors Federation. The main topics of discussion 
included updates to legislation and related guidance 
document as well as IMB expectations with regard 
to emerging issues such as the Falsified Medicines 
Directive, EU GDP guidelines, traditional herbal 
medicines and the regulation of cosmetics.
Meetings with Stakeholders –  
Veterinary Medicines
The IMB held several meetings during 2012 with 
interested parties, including the European Generics 
Group for Veterinary Medicines, the International 
Federation of Animal Health (Europe), the 
Environmental Protection Agency and the Health 
Protection Surveillance Centre. These meetings 
considered a wide variety of topics including the 
pending EU legislation on veterinary authorisation 
procedures, the inspection of establishments where 
animals for scientific purposes are kept and antibiotic 
resistance. 
The IMB also held a number of meetings with 
the Department of Health in relation to the 
implementation of Directive 2010/63/EU and with 
the Department of Agriculture, Food and the Marine 
in relation matters of mutual interest. In addition, 
the IMB attended a tripartite meeting with the UK’s 
Veterinary Medicines Directorate and the Department 
of Agriculture, Food and the Marine held in County 
Kildare with the goal of advancing the development 
of the new EU legislation on the authorisation and 
regulation of veterinary medicines. 
Several meetings also took place in the past year 
with applicants to discuss ongoing or proposed 
applications where IMB is to be the reference member 
state in future European application procedures. 
The IMB also held a number of meetings with 
agricultural stakeholders on the subject of regulation 
of veterinary medicinal products.
Furthermore, in preparation for the implementation 
of Directive 2010/63/EU, the IMB met with a 
broad range of additional stakeholders including 
representatives of the research institutions, 
research funding bodies and the animal protection 
community. 
Meetings with Stakeholders – Medical Devices 
In 2012, four meetings were held with the Irish 
Medical Device Association (IMDA). These meetings 
focused on developments in the regulation of 
medical devices issues including developments at 
European level. In addition, the IMB participated in 
the IMDA two yearly Global Access Conference held 
in Galway in May.
There were four meetings held with the National 
Standards Authority of Ireland (NSAI), the sole 
notified body for medical devices in Ireland. Regular 
meetings allow for discussion on designation and 
monitoring activities and regulatory developments 
in respect of medical devices. In addition, a number 
of additional meetings were held with the NSAI 
during 2012 arising from the joint plan for immediate 
actions which included a review of the designations 
of notified bodies.
Meeting with Stakeholders – Cosmetic Products
As part of our co-operation with the HSE 
Environmental Health Service and Public Analyst’s 
Laboratories regarding cosmetics regulation, a 
meeting of the National Cosmetics Surveillance 
Forum was held. The purpose of this meeting was to 
review and manage the national market surveillance 
strategy for cosmetic products.
Presentations to Stakeholders
As in previous years, the IMB invested significant 
time in delivering a programme of presentations 
and talks at a range of external stakeholder events 
such as meetings, seminars, conferences and training 
courses. In addition, a programme of presentations 
was delivered to undergraduate and post graduate 
students studying courses related to the role of  
the IMB.
The presentations are delivered by IMB staff from 
across the organisation and cover all products and 
functions under our remit. While some are general in 
nature and primarily focused on explaining the role 
of the IMB, others were more specific and dealt with 
specialist areas and/or new regulatory developments. 
A full list of all 2012 presentations is provided in 
Appendix 2.
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evenTS
Information Days
IMB information days and seminars provide 
regulatory guidance and updates to a range of 
stakeholders. As well as presentations from IMB staff 
and, where appropriate, external contributors, the 
events enable all attendees to submit questions, 
seek clarifications and network with colleagues. The 
following information sessions were held during 
2012:
•	 A	GMP	and	market	compliance	information	
day, aimed primarily at manufacturers of 
medicinal products and manufacturers of active 
substances, was held on 27 September. The event 
was focused on updating stakeholders on current 
regulatory topics and ongoing IMB activities 
and initiatives in this area. The programme 
was designed to allow greater opportunity for 
audience participation with smaller groups in 
parallel sessions and the use of interactive voting 
pads.
•	 A	wholesale	distribution	information	day	was	
held on 28 September. This event was aimed 
primarily at distributors of medicines and again 
focused on providing up-to-date regulatory 
information and advice. The programme was 
similarly designed to allow greater opportunity 
for attendees to actively participate and engage 
with speakers.
•	 A	clinical	trials	information	seminar	for	academic	
sponsors and investigators was held at the IMB 
in June 2012. Presentations were given by IMB 
staff members who also contributed to the 
questions and answers session that followed. 
Approximately 90 people attended the seminar 
including medical practitioners, pharmacists and 
nursing staff from the main teaching hospitals, 
clinical academic units and members of the IMB’s 
Advisory Committee for Human Medicines. The 
feedback received was very positive and has 
provided ideas for future seminars.
•	 A	training	seminar	for	distributors	of	cosmetic	
products was held in March. The seminar 
provided an overview of the current and future 
legislation with a particular emphasis on the 
distribution of cosmetics. The respective roles of 
the Department of Health, the HSE, the National 
Consumer Agency and the IMB were also 
outlined.
TOPRA Annual Symposium 2012
In October 2012, the IMB co-hosted The Organisation 
for Professionals in Regulatory Affairs (TOPRA) 
annual symposium which was held in University 
College Dublin. The event brought together over 
600 representatives of industry, regulatory agencies 
and the European Commission to review and discuss 
current regulatory issues and to debate future 
planned developments. 
The symposium, which is a key annual European 
forum for those working in healthcare regulatory 
affairs, consisted of 11 informative sessions covering 
topics such as clinical trials, the availability of 
medicines, falsified medicines, herbal medicines and 
the European pharmacovigilance legislation. There 
were also three parallel symposia focused on the 
regulation of medical devices, veterinary medicines 
and small to medium enterprises. A special session in 
relation to the roles and activities of the IMB was also 
held at this year’s forum, to mark the co-hosting of 
the symposium.  
Speakers over the course of the three day event 
included representatives from the European 
Commission, the European Medicines Agency, various 
European national authorities, the US FDA, industry 
and patient groups. IMB staff members also delivered 
a broad range of presentations. 
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City of Science ESOF Satellite Conference:  
Making Gene and Cell Therapy a Reality
The IMB and the Parenteral Drug Association (PDA) 
Ireland Chapter hosted a major two day scientific 
gathering entitled Making Gene and Cell Therapy 
Medicines a Reality on 10 and 11 July 2012. 
The two day event, which was organised as a satellite 
event to the EuroScience Open Forum (ESOF2012), 
focussed on the regulatory framework and challenges 
of translating the basic scientific discoveries related 
to molecular and cell biology into novel, commercial 
gene and cellular therapies. The meeting brought 
together leading experts from regulatory authorities 
including the European Medicines Agency, the US 
FDA and the IMB with expert academic and industrial 
scientists. It afforded delegates the opportunity 
to discuss regulatory developments in advanced 
therapy medicines and the opportunities these 
products provide in meeting unmet medical needs 
for patients. IMB staff presented on a number of 
topics including clinical trial applications and the 
assessment process.  
The IMB and PDA also presented a more publicly 
focussed session on the same theme on Thursday 12 
July within the main ESOF event and this generated a 
lot of interest from conference attendees. This event 
was in-keeping with one of the aims of ESOF 2012 
which was to bring science to the public.
BT young Scientist and Technology  
Exhibition 2012
Thousands of students as well as teachers, parents 
and members of the general public from all over 
Ireland visited the IMB’s exhibition stand at the BT 
Young Scientist Exhibition 2012. The exhibition took 
place in mid-January in the RDS and it was the third 
year in succession the IMB was involved. 
Our stand used interactive displays and other 
features to build awareness among attendees of the 
significant role the IMB plays in protecting public 
and animal health. In particular, the important 
issue of medicines and medical devices safety was 
highlighted. The stand also focused on the many 
interesting science related career opportunities that 
are available in the healthcare products industry.
BRAnd IdenTITy
The role and functions of the IMB have increased 
significantly over the 16 years since it was established 
in 1996. Consequently, our current name and brand 
identity does not accurately reflect the nature and 
character of our organisation and our identity has 
not evolved in step with our size and expanding 
new areas of responsibility. The current name of our 
organisation also contributes little to supporting 
our strategic objectives which now extend beyond 
medicines alone. 
As a result, it has been decided by the Board of the 
IMB to change the name of the organisation to better 
reflect the range of services it provides. The new 
name to the replace the Irish Medicines Board is the 
Health Products Regulatory Authority (HPRA). The 
introduction of the new name is provided for in the 
Health (Pricing and Supply of Medical Goods) Bill 
2012 and it is anticipated it will become operational 
in early 2014. We will also be launching a new 
corporate website at that time.
In preparation for the adoption of the new name, the 
IMB commenced a project to develop a new brand 
identity. This project, which will incorporate a logo 
and brand identity guidelines, will be completed in 
the first half of 2013. 
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PuBlIcATIonS
Safety Warning and Notices 
Throughout 2012, the IMB published various warning 
statements and notices on safety issues or benefit/
risk evaluations of human medicines. There were 
34 Direct Healthcare Professional Communications 
concerning human medicines published on the IMB 
website and issued to subscribers. 
In respect of medical devices, 19 safety notices 
were sent to the relevant stakeholder groups 
and published online in 2012. In addition, 441 
manufacturers field safety notices affecting the Irish 
market were highlighted on the IMB website.  
Guidance Documents
IMB guidance documents provide stakeholders, 
primarily from the industry sectors we regulate, 
with advice and direction in respect of legislation 
and regulatory requirements. New and updated IMB 
guidance documents are published regularly on our 
website with alerts issued to website subscribers. 
Among the new publications was a guidance 
document addressing cosmetic-biocide borderline 
products which was finalised in 2012 following 
collaboration between the IMB and the Department 
of Agriculture, Food and the Marine. This 
collaboration included the completion of a public 
consultation process which was initiated in 2011.
Further information concerning new and updated 
guidance documents published during 2012 is 
provided in Appendix 3. 
Newsletters
Medicinal Products Newsletter
This newsletter provides regulatory updates for those 
working in the pharmaceutical and cosmetics sectors 
on Irish and European legislation, new/revised IMB 
regulatory publications and stakeholder events such 
as information days. 
Three Medicinal Product Newsletters were published 
during 2012. Topics covered included:
•	 Implementation	of	the	new	EU	
pharmacovigilance	legislation;	
•	 Guidance	for	marketing	authorisation	holders	
when dealing with pharmacy level recalls on the 
Irish	market;
•	 Falsified	Medicines	Directive	2011/62/EU	and	API	
manufacturers,	importers	and	distributors;
•	 Audits	of	Type	IA	variations:	experience	to	date;
•	 Update	on	status	of	flukicides	without	an	MRL	for	
milk;
•	 Consumption	of	veterinary	antimicrobials	in	
Ireland;
•	 Tooth	whitening	products	-	new	legislation	on	
hydrogen peroxide.
The newsletter is published on the IMB website 
and issued to those who subscribe to the IMB alerts 
system via our website.
Drug Safety Newsletter
Six issues of the IMB’s Drug Safety Newsletter were 
distributed to doctors, dentists and pharmacists 
during 2012. The publication is circulated by a 
combination of post and email and is available to 
download from the IMB website. 
The 50th edition of the newsletter, which 
highlighted the changes arising from the revised 
pharmacovigilance legislation, was published in 
November and was marked by a introduction from 
the Chief Executive. Additionally, an information 
leaflet for patients and consumers on the safety 
monitoring of medicines in the context of the 
revised legislative framework was also distributed 
to patient organisations and published on the IMB 
website. A ‘Quick Guide to Medical Device Incident 
User Reporting’ was included as an insert in the 51st 
edition of the newsletter.
A full list of all the safety topics and issues covered  
in this publication during 2012 is included in 
Appendix 3.  
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Medical Devices Newsletter 
This newsletter provides regulatory and safety 
updates for those working in the medical devices 
sector and professionals working in the health area 
who regularly use or purchase medical devices. It 
provides updates on Irish and European legislation, 
on safety issues as well as details of IMB medical 
devices publications and stakeholder events. 
During 2012, the IMB published three editions of 
the Medical Devices Newsletters including a special 
edition focused on the Commission’s proposals to 
revise the legislative framework. The additional topics 
cover during the past year are listed in Appendix 3. 
External Articles
Pharmacovigilance
There were 14 IMB articles published in MIMS Ireland. 
One article was published each month while the 
remaining two were part of special supplements. 
MIMS (Monthly Index of Medical Specialities) is an 
independently edited publication designed as a 
prescribing guide for general practitioners. Two 
further articles were published in the Irish Medicines 
Formulary (IMF). The full list of topics covered in these 
articles in included in Appendix 3. All articles were 
also published on the IMB website.
Veterinary Medicines
Consistent with our objective to improve stakeholder 
knowledge on the use of veterinary medicines,  
we contributed several articles to the veterinary/ 
trade publications Veterinary Ireland Journal and  
It’s Your Field.
The topics covered in these articles are listed in 
Appendix 3.
Cosmetic Products
An article was published in the Journal of the Irish 
Dental Association in relation to the new legislation 
on tooth whitening products. Additionally, a joint 
communiqué was issued to dentists by the Dental 
Council and the IMB regarding the same topic.
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MedIA coMMunIcATIonS
We continued to develop our proactive media 
communications programme to highlight important 
safety messages and to build awareness of the role 
of the IMB. We issued 38 press releases concerning 
safety and regulatory issues to ensure consumers, 
healthcare professional and other stakeholders 
received timely and accurate information and advice. 
In a number of instances, these communications 
resulted in national and regional media interviews 
with an IMB spokesperson. 
Among the press releases issued during the past year 
were:
•	 IMB	urges	continued	vigilance	of	children’s	
cosmetics ahead of Halloween 
•	 IMB,	Customs	and	Gardaí	in	global	INTERPOL	
operation 
•	 IMB	advises	against	use	of	echinacea	in	children	
under 12 years  
•	 IMB	announces	new	dosage	instructions	for	
children’s liquid paracetamol medicines 
•	 IMB	cautions	consumers	against	purchase	of	
illegal online medicines
In addition, we responded to 532 queries from 
national, local and specialist media during the year. 
This represents a 20% increase in the number of 
queries compared to 2011. Drafting responses to 
such queries involves subject matter experts from 
across the organisation.
PuBlIc conSulTATIonS
Public consultations enable the IMB to identify the 
needs and expectations of stakeholders so that we 
may incorporate their views into the way our  
services are planned and delivered.
During 2012, the IMB completed public  
consultations on:
•	 Fees	for	2013	
•	 An	updated	enforcement	strategy	for	2012-2016	
•	 Hospital-based	advanced	therapy	medicinal	
products  
The IMB also makes submissions to third party 
consultations where the topic is related to or 
impacts our regulatory functions and the broader 
public health agenda. In 2012, we provided 
comments in respect of 12 public consultations 
from the Department of Health, the HSE, HIQA, the 
Pharmaceutical Society of Ireland, and other bodies.
WeBSITe
The website www.imb.ie is a critical element of 
our communications programme. The site outlines 
the primary functions and activities of the IMB 
and facilitates the dissemination of information 
to a wide variety of audiences including patients 
and consumers, healthcare professionals and 
industry personnel. We are focused on its continued 
development and enhancement to ensure it remains 
an attractive and user-friendly resource. As part of 
this process, a user survey was completed in 2012 to 
identify potential areas for improvement.
2012 Statistics
•	 More	171,000	unique	visitors	accessed	the	
website during the past twelve months 
representing an annual increase of 36%. There 
were close to 434,000 visits in total. 
•	 Of	those	who	accessed	the	site	in	2012,	37%	were	
new or first time visitors. 
•	 Among	the	most	popular	sections	of	the	website	
were the human and veterinary medicines 
product listings.
Pharmacovigilance
The dedicated webpage on the new 
pharmacovigilance legislation was further updated 
with additional information and guidance while 
the highlights from the PRAC meetings were also 
published online. A dedicated webpage, Resources 
for Healthcare Professionals, was also developed 
and includes specific information for healthcare 
professionals in respect of IMB pharmacovigilance 
activities. It features a link to the Irish Academy of 
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Continuing Medical Education (iaCME) website, 
where a CPD module based on the key messages and 
advice to healthcare professionals included in the 
IMB’s Drug Safety Newsletter has been developed. 
The intention of the module is to help healthcare 
professionals to apply learnings from the newsletter 
to their individual practices.
New Website
In late 2012, the IMB also commenced a procurement 
process to appoint a website development company 
to plan for and develop a new corporate website (for 
early 2014). It is intended that the new website will 
better reflect the broad range of services delivered 
by the IMB as well as supporting new technologies. 
In addition, it will coincide with the introduction of 
the Health Products Regulatory Authority name and 
brand identity. 
fReedoM of InfoRMATIon
The IMB is subject to the Freedom of Information Acts 
1997 and 2003. The Acts assert the right of members 
of the public to obtain access to official information 
to the greatest extent possible consistent with public 
interest and the right to privacy of individuals. During 
2012, the IMB received 11 Freedom of Information 
requests consisting of six non-personal requests and 
five personal requests.
PARlIAMenTARy AffAIRS 
Oireachtas Joint Committee on Health and 
Children 
The IMB attended four meetings of the Joint 
Committee on Health and Children. These related to 
the PIP breast implants, DePuy ASR Articular Surface 
Replacement and ASR XL Acetabular system, the 
safety profile of the HPV vaccine Gardasil and the 
responsibilities of the IMB.
Meeting with Members of the European 
Parliament
A delegation from the IMB met with the Irish and 
Northern Irish Members of the European Parliament 
in Strasbourg to discuss regulatory developments 
relevant to the Irish Presidency of the Council of 
European Union in the first half of 2013.
Parliamentary Questions 
During 2012, the IMB received and responded to 
98 parliamentary questions, an almost trebling of 
the number received in 2011. There were also 57 
other requests from the Department of Health, 
other government departments or members of the 
Oireachtas during the year. Of the total number of 
queries (155), the three largest categories related 
to human medicines (66), staff and payroll (33) and 
medical devices (16). Many of the queries relating 
to human medicines concerned the availability 
or supply of product, market shortages, or 
reimbursement issues.
cuSToMeR SeRvIceS
The customer services team responded to over 3,000 
queries from industry representatives, healthcare 
professionals and members of the public. Queries 
were received primarily via email and by phone. 
In addition to the queries managed by customer 
services staff, a range of stakeholder queries are 
addressed by specialist staff across the organisation. 
Many of these queries come from healthcare 
professionals requesting information about specific 
medicines.
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ReSeARch
IMB Website – user Satisfaction Survey
In July 2012, the IMB carried an online survey among 
the users of our website. The goal of the survey was 
to identify potential areas for improvement as well as 
any new content or features that users feel should be 
included on the site. The survey was highlighted via 
the homepage while a link and request to participate 
were also sent to key stakeholder groups including 
patient, healthcare professional and industry 
representative bodies. The helpful and informative 
feedback we received from a total of 334 users will be 
used to guide the future development of our online 
presence.
Impact of Direct Healthcare Professional 
Communications
IMB research, conducted in collaboration with 
the School of Pharmacy in Trinity College Dublin, 
was presented at the Health Services Research 
and Pharmacy Practice (HSRPP) conference. The 
research involved the assessment of the impact of 
Direct Healthcare Professional Communications on 
pharmacy practice in Ireland.
Sources of Medicines Information and  
the use of the Internet 
In late 2012, the IMB commissioned research to 
examine how Irish consumers source information 
about the medicines they take. The research will 
also examine the use of the internet as a source of 
medicines information and supply. The results of the 
research will be published in the first half of 2013.
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ORGANISATIONAL MANAGEMENT 
AND DEVELOPMENT
A key strategic goal of the IMB is to build the future capabilities 
of the organisation. In particular, there must be effective systems 
in place to manage quality and risk across all of our processes, to 
support learning and development of our staff and to provide 
information technology and telecommunications services to 
staff and stakeholders. We must be flexible and proactive as 
an organisation to respond to regulatory and other external 
developments, and to adopt necessary changes in how we 
deliver our services. We must also ensure that the highest levels of 
corporate governance are developed and maintained.
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huMAn ReSouRceS 
The IMB’s people management practices and policies 
are central to the achievement of our strategic goals 
and are designed to attract and retain the skills 
necessary to maintain organisation capability.  Our 
policies are kept under continuous review and we 
adapt our work practices as required to enable us 
to manage our human resources with the flexibility 
necessary to respond to changing circumstances. 
Amongst the primary projects and statistics from 
2012 were the following:
•	 The	IMB’s	first	leadership	development	
programme commenced in 2012 based on 
requirements identified in our Learning and 
Development Strategy (2010). The eight 
participants in the programme engaged in a 
range of activities throughout the past year 
and this initial course will conclude in Q1 2013. 
The programme has been awarded external 
accreditation from the Institute of Leadership 
and Management (ILM). Also in 2012, arising 
from the Learning and Development Strategy, we 
maintained our commitment to staff continuous 
learning and development with the launch of 
a number of new initiatives throughout the 
year. These included access to a range of online 
courses and resources, language classes and a 
series of cross-departmental awareness sessions 
to facilitate greater staff engagement.
•	 We	also	maintained	our	focus	on	empowering	
line managers by providing proactive support to 
assist them with staff management. During 2012, 
14 managers participated in IMB bespoke new 
manager training sessions. 
•	 Project	planning	progressed	in	respect	of	the	
replacement of the human resources IT systems 
and this will continue throughout 2013.   
•	 As	in	previous	years,	the	business	plans	for	each	
internal department provided the framework for 
performance management within the IMB. The 
PDP (Performance Development Programme) 
aims to ensure achievement of strategic and 
business goals, to develop employee skills and 
to promote clear two-way discussion between 
employees and their managers. As well as 
incorporating key performance indicators 
against which individuals are evaluated, there 
are organisational and personal competencies 
prioritised while specific training and 
development needs for the year ahead are 
also identified. This process recognises good 
performance as well as addressing any under-
performance and/or training needs.
•	 During	2012,	we	recruited	new	specialist	staff	for	
those areas of additional competencies arising 
from the introduction of new EU legislation and 
assigned to the IMB by the Department of Health. 
This included the requirements arising from the 
EU pharmacovigilance legislation, the Directive 
on standards of quality and safety of human 
organs intended for transplantation and the 
Directive relating to animals used for scientific 
purposes.
•	 The	IMB	continued	to	be	in	compliance	with	the	
3% target set by the Disability Act 2005.
•	 Absence	management	practices	are	in	place	
and attendance statistics are included in regular 
management and Board reports. The overall 
absence rate for 2012 was maintained at 2.4%.
InfoRMATIon Technology And chAnge 
MAnAgeMenT 
The Information Technology and Change 
Management department delivers specialist 
business analysis, information technology and 
telecommunications services throughout the 
organisation. Change management and business 
process improvement initiatives are also co-ordinated 
by the department, reflecting the IMB’s commitment 
to the agenda of transformation in the public sector.
Information Technology
The IMB utilises a range of technologies to support 
the management of core activities such as product 
and establishment licensing together with ongoing 
safety monitoring and reporting. In addition, the 
IMB is also party to certain pan-European and 
international systems and provides data feeds into a 
number of databanks throughout the year.  
During 2012, work progressed on the delivery of the 
IMB’s IT Strategy (2011 to 2015). The requirement, 
identified as part of this strategy, to introduce more 
robust disaster recovery arrangements as well 
as enhanced online tools, highlight the growing 
dependence on information technology in delivering 
services to stakeholders. 
In line with Government initiatives for shared services, 
in 2012 the IMB worked closely with bodies such as 
the Office of the Revenue Commissioner and the 
HSE. Our information technology team also provided 
support to a range of third party organisations 
seeking assistance in developing and implementing 
technology solutions during the course of the year.
The IMB is also part of the wider European regulatory 
network focussed on EU telematics. This work 
programme is designed to support licensing and 
safety related activities across the EU. One of the 
most significant IMB achievements in this regard 
during 2012 was our continued development of the 
Common European Submission Portal (CESP).   
CESP Homepage
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This system was launched in 2011 and widely 
adopted across the EU during 2012. As a result, 
multiple Member States are now utilising the 
services of the IMB to manage the secure delivery 
of medicines data. Over 20 Member States are 
scheduled to formally agree a three year contract 
with the IMB in respect of CESP usage during the 
Irish EU Presidency in early 2013. Additionally, 
the pharmaceutical industry has welcomed the 
introduction of a single portal to manage the 
medicines regulatory process.    
The IMB was also active in a number of other EU 
information technology projects during 2012.
These included projects associated with the new 
pharmacovigilance legislation as well as forthcoming 
falsified medicines and clinical trials legislation.
Throughout 2012, the IMB also acted in an advisory 
capacity to the Board of the European Medicines 
Agency and to the HMA.
Change Management
The IMB has a strong track record in change 
management. The adoption of best practice models, 
both for organisational structures and business 
processes, has been part of our corporate strategy for 
over 10 years.
In 2012, the IMB continued on this path of continuous 
improvement by introducing an organisational 
project management office (PMO) tasked with 
supporting the planning process, ensuring alignment 
with the organisational objectives, and developing 
consistent management and control mechanisms.   
While the PMO is in its infancy, a range of regulatory, 
organisational and technology programmes are 
already benefiting from the new model, offering 
improved prioritisation and project management 
services.
PMO
Risk
Management
Reporting
& Metrics
Process
Standardisation
& Improvement
Portfolio
Management
Project
Request
FacilitationGovernance
& Strategic
Alignment
Resource
Management
Capability
Development
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The development of a new IMB Enforcement 
Strategy was completed in 2012 following extensive 
stakeholder engagement both nationally and 
internationally. An associated public consultation 
document was also published in mid 2012. This new 
strategy is strongly focussed on targeting high risk 
areas in line with organisational capacity. Planning for 
the implementation of the strategy commenced in 
the last quarter of 2012.
The introduction of new EU pharmacovigilance 
legislation was a significant focus of the IMB 
throughout 2012 as a range of process changes were 
implemented to support the new requirements. 
Further details are provided on page 51.
The IMB also developed new processes and 
technology interfaces to assist with the introduction 
of generic medicines legislation. Once this legislation 
is introduced, the IMB website will include lists of 
interchangeable medicines that will be accessible to 
healthcare professionals and members of the public. 
New data feeds have also been established from the 
IMB’s national database of licensed medicines to  
the HSE. 
chIef eXecuTIve’S offIce
The Chief Executive’s Office is responsible for 
communication, strategy and planning, quality 
management and a number of information functions 
for external stakeholders. It also provides the 
secretariat for the benchmarking programme across 
EU medicines agencies. 
BEMA
The Benchmarking of European Medicines Agencies 
(BEMA) programme provides assurance to the heads 
of the EU medicines agency network with respect 
to the quality of the systems and practices in place 
in agencies and is a resource for sharing of best 
practices. The IMB’s chief executive is co-chair of 
the BEMA steering group with the head of the Paul 
Ehrlich Institute in Germany. The IMB provides the 
secretariat for the group and is responsible for visit 
logistics. During 2012, we continued to lead the 
steering group as preparations for the third cycle 
were finalised and the first visits began.
Quality Management 
During 2012, the IMB’s quality management system 
continued to be extended with respect to a number 
of new functions and legislative requirements. Good 
progress was made with implementing the new 
pharmacovigilance activities (Directive 2010/84/
EU) where GVP modules had been adopted, and 
systems and processes were in place at the European 
Medicines Agency. Full implementation in some 
areas will await the finalisation and adoption of the 
remaining GVP modules and the development and 
deployment of IT systems, including a repository 
for PSURs, and the corresponding processes at the 
European Medicines Agency. Other implementation 
areas included the development of the quality 
system for ‘scientific animal protection’ according to 
the European Union (Protection of Animals Used for 
Scientific Purposes) Regulations 2012, and for new 
and amended processes under the falsified medicines 
Directive, 2011/62/EU.
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coRPoRATe AffAIRS
Corporate Affairs is responsible for the delivery 
of a number of core service areas to colleagues 
across the organisation. These include building 
and accommodation management as well as the 
provision of reception, canteen, travel, library and 
event management services. The department also 
manages legal issues and Freedom of Information 
requests. In addition, it provides secretarial support 
to the Board and Committees ensuring adherence 
to best practice in the area of corporate governance. 
2012 was another busy and productive year across all 
these functions.
Event Management
The IMB held six events in 2012 all of which were 
organised and managed in-house. This approach 
ensures cost effective delivery of events while also 
allowing IMB staff to deal directly with stakeholders. 
This has resulted in very positive feedback from 
attendees via event questionnaires. 
The six events consisted of four information days and 
two training seminars. The information days, which 
typically provide regulatory guidance and updates to 
interested parties, were focused on GMP, wholesale 
distribution, clinical trials and cosmetics distribution. 
The number of delegates attending these events 
ranged from 100 to 350.
In addition, the two training events consisted of a 
course (duration three days) in Substances of Human 
Origin Vigilance and Surveillance (SOHOV&S) and a 
course (duration 4½ days) under the Pharmaceutical 
Inspection Co-operation Scheme (PIC/S). 
Freedom of Information
During 2012, the IMB received 11 Freedom of 
Information requests consisting of six non-personal 
requests and five personal requests (see also page 
70). 
Board and Committees
Corporate Services provides secretarial support to 
the Board and Committees of the IMB and ensures 
adherence to best practice in the area of corporate 
governance.
•	 The	Board	of	the	IMB	met	six	times	in	2012	
and considered a number of strategic matters 
including corporate policy, planning and 
finance matters. The latter included monthly 
management accounts, annual budgets and the 
financial statements for 2011. The Board also 
reviewed update reports from the Statutory 
Advisory Committees and the Audit Committee. 
In addition, it reviewed the licences for all 
medicinal healthcare products as approved by 
the Management Committee.
 The number of meetings attended by each Board 
member during 2012 is as follows:
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Board Member number  number 
 of meetings of meetings 
 held during  attended during 
 the period  the period  
 the member the member 
 was on was on
 the Board the Board 
Mr. Michael Hayes (Chair) 6 6
Mr. Pat Brangan  6 5
Mr. Wilfred Higgins  6 6
Ms. Ann Horan  6 5
Prof. Mary Horgan 6 5
Dr. Elizabeth Keane 1 1
Mr. Brendan McLaughlin 6 6
Mr. Noel O’Donoghue 6 5
Prof. Caitriona O’Driscoll 6 4
•	 The	Audit	Committee,	a	subcommittee	to	the	
Board, met four times in 2012. Further details are 
provided in the financial statements.
•	 Also	during	the	year	in	review,	the	Advisory	
Committee for Human Medicines met four times, 
the Advisory Committee for Veterinary Medicines 
met three times and the Advisory Committee for 
Medical Devices met four times. 
•	 The	Herbal	Medicines	Committee,	a	
subcommittee to the Advisory Committee for 
Human Medicines, met twice in 2012. The Clinical 
Trials Committee is also a subcommittee to the 
Advisory Committee for Human Medicines and it 
met twelve times in the past year. 
fInAnce
It is the role of Finance section to safeguard the 
finances of the IMB while managing the day-to-
day financial running of the organisation. It must 
ensure that the IMB fulfils its legislative requirements 
and applies best practice to the governance of its 
affairs. All procedures are carried out using standard 
operating procedures under the quality management 
system. The finance section also provides financial 
information and analysis to the Board and the 
Management Committee.
The 2012 financial statements presented in this report 
were prepared by the finance team and submitted 
for audit to the Comptroller and Auditor General. All 
financial transactions during the period under review 
are reflected and reported upon in these statements 
as is our commitment to the highest standards of 
corporate governance. 
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oveRvIeW of eneRgy uSAge In 2012
Since 1 January 2011, the IMB, as a public sector  
body, has been required to report annually on 
its energy usage and actions taken to reduce 
consumption in accordance with S.I. 542 of 2009. 
These regulations transpose the Energy End Use 
Efficiency and Energy Services Directive (Directive 
2006/32/EC) into Irish law. 
The IMB uses electricity for lighting, air conditioning 
or heating as required and the provision of hot water. 
Natural gas is used for central heating. 
In 2012, the IMB consumed 648 MWh of energy, 
consisting of:
•	 575	MWh	of	electricity;
•	 0	MWh	of	fossil	fuels;	
•	 73	MWh	of	renewable	fuels.		
Actions undertaken in 2012
In the past year, the IMB continued to focus on energy 
performance by maintaining framework agreements 
for the supply of both electricity and natural gas. Both 
of these framework agreements were established 
by the National Procurement Service for the supply 
of electricity and natural gas to the Irish public 
sector. The agreements are intended to maximise 
volume discounts and provide for reductions in 
administrative and transaction costs for suppliers and 
public sector purchasers. IMB cost savings were in the 
region of 6% for electricity and 5% for gas (compared 
to the cost of going directly to the market). Energy 
savings amounted to 103 MWh. 
Total Energy Savings
In total, initiatives undertaken prior to 2010 and 
the measures outlined above are saving the IMB 
117 MWh on average annually. The IMB used very 
little gas in 2012 as a result of a boiler upgrade 
which reduced total energy usage for 2012 by 15% 
compared to the year previous. 
Actions Planned for 2013
In 2013, the IMB intends to maintain energy 
performance by continuing its participation in newly 
contracted framework agreements for the supply 
of both electricity and natural gas to the public 
sector. It is anticipated that both these framework 
agreements, which will again be accessed via the 
National Procurement Service, will deliver savings 
when compared to the costs of going directly to 
the market. It is important to note that the National 
Procurement Service contract rates are fixed until the 
end of 2013. During next year, the IMB also intends to 
replace its single glazed windows on the upper floors 
to more energy efficient triple glazed windows which 
will result in greater energy savings.  
79IMB ANNUAL REPORT 2012
financial Statement
80 IMB ANNUAL REPORT 2012
FINANCIAL STATEMENTS
81IMB ANNUAL REPORT 2012
BoARd MeMBeRS And oTheR InfoRMATIon
Board Members: Mr. Michael Hayes (Chairman) 
 Mr. Pat Brangan
 Mr. Wilfrid Higgins
 Ms. Ann Horan
 Prof. Mary Horgan *
 Dr. Elizabeth Keane **
 Mr. Brendan McLaughlin
 Mr. Noel O’Donoghue
 Prof. Caitriona O’Driscoll
 The Board was appointed by the Minister for Health 
 on 18th January 2011.
  * Prof. Mary Horgan was appointed on 08/11/2011.
 ** Dr. Elizabeth Keane was appointed on 24/10/2012.
 
Bankers: Allied Irish Bank
 Lower Baggot Street
 Dublin 2
 Bank of Ireland Corporate
 Lower Baggot Street
 Dublin 2
Solicitors: Eugene F. Collins
 Temple Chambers
 3, Burlington Road
 Dublin 4
Head Office: Kevin O’Malley House
 Earlsfort Centre
 Earlsfort Terrace
 Dublin 2
Auditors: Comptroller and Auditor General
 Dublin Castle
 Dublin 2 
CORPORATE GOVERNANCE
The Irish Medicines Board (the IMB) was established under the terms of the Irish Medicines Board 
Act, 1995 (as amended), and is governed by a Board which was appointed by the Minister for Health. 
The Board of the IMB (the Board) consists of a chairman and eight unremunerated non executive 
members.
The IMB is committed to the highest standards of Corporate Governance and has implemented the 
Department of Finance “Code of Practice for the Governance of State Bodies”. This Code of Practice, 
which was issued to the IMB in January 2002, incorporates many of the principles under which the 
IMB operates, taking account of the size and legal nature of the organisation. 
An updated Code of Practice was published by the Minister for Finance in June 2009, to take account 
of administrative and legislative developments in the corporate governance framework since 2001. 
The IMB has carried out a detailed review of this updated Code, to ensure that its provisions are still 
reflected in the principles under which the IMB operates.
The IMB has in place an extensive Code of Conduct and conflicts of interest policy for all staff, 
committees and Board members. The IMB applies the highest standards of disclosure and 
transparency in respect of interests held by staff, committees and Board members.
AudIT coMMITTee
The IMB has an audit committee comprising three Board members, which met on 4 occasions during 
2012. This committee is responsible for reviewing internal control matters, together with any other 
issues raised by the external auditors, the Board or management. The external auditor is invited 
annually to meet with the audit committee to brief them on the outcome of the external audit 
and the audit committee meets annually with the internal auditor. In 2010 the IMB re-appointed 
Crowleys DFK as internal auditor to the Board under a three-year contract. During 2012 the internal 
auditors reviewed the areas of procurement and payments, banking and finance, and financial and 
asset management and reported their findings to the audit committee. The audit committee has 
also been involved with the review of the quality systems as described below.
quAlITy SySTeMS
During 2012, the finance section of the IMB continued the process of implementing and reviewing 
standard operating procedures (SOPs) under the quality management system. This process 
involved a critical review and analysis of internal controls and processes throughout the section 
with particular emphasis on risk management. This system now underpins the internal control 
environment and feeds into the internal audit process and ultimately into the audit committee.
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ReMuneRATIon PolIcy - BoARd MeMBeRS And eXecuTIve dIRecToRS
Remuneration and travel expenses paid to Board members are disclosed in note 17 to the 
financial statements. The Chairman receives remuneration as directed by the Minister for Health in 
accordance with the Irish Medicines Board Act, 1995. Other Board members receive travel expenses 
in accordance with circulars issued by the Department of Health. The Chief Executive is remunerated 
in accordance with guidelines issued from Government and other Executive Directors are paid in 
accordance with Department of Health pay scales. 
ReMuneRATIon coMMITTee
The IMB has established a remuneration committee as a sub-committee of the Board to review the 
remuneration of the Chief Executive, in accordance with guidelines issued by the Department of 
Finance and the Department of Health. The Chief Executive’s remuneration is disclosed in note 18 to 
the Financial Statements.
InTeRnAl conTRol
The Board is responsible for the IMB’s systems of internal control. Such systems can only provide 
reasonable and not absolute assurance against material misstatement or loss. The systems of 
internal controls in use in the IMB are described more fully in the Chairman’s report on page 84.
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STATeMenT on InTeRnAl fInAncIAl conTRolS
1. I, as Chairman, acknowledge that the Board is responsible for the body’s system of internal 
financial control.
2. The IMB system of internal financial control can provide only reasonable and not absolute 
assurance against material error, misstatement or loss.
3. The Board confirms that there is an ongoing process for identifying, evaluating and managing 
the significant risks faced by the IMB. The IMB maintains a risk register which is reviewed and 
updated by management, considered by the audit committee and presented to the Board 3 
times a year.
 Management are responsible for the identification and evaluation of significant risks applicable 
to their areas of business together with the design and operation of suitable internal controls. 
These risks are assessed on a continuing basis and may be associated with a variety of internal 
or external sources including control breakdowns, disruption in information systems, natural 
catastrophe and regulatory requirements. These risks are recorded in the risk register.
 Management reports fortnightly on operational issues and risks and how they are managed 
to the Management Committee. The Management Committee’s role in this regard is to review 
on behalf of the Board the key risks inherent in the affairs of the IMB and the system of actions 
necessary to manage such risks and to present their findings on significant matters via the Chief 
Executive to the Board.
 The Chief Executive reports to the Board on behalf of the executive management on significant 
changes in the work of the IMB and on the external environment, which affects significant risks. The 
Director of Finance and Corporate Affairs provides the Board with monthly financial information, 
which includes key performance indicators. Where areas for improvement in the system are 
identified, the Board considers the recommendations made by the Management Committee.
 An appropriate control framework is in place with clearly defined matters which are reserved 
for Board approval only or, as delegated by the Board, for appropriate Management Committee 
approval. The Board has delegated the day-to-day management of the IMB and established 
appropriate limits for expenditure authorisation to the Management Committee. The Chief 
Executive is responsible for implementation of internal controls, including internal financial control.
 The system of internal financial control is monitored in general by the processes outlined above. 
In addition, the Audit Committee of the Board reviews specific areas of internal control as part of 
their terms of reference.
4. The Board have carried out a review of the effectiveness of internal financial control, in order to 
demonstrate compliance with the Code of Practice. This review was carried out at its meeting on 
22nd May 2013.
Mr. Michael Hayes 
Chairman to the Board
24 June 2013
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STATEMENT OF BOARD MEMBERS’ RESPONSIBILITIES
The Board is required by the Irish Medicines Board Act, 1995 to prepare financial statements for each 
financial year which give a true and fair view of the state of affairs of the IMB and of its surplus or 
deficit for that period.
In preparing those statements the Board is required to:
•	 select	suitable	accounting	policies	and	apply	them	consistently
•	 make	judgements	and	estimates	that	are	reasonable	and	prudent
•	 disclose	and	explain	any	material	departures	from	applicable	accounting	standards,	and
•	 prepare	the	financial	statements	on	a	going	concern	basis	unless	it	is	inappropriate	to	presume	
that the IMB will continue in existence.
The Board is responsible for keeping proper accounting records which disclose with reasonable 
accuracy at any time the financial position of the IMB and which enable it to ensure that the financial 
statements comply with the IMB Act and with accounting standards generally accepted in Ireland.  It 
is also responsible for safeguarding the assets of the IMB and hence for taking reasonable steps for 
the prevention and detection of fraud and other irregularities.
 
  
On behalf of the Board
chairman Board Member
Mr. Michael Hayes Ms. Ann Horan 
24 June 2013
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COMPTROLLER AND AuDITOR GENERAL 
REPORT FOR PRESENTATION TO THE HOuSES OF THE OIREACHTAS
I have audited the financial statements of the Irish Medicines Board for the year ended 31 December 
2012 under the Irish Medicines Board Act, 1995. The financial statements, which have been prepared 
under the accounting policies set out therein, comprise the accounting policies, the statement of 
income and expenditure, the balance sheet, the cash flow statement and the related notes. The 
financial statements have been prepared in the form prescribed under Section 18 of the Act, and in 
accordance with generally accepted accounting practice in Ireland as modified by the directions of 
the Minister for Health in relation to accounting for superannuation costs.
ReSPonSIBIlITIeS of The BoARd
The Board is responsible for the preparation of the financial statements, for ensuring that they give 
a true and fair view of the state of the Board’s affairs and of its income and expenditure, and for 
ensuring the regularity of transactions.
ReSPonSIBIlITIeS of The coMPTRolleR And AudIToR geneRAl 
My responsibility is to audit the financial statements and report on them in accordance with 
applicable law.
My audit is conducted by reference to the special considerations which attach to State bodies in 
relation to their management and operation.
My audit is carried out in accordance with the International Standards on Auditing (UK and Ireland) 
and in compliance with the Auditing Practices Board’s Ethical Standards for Auditors.
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ScoPe of AudIT of The fInAncIAl STATeMenTS
An audit involves obtaining evidence about the amounts and disclosures in the financial statements, 
sufficient to give reasonable assurance that the financial statements are free from material 
misstatement, whether caused by fraud or error. This includes an assessment of
•	 whether	the	accounting	policies	are	appropriate	to	the	Irish	Medicines	Board’s	circumstances,	
and have been consistently applied and adequately disclosed.
•	 the	reasonableness	of	significant	accounting	estimates	made	in	the	preparation	of	the	financial	
statements, and
•	 the	overall	presentation	of	the	financial	statements.
I also seek to obtain evidence about the regularity of financial transactions in the course of audit.
In addition, I read the Board’s annual report to identify material inconsistencies with the audited 
financial statements. If I become aware of any apparent material misstatements or inconsistencies, I 
consider the implications for my report.
oPInIon on The fInAncIAl STATeMenTS
In compliance with the directions of the Minister for Health, the Board recognises the costs of 
superannuation entitlements only as they become payable. This basis of accounting does not 
comply with Financial Reporting Standard 17 which requires such costs to be recognised in the year 
the entitlements are earned. 
Except for the non-recognition of the Board’s superannuation costs and liabilities in accordance with 
Financial Reporting Standard 17, the financial statements give a true and fair view, in accordance 
with generally accepted accounting practice in Ireland, of the state of the Board’s affairs at 31 
December 2012 and of its income and expenditure for 2012.
In my opinion, proper books of account have been kept by the Board. The financial statements are in 
agreement with the books of account.
MATTeRS on WhIch I RePoRT By eXcePTIon
I report by exception if
•	 I	have	not	received	all	the	information	and	explanations	I	required	for	my	audit,	or
•	 my	audit	noted	any	material	instance	where	money	has	not	been	applied	for	the	purposes	
intended or where the transactions did not conform to the authorities governing them, or
•	 the	information	given	in	the	Board’s	annual	report	is	not	consistent	with	the	related	financial	
statements, or
•	 the	Statement	on	Internal	Financial	Control	does	not	reflect	the	Board’s	compliance	with	the	
Code of Practice for the Governance of State Bodies, or
•	 I	find	there	are	other	material	matters	relating	to	the	manner	in	which	public	business	has	been	
conducted.
I have nothing to report in regard to those matters upon which reporting is by exception.
Patricia Sheehan 
For and on behalf of the
Comptroller and Auditor General 
30 June 2013
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ACCOuNTING POLICIES
 
hISToRIcAl coST convenTIon
The Financial Statements are prepared in accordance with generally accepted accounting principles 
under the historical cost convention and comply with the financial reporting standards of the 
Accounting Standards Board, with the exception of superannuation - see note below.
IncoMe RecognITIon
Income is recognised in the financial statements on the following basis:
•	 In	the	case	of	applications	for	marketing	authorisations	(new	applications,	variations	to	existing	
authorisations, or transfers) and clinical trial applications, income is recognised in the financial 
statements when a valid application form is received.  
•	 In	the	case	of	wholesale	and	manufacturing	licences	and	maintenance	of	marketing	
authorisations, fees are payable annually and a full year’s income is accrued in each financial 
year.
eXPendITuRe RecognITIon
Expenditure is recognised in the financial statements on an accruals basis as it is incurred.
RePoRTIng cuRRency And cuRRency TRAnSlATIon
The financial statements are prepared in euros.
Transactions in currencies other than euro are recorded at the rates ruling at the date of the 
transactions or at a contracted date.  Monetary assets and liabilities are translated into euro at the 
balance sheet date or at a contracted date.  Exchange differences are dealt with in the income and 
expenditure account.  
TAngIBle ASSeTS
Tangible Assets excluding Premises
Tangible assets excluding premises are stated at cost less accumulated depreciation.  Depreciation is 
calculated in order to write off the cost of tangible assets to their estimated residual values over their 
estimated useful lives by equal annual instalments.
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The estimated useful lives of tangible assets by reference to which depreciation has been calculated 
are as follows:
Fixtures and Fittings :  5 years
Computer Equipment :  3 years
Improvements to Premises : 10 years
Premises
The IMB purchased its premises at Kevin O’Malley House, Earlsfort Centre, Earlsfort Terrace, Dublin 2 
on 22 December 2004. The value capitalised was equal to the purchase price plus those costs directly 
attributable to bringing the asset into use.
No depreciation has been calculated on the value of premises, as the remaining useful economic life 
is estimated to be greater than 50 years.
TAXATIon
The IMB is exempt from liability to Corporation Tax under Section 227 of the Taxes Consolidation Act, 
1997.
deBToRS
Known bad debts are written off and specific provision is made for any amount the collection of 
which is considered doubtful. 
SuPeRAnnuATIon
The superannuation scheme operated by the IMB is in accordance with the Local Government 
(Superannuation Revision) (Consolidation) Scheme, 1986. It is an unfunded statutory scheme and 
benefits are met from current income as they arise.
The charge to salaries and wages is stated gross of superannuation deductions of €687,798 (2011 -       
€689,860). The surplus for the year on page 92 is then shown both before and after superannuation 
transactions for the year. The income and expenditure reserve on the balance sheet is split between 
retained reserves and superannuation reserves in note 11.
By direction of the Minister for Health, the provisions of FRS 17 are not being complied with.  
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PRovISIonS
A provision is recognised when the IMB has a present obligation as a result of a past event, it is 
probable that this will be settled at a cost to the IMB and a reliable estimate can be made of the 
amount of the obligation.
lIBRARy
No value has been placed on the books, audio-visual resources and electronic databases in the 
library.  Expenditure on these items is written off in the year in which it is incurred.
leASeS
All leases are treated as operating leases and the rentals thereunder are charged to the Income and 
Expenditure account on a straight line basis over the lease period. 
91IMB ANNUAL REPORT 2012
  2012 2011
 Notes € €
Fee Income 2  20,065,633  21,399,720 
Other Income 3  3,927,031  3,546,480 
   
   23,992,664  24,946,200 
    
 
     
Salaries and Wages 4  17,215,472  16,433,330   
Other Operating Costs 5 5,190,035  6,679,498 
Depreciation 1  1,027,957 1,272,749 
     
   23,433,464  24,385,577 
    
Surplus for the year before write     
back of Superannuation contributions  559,200  560,623 
    
Staff Superannuation Contributions   687,798  689,860 
    
 
Surplus for the year   1,246,998  1,250,483
    
 
Balance brought forward   21,626,901  20,376,418  
    
Balance carried forward    22,873,899  21,626,901 
    
 
All income and the surplus for the year arises from continuing activities. 
chairman Board Member
Mr. Michael Hayes Ms. Ann Horan
24 June 2013
The accounting policies on pages 89 to 91 and the notes on pages 95 to 101 form part of the financial 
statements.
 
STATeMenT of IncoMe And eXPendITuRe AccounT
for the year ended 31 December 2012
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  2012 2011
 Notes € €
Tangible Assets 1 23,162,452  23,019,503 
     
Current Assets     
Debtors and Prepayments 6 948,557  1,420,295 
Stock of Stationery  2,703  2,469 
Cash at Bank and in Hand 12  187,175 36,890 
Short Term Deposits   15,500,825  14,669,317
      
  16,639,260 16,128,971
    
 
Creditors - Amounts falling     
due within one year    
 
Creditors and Accruals 7  7,407,809  7,208,237
Mortgage 13 793,332  793,332 
     
  8,201,141  8,001,569 
    
Net Current Assets   8,438,119   8,127,402  
    
Long Term Liabilities     
Mortgage 13  8,726,672  9,520,004
    
 
TOTAL NET ASSETS   22,873,899  21,626,901 
    
 
Financed by     
Income and Expenditure Reserve 11  22,873,899  21,626,901 
     
  22,873,899 21,626,901
     
 
chairman Board Member
Mr. Michael Hayes Ms. Ann Horan
24 June 2013
The accounting policies on pages 89 to 91 and the notes on pages 95 to 101 form part of the financial 
statements.
 
BAlAnce SheeT
as at 31 December 2012
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  2012 2011
 Notes € €
Reconciliation of surplus to net cash     
inflow from operating activities     
 
Surplus for Year  1,246,998 1,250,483 
Depreciation Charge  1,027,957 1,272,749 
(Increase)/Decrease in Debtors  487,014 139,654
(Increase)/Decrease in Stocks  (234) (103) 
Increase/(Decrease) in Creditors - amounts    
falling due within one year  203,671 862,733
Deposit Interest   (272,921) (256,205) 
Bank Interest and Charges  422,839 460,323 
Loss/(Gain) on Disposal of Fixed Assets  (460) 458 
    
Net Cash Inflow      
from Operating Activities  3,114,864 3,730,092 
     
Cash Flow Statement     
 
Net Cash Inflow from Operating Activities  3,114,864 3,730,092 
     
Return on Investments and Servicing of Finance 8 (169,293) (233,446)
Capital Expenditure 8 (1,170,446) (539,463) 
Management of Liquid Resources 8 (831,508) (2,151,221) 
Financing 8 (793,332) (793,332)
 
Increase/(Decrease) in Cash   150,285 12,630
    
Reconciliation of net cash flow to movement in net debt     
    
Increase/(Decrease) In Cash  150,285 12,630
Increase/(Decrease) In Short Term Deposits  831,508 2,151,221
(Increase)/Decrease In Long Term Finance  793,332 793,332
    
Change In Net Funds/(Debt)  1,775,125 2,957,183
Net Debt at start of year  4,392,871 1,435,688
    
Net Funds/(Debt) at end of year 9 6,167,996 4,392,871
 
The accounting policies on pages 89 to 91 and the notes on pages 95 to 101 form part of the financial 
statements.
cash flow Statement
for the year ended 31 December 2012
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1. Tangible Assets Fixtures and Computer  Leasehold Improvements Premises Total  
 Fittings Equipment Improvements Premises    
 € € € € € €
 Cost       
Balance as at        
1 January 2012  978,235 8,606,936 502,445 3,551,410 20,383,000 34,022,026
         
Additions for the year  11,271  422,252  - 23,148 714,235 1,170,906
 Disposals for the year (1,025) (24,986)  -  -  - (26,011)
    
 As at        
31 December 2012 988,481 9,004,202 502,445  3,574,558 21,097,235 35,166,921
    
 Depreciation       
Balance as at        
1 January 2012 847,682 8,044,061   350,458 1,760,322 -  11,002,523
         
Charge for the year 77,215 543,041 50,245 357,456   - 1,027,957
 Disposals for the year  (1,025)  (24,986)  -     -     -  (26,011)
        
 As at        
31 December 2012  923,872 8,562,116 400,703  2,117,778  - 12,004,469
         
   
 Net Book value at        
31 December 2012  64,609 442,086 101,742 1,456,780 21,097,235 23,162,452
        
 Net Book value at        
1 January 2012  130,553 562,875 151,987  1,791,088 20,383,000 23,019,503
2. Income
      2012     2011
      €     €
 Fee Income  
 Clinical Trials 148,326  123,617 
 Human Medicine - National Fees 6,875,259  7,750,395 
 Human Medicine - European Fees 5,943,402  7,056,707 
 Veterinary Medicine - National Fees 1,163,520  1,104,294
 Veterinary Medicine - European Fees 1,564,656  1,339,833 
 Compliance Department 4,123,445  3,773,733
 Medical Devices 247,025  251,141 
   20,065,633  21,399,720 
 Other Income ( Note 3 ) 3,927,031  3,546,480 
 Total Income 23,992,664 24,946,200 
    
 Certain fees, totalling €16,725,422 are required by law to be disposed of in accordance  
with the directions of the Minister for Finance.    
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3. Other Income 2012     2011
      €     €
 Dept of Health Funding 3,545,000  3,230,479 
 Conference Fee Income 108,650  60,254 
 Deposit Interest 272,921  256,205 
 (Loss)/Gain on Disposal of Fixed Assets 460 (458)
     
  3,927,031 3,546,480
4. Salaries and Wages
  2012     2011
      €     €
 Salaries and Wages  15,822,480  15,144,077 
 Social Welfare Costs 1,392,992  1,289,253 
 
  17,215,472  16,433,330 
    
 The average number of staff employed during the year was 297 (2011 - 289).   
Staff employed at 31 December 2012 can be analysed across the following departments:    
 
  2012 2011 
 
 Chief Executive 12  10 
 Compliance 60  58 
 Finance & Corporate Affairs 18  16 
 Human Products Authorisation & Registration 105  108 
 Human Products Monitoring  42  36 
 Human Resources  8  7 
 IT & Change Management 14  13 
 Scientific Affairs 2  2 
 Veterinary Sciences  23  19 
 Pensioners  24  21 
 
   308  290
 Pension related deductions for Public Servants of €986,483 were deducted from staff   
during the year and paid over to the Department of Health.   
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5. Operating Costs 2012     2011
      €     €
 
 Accommodation Costs 1,464,548  1,347,919
 Travel, Representation and Training  734,240  720,158 
 Bank Charges and Interest 428,324  460,323 
 Legal & Professional Fees  151,892  1,780,330 
 Stationery, Publications and Postage 419,163  438,945 
 Other Operating Costs 1,991,868  1,931,823
    
   5,190,035  6,679,498
 Other operating expenses of €1,991,868 includes an amount of €4,185 related to staff hospitality. 
6. Debtors (all due within one year) 2012     2011
      €     €
 
 Trade Debtors 431,040 788,523 
 Prepayments 324,609 357,405 
 Other Debtors  192,908  274,367 
    
  948,557  1,420,295
 
7. Creditors (amounts falling due within one year) 2012     2011
      €     €
 
 Trade Creditors  379,248 540,975 
 Accruals 6,519,183 6,146,590 
 Revenue Commissioners 509,378 520,672 
    
   7,407,809  7,208,237 
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notes to the financial Statements
for the year ended 31 December 2012
8. Gross Cash Flows 2012     2011
      €     €
 Returns on Investment and Servicing of Finance:  
 Deposit Interest 257,645  226,521
 Bank Interest and Charges (426,938) (459,967)
     
 (169,293) (233,446) 
 
 Capital Expenditure  
 Payments to acquire Tangible Fixed Assets (1,170,906) (539,663) 
 Receipts from sales of Tangible Fixed Assets 460 200  
     
 (1,170,446) (539,463) 
 Management of Liquid Resources  
 (Increase)/Decrease in Short Term Deposits (831,508) (2,151,221) 
     
 (831,508) (2,151,221) 
 Financing  
 Increase/(Decrease) in Long Term Finance (793,332) (793,332) 
     
 (793,332) (793,332) 
    
9. Analysis of Changes in Net Funds/(Debt) As At  As At
  01/01/2012 Cashflow 31/12/2012
 Cash at Bank and in Hand  36,890  150,285 187,175 
 Short Term Deposits  14,669,317  831,508 15,500,825 
 Debt Due Within One Year (793,332) 0 (793,332)
 Debt Due After One Year (9,520,004) 793,332  (8,726,672)
  4,392,871 1,775,125  6,167,996
10. Administration Expenses 2012 2011
 Surplus for the year was calculated having charged :     
 Auditor’s Remuneration 17,390  17,390 
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11. Movement on Income and Expenditure Reserves As At  As At
  01/01/2012 Movement 31/12/2012
 
 Retained Reserves  15,840,655  559,200  16,399,855
 Staff Superannuation Contributions  5,786,246   687,798  6,474,044 
      
  21,626,901  1,246,998 22,873,899
12. Cash and Bank Balances 2012     2011
      €     €
 Current Account Balances 186,798  35,976 
 Cash on Hand 377  914 
    
  187,175  36,890
13. Long Term Liabilities 
  Mortgage  
 On 22 December 2004 the Board purchased its premises at Kevin O’Malley House, Earlsfort Centre,   
Earlsfort Terrace, Dublin 2. The purchase was financed by way of a mortgage, secured on the premises,  
of  €20,400,000 over 20 years from Bank of Ireland Corporate Lending.   
 
  The Irish Medicines Board is committed to making the following capital repayments on its mortgage :
  2012     2011
      €     €
 - within one year 793,332  793,332 
 - between one and five years 3,173,328  3,173,328 
 - after five years 5,553,344  6,346,676
    
   9,520,004  10,313,336 
14. Interest Rate Exposure 
 The IMB has taken all necessary steps to minimise its interest rate exposure by fixing 2/3s of the borrowings 
for the mortgage duration. The balance of the borrowings are fully offset by cash reserves. For 2013 it is 
estimated that the net borrowings for which an interest rate  exposure may arise is  €0.   
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15.  Financial Commitments  2012     2011
      €     €
 Operating Leases
 Amounts payable during the next twelve   
months in respect of leases which expire
 - within one year (in respect of Ormonde House) 54,530  -   
 - within one year (in respect of Longphort House) 70,369 -
 - between one and five years (in respect of Longphort House) - 167,056 
 - after five years (in respect of Alexandra House) 285,984  285,984 
    
   410,883  453,040 
    
 Included in Accommodation Costs (Note 5) is expenditure of €476,250 under operating leases. 
 On 22 December 2004 the IMB signed a leasehold interest in respect of the 5th floor, Alexandra House, 
 Earlsfort Centre, Dublin 2. At 31 December 2012 this lease had 9 years and four months remaining. On 
1 June 2010 the IMB signed a leasehold interest in respect of the 3rd floor, Longphort House, Earlsfort 
Centre, Dublin 2. At 31 December 2012 this lease had 5 months remaining. 
 On 1 September 2012 the IMB signed a leasehold interest in respect of the ground floor, Ormonde House,  
Earlsfort Centre, Dublin 2. 
 At 31 December 2012 this lease had 8 months remaining.
16.  Capital Commitments  2012     2011
      €     €
 Contracted For (Contract Signed )  2,657,000  145,000 
 Not Contracted For 890,000  5,212,000 
    
   3,547,000  5,357,000
17.  Board Remuneration  2012     2011
      €     €
 Chairman’s Salary  20,520 19,596 
 Board Members’ Travel Expenses 8,554  4,723 
    
   29,074 24,319 
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18.  Staff Remuneration  2012     2011
      €     €
 Chief Executive’s Total Remuneration    
Basic Salary 156,386 156,386
 
   156,386  156,386 
 The Chief Executive’s pension entitlements do not extend beyond the standard entitlements in the model 
public sector defined benefit superannuation scheme.
19. Related Party Transactions    
There have been no transactions with related parties which require disclosure under Financial Reporting 
Standard 8.    
 
      
20. Prompt Payment Of Accounts    
The Irish Medicines Board ( IMB ) confirms that it is complying with EU law in relation to prompt payments 
of account.    
 
      
21. Exchange Rates     
The exchange rates used in preparing these financial statements were as follows :     
 
 2012      €1 = STG £0.8174     
 2011      €1 = STG £0.838     
      
22. Provisions    
The Board has been notified of a number of legal proceedings or potential proceedings.  The information 
usually required by FRS 12 Provisions, contingent liabilities and contingent assets is not disclosed as the 
Board believes that to do so would be prejudicial to the outcome. In 2009 the Board was the unsuccessful 
defendant in a Supreme Court appeal and the issue of damages was referred back to the High Court. 
In advance of the High Court hearing the Board settled all outstanding matters through mediation. The 
provision was sufficient to cover all costs.
      
23. Going Concern    
The Board has a reasonable expectation, at the time of appoving the financial statements, that the IMB 
has adequate resources to continue its operations. For this reason, the Board continues to adopt the 
going concern basis in preparing the financial statements.    
 
      
24. Approval of Financial Statements    
The financial statements were approved by the Board on 22 May 2013.
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APPENDIX 1
COMMITTEE MEMBERS
MAnAgeMenT coMMITTee
Mr. Pat O’Mahony     
Chief Executive
Dr. Gabriel Beechinor    
Director of Veterinary Sciences
Dr. Joan Gilvarry      
Director of Human Products Monitoring
Ms. Frances Lynch 
Director of Human Resources
Mr. John Lynch     
Director of Compliance
Ms. Suzanne McDonald    
Director of Information Technology and Change 
Management
Dr. Mike Morris     
Director of Scientific Affairs
Ms. Ann O’Connor    
Director of Human Products Authorisation and 
Registration
Ms. Rita Purcell     
Director of Finance and Corporate Affairs
BoARd
Mr. Michael D Hayes – Chairman
Mr. Pat Brangan
Mr. Wilfrid J. Higgins
Ms. Ann Horan
Prof. Mary Horgan
Dr. Elizabeth Keane (appointed October 2012)
Mr. Brendan McLaughlin
Mr. Noel O’Donoghue
Prof. Caitriona O’Driscoll
AudIT coMMITTee
Mr. Pat Brangan
Ms. Ann Horan
Mr. Brendan McLaughlin
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AdvISoRy coMMITTee foR huMAn 
MedIcIneS
Prof. Mary Horgan – Chairman
Dr. Paul Browne
Dr. Kevin Connolly
Dr. Desmond Corrigan
Prof. David Kerins
Ms. Marita Kinsella
Prof. Patrick Murray
Mr. Ronan Quirke
Dr. Patrick A. Sullivan
Prof. Peter Weedle
AdvISoRy coMMITTee foR veTeRInARy 
MedIcIneS
Mr. Pat Brangan – Chairman
Dr. Ruaidhri Breathnach
Ms. Eugenie Canavan
Mr. Michael F. Clancy
Dr. Martin Danaher
Dr. Rodhri Evans
Dr. Helena Kelly
Mr. Des Leadon
Dr. Nola Leonard
Mr. Ciaran Mellet
Mr. John Moriarty
Mr. John Underhill
AdvISoRy coMMITTee foR MedIcAl 
devIceS
Mr. Wilfrid J. Higgins – Chairman
Dr. Gillian Carlos McDowell
Dr. Geoffrey Chadwick
Mr. Darragh Hynes
Prof. Fergal O’Brien
Prof. Richard Reilly
Ms. Mary Sharp
Ms. Maebh Smith
Dr. Declan Sugrue (resigned June 2012)
Mr. Sean Paul Teeling
Prof. Wil van der Putten
Dr. Vivion Crowley
clInIcAl TRIAl SuB-coMMITTee of 
AdvISoRy coMMITTee foR huMAn 
MedIcIneS
Dr. Patrick A. Sullivan – Chairman
Dr. Liam Bannan
Prof. David Bouchier-Hayes
Dr. Geraldine Boylan
Dr. Paul Browne
Dr. Peter Daly
Prof. Timothy Dinan
Dr. Catherine Kelly (from December 2012)
Dr. Thomas Peirce
Dr. John Taaffe
Dr. Bryan Whelan
Dr. Lee Helman (CT Expert)
Dr. Filip Janku (CT Expert)
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AdvISoRy SuB-coMMITTee foR heRBAl 
MedIcIneS
Dr. Des Corrigan – Chairman
Dr. James Barlow
Dr. Kevin Connolly
Ms. Nicola Darrell (resigned August 2012)
Mrs. Ingrid Hook
Ms. Claudine Hughes
Ms. Anna-Maria Keaveney 
Dr. Celine Leonard
Dr. Diarmaid O’Connell (resigned July 2012)
Dr. Donal O’Mathuna
Dr. Camillus Power
Dr. Helen Sheridan
Ms. Anne Varley
eXPeRTS SuB-coMMITTee of The 
AdvISoRy coMMITTee foR huMAn 
MedIcIneS
Prof. Mary Horgan – Chairman
Dr. Colin Buckley
Dr. Owen Carey
Dr. Kevin Connolly
Dr. Noreen Dowd
Dr. Stephen Eustace
Dr. Stephen Flint
Dr. Tim Fulcher
Dr. Joseph Galvin
Dr. Patrick Gavin
Dr. Kevin Kelleher
Dr. Catherine Kelly 
Dr. Mary Keogan
Prof. David Kerins
Dr. Lorraine Kyne
Dr. Mark Ledwidge
Dr. Patricia McCormack (resigned June 2012)
Prof. Aidan McCormick
Dr. Frank Murray
Dr. Yvonne O’Meara
Mr. Ashley Poynton
Dr. Brion Sweeney
Dr. Jogin Thakore
Dr. Douglas Veale (resigned July 2012)
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APPENDIX 2      
PRESENTATIONS 2012
ThIRd level PReSenTATIonS
college course Presentation Title
Athlone IT Veterinary Nursing Regulation of Veterinary Medicines 
DCU Chemical and Pharmaceutical Sciences  Irish pharmaceutical Industry Regulation  
  and the Role of the IMB
DIT  Pharmaceutical Validation Technology Regulatory Inspectional Findings
Dundalk IT Veterinary Nursing Regulation of Veterinary Medicines (2 presentations)
Letterkenny  Veterinary Nursing Regulation of Veterinary Medicines  
IT
RCSI Nurse Midwife Prescribing Role of the IMB (2 presentations)
RCSI Nurse Midwife Prescribing Pharmacovigilance (2 presentations)
RCSI Pharmacy Evolution of Medicines Regulation
Sligo IT Medical Biotechnology and  IMB Inspections / Pharmacovigilance 
 Pharmaceutical Science  
Sligo IT Industrial Pharmaceutical Science  The Role of the IMB, Manufacturers and the QP
St. Johns, Veterinary Nursing Regulation of Veterinary Medicines  
Cork
TCD Pharmacy Quality Defects & Drug Withdrawals
TCD Pharmacy Regulation of Medicines and the Role of the IMB
TCD Pharmacy (QP Forum) Manufacture of Sterile Medicinal Products – GMP Inspections
TCD Biomedical Sciences  Biopharmaceuticals – Introduction to EU Regulation
TCD Pharmaceutical Medicine New EU Pharmacovigilance Legislation
TCD Pharmaceutical Medicine  Communicating Drug Safety Data 
TCD Pharmaceutical Medicine  Role of the Pharmacopoeia in the Regulation of Medicines
TCD Pharmaceutical Medicine Regulation of Medical Devices
TCD Pharmaceutical Medicine The Role of the CMDh
TCD Pharmaceutical Medicine Pharmacovigilanc
TCD Nursing/Midwife Prescribing Role of IMB
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ThIRd level PReSenTATIonS
college course Presentation Title
TCD Nursing/Midwife Prescribing Pharmacovigilance
TCD Pharmaceutical Analysis Specification Setting for Drugs
UCC Pharmacy and Medicine Adverse Reactions
UCC Pharmacy and Medicine Risk Minimisation Tools
UCD Nursing - Prescription of Medication  Role of IMB (2 presentations)
UCD Nursing - Prescription of Medication  Pharmacovigilance (2 presentations)
UCD Veterinary Medicine Regulation of Veterinary Medicines 
UCD Biotechnology  Biopharmaceuticals – Introduction to EU Regulation
UCD Biotechnology Regulation of Medical Devices
UCD Pharmaceutical Management Regulatory Environment and the Irish Pharmaceutical   
  Industry
UCD Clinical & Translational research Medical Device Studies
UCG Medical Physics Regulation of Medical Devices
RegulAToRy PReSenTATIonS
event/organiser Presentation Title
Annual Risk and Safety Workshop Medical Devices: The Role of the IMB
APIC Conference International Inspection Collaboration
Association of Pharmaceutical  E-submissions 
Manufacturers in Ireland 
BARQA Ireland Regional Forum Regulatory Update
Biocides Symposium Classification of Borderline Products
DIA Europe EudraVigilance
DIA Europe EU Pharmacovigilance legislation
Drug Safety Research Unit Pharmacovigilance
EMA Stakeholder Days  Number of presentations on the implementation of the new  
 pharmacovigilance legislation.
EU Pharmaceutical Law Forum Regulatory Framework in Medical Technology Law
Health Services Research and  Impact of DHPCs on Pharmacy Practice: MC Kennedy (TCD), 
Pharmacy Practice Conference  A Spooner, M Henman (TCD)
IBEC Commercialisation of Drug, Device and Biologic Combination  
 Products
Informa Process Validation, Sampling and Control Strategy
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event/organiser Presentation Title
Informa Validation Process
Informa Pharmaceutical Labelling
Informa Pharmacovigilance and Risk Management
Informa Labelling Compliance for Medical Devices
Inter-Agency docuBridge User Group IMB Experience
International Pharmaceutical Federation (FIP) Dissolution Testing - Regulatory Consideration
International Pharmaceutical Federation (FIP) Multinational Pharmacopoeial Harmonisation
Irish Cleanroom Society GMP Inspections
Irish Medication Safety Network Quality Defects and Recalls
Irish Pharmaceutical Healthcare Association Compliance Monitoring through Adverse Reaction Reporting
Irish Society of Rheumatology Clinical Trials
ISPE Process Validation
IVT Validation Week Qualification and Validation
Medical Device Directive and the Recast Medical Devices Directive
Medicrime Convention Significance of Medicrime Convention
Official Medicines Control Laboratories Market Surveillance Project
PCI Conference Variations (2 presentations)
PCI Conference Deficiencies in CMC Part of Application
PDA / IMB ESOF 2012 Satellite Conference Multiple IMB presentations on the regulation gene and cell  
 therapy medicines
PharmaChemical Ireland Quality Risk Management Activities (2 presentations)
Pharmigs Annual Irish Conference Application of Annex 1 Principles to Biological Drug  
 Substance Manufacturing
PHSS Bio-contamination Control and Monitoring
PIC/S GMP Inspector Training Course Multiple IMB Presentations
PIC/S New Inspector Training Course Multiple IMB Presentations
Pompidou Group Information Exchange Initiatives
Quality & OPEX in Pharma and Biotech Compliance
RCPI – Rational and Safe Prescribing The Role of the IMB
RCPI – St. Luke’s Day Symposium The Medicines Regulator
TOPRA Symposium 2012, Dublin Multiple IMB presentations across human and veterinary 
medicines, and medical devoices
TOPRA Symposium Launch Event Regulatory News
Vigilance and Surveillance of Substances of  Effective Vigilance and Surveillance Systems 
Human Origin  
APPENDIX 3
PUBLICATIONS AND ARTICLES 2012
dRug SAfeTy neWSleTTeRS 
edition Articles
February 2012 − Proton-pump inhibitors: Association with hypomagnesaemia 
46th Edition − Metoclopramide: New Recommendations for treatment of children 
 − Gonadotrophin releasing hormone-Risk of depression 
 − HMG-CoA reductase inhibitors: Risk of new onset diabetes in patients already at   
  increased risk of developing diabetes. 
 − Varenicline (Champix) and cadiovascular safety 
 − Adverse Drug Reaction Reporting Experience during 2010 
 − Adverse reaction and quality defect reporting including herbal medicines.
April 2012 − Aliskiren: New contraindications and warnings due to the risks of cardiovascular and  
47th Edition  renal adverse reactions  
 − Proton pump inhibitors: Small increased risk of bone fractures with long term use in  
  patients with risk factors. 
 − Oral methotrexate: Risk of unintentional overdose due to medication errors. 
 − Miconazole oral gel (Daktarin oral gel): Interaction with warfarin. 
 − Childrens liquid paracetamol medicines: New dosage instructions.
June 2012 − Topical tacrolimus (Protopic): Important recommendations for appropriate use to  
48th Edition  minimise risks 
 − Strontium (Protelos and Osseor): Updates to product information on risks of venous  
  thromboembolism and severe allergic skin reactions 
 − Vernakalant (Brinavess): Risk of severe hypotension and bradycardia 
 − Fingolimod (Gilenya): Updated recommendations on cardiovascular monitoring during  
  treatment initiation
August 2012 − Ondansetron (Zofran): Risk of QTc prolongation and new intravenous dose restriction 
49th Edition − Levodopa, dopamine agonists and COMT inhibitors: Risk of impulse control disorders 
 − Miacalcic (calcitonin, salmon) nasal spray: Association with malignancies with long  
  term use. 
 − Adverse Reaction Reporting Experience during 2011 
 − Donepezil: Risk of neuroleptic malignant syndrome 
 − Dabigatran (Pradaxa): Furhter information on contraindications and management  
  of bleeding
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dRug SAfeTy neWSleTTeRS 
edition Articles
November 2012 − Update on new pharmacovigilance legislation   
50th Edition 
December 2012 − Diclofenac: Further evidence that the cardiovascular risk with diclofenac is higher than  
  other non-selective NSAIDs and similar to the selective COX-2 inhibitors 
 − Valdoxan (agomelatine)-reports of serious hepatotoxicity 
 − Evicel-Recommendations to minimise the risk of gas embolism during application 
 − Exempt medicinal products-prescribing products that have been suspended in Ireland  
  for safety reasons 
 − User reporting of medical device incidents 
 − Additional insert: Quick guide to medical device incident user reporting
IMB huMAn MedIcIneS ARTIcleS – eXTeRnAl PuBlIcATIonS 
Topic Publication Month
Domperidone: Risk of cardiac disorders MIMS January
Citalopram and Escitalopram: Risk of QT interval prolongation MIMS February
Direct Healthcare Professional Communications IMF February
Metoclopramide: New recommendations for treatment of children MIMS March
HMG-CoA reductase inhibitors: Risk of new onset diabetes in patients already  MIMS April 
at increased risk of developing diabetes. 
Aliskiren: New contraindications and warnings due to the risks of cardiovascular  MIMS May 
and renal adverse reactions  
Revlimid (lenalidomide): Risk of second primary malignancies in authorised indication  MIMS May 
(oncology supplement) 
Strontium (Protelos and Osseor): Updates to product information on risks of venous  MIMS June 
thromboembolism and severe allergic skin reactions 
Vemakalant (Brinavess): Risk of severe hypotension and bradycardia MIMS July
Topical tacrolimus (Protopic): Important recommendations for appropriate  MIMS August 
use to minimise risks 
HMG-CoA reductase inhibitors: Risk of new onset diabetes in patients already  IMF August 
at increased risk of developing diabetes 
Oral Methotrexate: Risk of unintentional overdose due to medication errors MIMS September
Ondansetron (Zofran): Risk of QYc prolongation and new intravenous dose restriction MIMS October
Valdoxan (agomelatine): New reports of serious hepatotoxicity MIMS November
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IMB huMAn MedIcIneS ARTIcleS – eXTeRnAl PuBlIcATIonS 
Topic Publication Month
HMG-CoA Reductase Inhibitors: Risk of new onset diabetes in patients already  MIMS  November 
at increased risk of developing diabetes (Diabetes Supplement) 
Updated Pharmacovigilance Legislation MIMS December
IMB veTeRInARy MedIcIneS ARTIcleS – eXTeRnAl PuBlIcATIonS 
Topic Publication Month
IMB Veterinary Medicinal Updates for 2011 Veterinary Ireland Journal March
Suspected Adverse Events for Veterinary Medicinal Products 2011 Veterinary Ireland Journal August
Forthcoming Changes to Labelling of Certain Wormers for Sheep It’s Your Field Spring
Withdrawal Periods and Residue Controls on Yeterinary Medicines It’s Your Field Summer
Veterinary Pharmacovigilance It’s Your Field Autumn
Identifying Borderline Products which have been Judged by the  It’s Your Field Winter 
IMB as not Requiring a Marketing Authorisation 
IMB MedIcAl devIceS neWSleTTeR – SAfeTy ARTIcleS 
edition Main Topics
June −   Medical devices joint action plan 
 −   User reporting 
 −   Unique device identifiers  
 −   E-labelling regulation 
October −   MEDDEV 2.1/6 on stand alone software 
 −   Medical devices containing tissues of animal origin 
 −   Unique device identification  
 −   Medical devices containing mercury: New restrictions.   
 −   Transition from the Global Harmonisation Task Force (GHTF) 
      to the International Medical Device Regulators Forum (IMDRF)
December −   A special edition focused on the proposals for new Regulations on medical devices.
InduSTRy guIdAnce docuMenTS 
document title new/Revision date
Guide to Traditional Herbal Medicinal Products Registration Scheme Revision January
Guide for Suppliers of First Aid Kits, containing Medicinal Products,  Revision March 
Supplying solely to the End-user   
Guide to Invented Names of Human Medicines   Revision April
Guide to Labels and Leaflets of Human Medicines   Revision May
Guide to Submission of Risk Minimisation Plans   Revision May
InduSTRy guIdAnce docuMenTS 
document title new/Revision date
Guide to the In-vitro Diagnostic Medical Devices Legislation   Revision June
Guide to Electronic Submissions - Human Medicines Revision June
Guide to Parallel Imports - Human Medicines Revision June
Guide for Custom-made Medical Device Manufacturers on Compliance with  Revision June 
European Communities (Medical Devices) Regulations, 1994   
Guide to Completion of the Tissue Establishment Annual Report for Reproductive  Revision July 
Tissues and Cells   
Guide to Completion of the Tissue Establishment Annual Report   Revision July
Guide to Registration of Persons Responsible for Placing Medical Devices on the Market   New July
Guide to Registration of Persons Responsible for Placing In-Vitro Diagnostic  New July 
Medical Devices on the Market   
Guide to Incident Reporting for General Medical Devices and Active  Revision July 
Implantable Medical Devices   
Guide to an Application for a variation to a Manufacturing/Importation Authorisation  Revision July 
or Wholesaler’s Authorisation 
Guide to Notification of Marketing Status of Human Medicines Revision August
Guide to the On-line Registration System for Medical Devices   New August
Guide to Field Safety Corrective Actions for Medical Devices and In-vitro  Revision August 
Diagnostic Medical Devices   
Guide to the Vigilance System for Medical Devices   Revision August
Guide to Incident Reporting for In-vitro Diagnostic Medical Devices   Revision August
Guide to Applications for Certificates of Free Sale for Medical Devices   Revision September
Guide to Reporting of Quality Defects   Revision October
Guide to the Registration of Homeopathic Veterinary Medicinal Products   Revision November
Guide to Notification of Marketing Status of Veterinary Medicines   Revision November
Guide to Withdrawal of Authorisations or Certificates for Veterinary Medicines   Revision November
Guide to Renewal of Veterinary Product Authorisations   Revision November
Guide to the Implementation of Packaging Changes to Authorised Veterinary  Revision November 
Medicinal Products   
Guide to the Definition of an Animal Remedy and the Classification Process   Revision November
Guide to Registration for Brokers of Finished Medicinal Products   New December
Guide to the Completion of the Hospital Blood Bank Annual Report   Revision December
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APPENDIX 4
EUROPEAN AND NATIONAL   
COMMITTEE / WORKING GROUP   
PARTICIPATION
euRoPeAn And nATIonAl coMMITTee/WoRkIng gRouP PARTIcIPATIon
committee/Working group organisation Meetings Per  
  Annum
Central Management Committee (CMC) CAMD 2
Competent Authority for Medical Devices (CAMD) CAMD 2
Notified Body Operations Group (NBOG) CAMD 3
NBOG subgroup on joint assessment of notified bodies CAMD 3
Medical Devices Recast Working Group CAMD 2
Compliance and Enforcement Working Party (COEN) CAMD 3
P-SC-COS (Committee of Experts on Cosmetics) Council of Europe 1
Pompidou Group – Drug Precursors Council of Europe 1
Official Medicines Control Laboratories Network Council of Europe 2
Working Group on Anti-counterfeiting Council of Europe 2
Medication Safety Forum  Department of Health 4
National Steering Group on Organs for Human Transplantation Department of Health 5
Market Surveillance Forum Department of Jobs, Enterprise  4 
 and Innovation 
Committee for Advanced Therapies  EMA 11
Committee for Medicinal Products for Human Use (CHMP)  EMA 11
Committee for Medicinal Products for Veterinary Use (CVMP) EMA 11
Committee for Orphan Medicinal Products (COMP) EMA  11
Committee on Herbal Medicinal Products (HMPC)  EMA 6
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committee/Working group organisation Meetings Per  
  Annum
Efficacy Working Party (of CVMP) EMA 4
EudraCT (Clinical Trials Database) EMA 3
GCP/Pharmacovigilance Inspectors Working Group EMA 8
GDP Drafting Group EMA 2
GMDP Inspectors Working Group EMA 4
Immunologicals Working Party (of CVMP) EMA 3
Paediatric Committee (PDCO)  EMA 12
Pharmacovigilance Working Party (Final meeting July 2012)  EMA 7
Pharmacovigilance Risk Assessment Committee (First meeting July 2012) EMA 4
Quality Working Party (CHMP/CVMP) EMA 4
Safety Working Party (of the CHMP) EMA  2 (+  8 virtual ½  
  day meetings)
Scientific Advice Working Party EMA 11
Biologics Working Party EMA 11
Working Group on Quality Review of Documents (QRD)  EMA 3 
Telematics Committee - Management Board EMA 4
New and Emerging Technologies Working Group EU Commission  2
In-Vitro Diagnostic Technical Working Group EU Commission 1
Ad hoc group for the development of implementing guidelines  EU Commission 4 
for Directive 2001/20/EC  
Borderline and Classification Medical Device Expert Group (MDEG) EU Commission 2
Clinical Investigation and Evaluation Working Group EU Commission 3
Competent Authorities for (1) Blood, (2) Tissues and Cells and  EU Commission 6 
(3) Organs for Transplantation 
Haemovigilance – Common Approach EU Commission 1
Cosmetic Borderline Working Group EU Commission 2
Cosmetic Standing Committee and Working Group EU Commission 2
Cosmetics Sub-group on Skin Allergies EU Commission 1
Drug Precursors Working Group EU Commission 2
EUDAMED Working Group EU Commission 3
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committee/Working group organisation Meetings Per  
  Annum
MDEG Software Working Group EU Commission 2
MDEG Working Group on Vigilance EU Commission  2
Medical Device Expert Group EU Commission 3
PEMSAC (Platform of European Market Surveillance  EU Commission 4 
Authorities for Cosmetics)  
Regulatory Committee for Medical Devices EU Commission 0
Unique Device Identifier Group EU Commission  2
Guidance on Investigation and Reporting of SAR/E  EU Commission / SoHO V & S 3 
Associated with Tissues and Cells 
Tissues and Cells – Common Approach EU Commission / SoHO V & S 1
Clinical Trial Facilitation Group (CTFG) HMA 6
Co-ordination Group for Mutual-recognition and Decentralised  HMA 11 
Procedures (Human) CMD(h) 
Co-ordination Group for Mutual-recognition and Decentralised  HMA 11 
Procedures (Veterinary) CMD(v) 
Working Group of Enforcement Officers (WGEO) HMA 2
HMA ICT Working Groups HMA 
Homeopathic Medicinal Products Working Group (HMPWG) HMA 2
PSUR Work-Sharing Working Party HMA 11
HMA-CAMD workshops HMA/CAMD 3
Steering Group on Medicines for Older People HSE 2
Anti-doping Committee  Irish Sports Council 4
Cosmetics Standards Advisory Group NSAI 2
Permanent Forum on International Pharmaceutical Crime PFIPC  1
Committee of Officials PIC/S 2
GDP working group PIC/S 2
Heads of Medicines Agency meetings – Human  Presidency 4
Heads of Medicines Agency meetings – Veterinary  Presidency 4
National Immunisation Advisory Committee RCPI 6
Board of the UMC/WHO Collaborating Centre  WHO 3
WHO National Pharmacovigilance Centres Meeting  WHO 1
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APPENDIX 5      
GLOSSARY
APMI Association of Pharmaceutical Manufacturers in Ireland 
ASR Annual Safety Report 
ATMP Advanced Therapy Medicinal Product
BEMA Benchmarking of European Medicines Agencies
CAMD Competent Authority for Medical Devices 
CAT Committee for Advanced Therapies 
CD Controlled Drugs 
CESP Common European Submission Portal
CHMP Committee for Medicinal Products for Human Use 
CMC Central Management Committee 
CMD(h) Co-ordination Group for Mutual Recognition and Decentralised Procedures - Human
CMD(v) Co-ordination Group for Mutual Recognition and Decentralised Procedures - Veterinary 
CMS Concerned Member State
COMP  Committee for Orphan Medicinal Products 
CPD   Continuing Professional Development
CTFG  Clinical Trials Facilitation Group 
CVMP  Committee for Medicinal Products for Veterinary Use 
DCP  Decentralised Procedure 
EDQM European Directorate for Quality of Medicines 
EEA European Economic Area 
EMA European Medicines Agency 
ESOF   EuroScience Open Forum
EUDAMED European Database on Medical Devices
FAQ Frequently Asked Questions 
GCP Good Clinical Practice 
GDP Good Distribution Practice 
GMP Good Manufacturing Practice
GVP Good Vigilance Practice 
HIQA Health Information and Quality Authority 
HMA Heads of Medicines Agency
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HMPC Committee on Herbal Medicinal Products 
HPRA      Health Products Regulatory Authority
HPSC Health Protection Surveillance Centre 
HPV Human Papillomavirus 
HSE Health Service Executive
IBTS Irish Blood Transfusion Service 
ICH International Conference of Harmonisation 
ICSR  Individual Case Safety Report
IMDA Irish Medical Devices Association 
IMF Irish Medicines Formulary 
IPHA Irish Pharmaceutical Healthcare Association
IVD In-Vitro Diagnostics 
MAH Marketing Authorisation Holder 
MEDDEV Medical Devices Guidance Document from the European Commission
MIMS Monthly Index of Medical Specialities
MRLs Maximum Residue Limits 
MRP Mutual Recognition Procedure 
NBOG  Notified Body Operations Group 
NCA National Consumer Agency 
NHO National Haemovigilance Office 
NSAI National Standards Authority of Ireland 
OMCL Official Medicines Control Laboratories 
OTC  Over-the-Counter 
PCI Pharmachemical Ireland 
PDA Parenteral Drug Association
PDCO  Paediatric Committee 
PDP Performance Development Programme
PIC/S Pharmaceutical Inspection Co-operation Scheme 
POM Prescription-only Medicine
PRAC  Pharmacovigilance Risk Assessment Committee
PSUR Periodic Safety Update Report
QWP Quality Working Party 
RMP Risk Management Plan 
RMS  Reference Member State 
SoHOV&S Substances of Human Origin Vigilance and Surveillance 
THMP Traditional Herbal Medicinal Product
UMC Uppsala Monitoring Centre 
VMD Veterinary Medicines Directorate 
WHO World Health Organization 
Our Mission
To protect and enhance public and animal health 
through the regulation of medicines, medical devices 
and healthcare products.
Our strategIc gOaLs and BaLanced scOrecard
STAKEHOLDERS 
Enhance healthcare product safety and patient outcomes by effective risk management 
and market surveillance.
Deliver clear, relevant and timely communications to patients, consumers and 
healthcare professionals.
PROCESSES 
Improve service delivery within a high quality, risk-based regulatory framework.
ORGANISATIONAL DEVELOPMENT 
Improve service delivery within a high quality, risk-based regulatory framework.
Influence legislation and policy development at European and international levels for 
the benefit of public and animal health.
HUMAN RESOURCES DEVELOPMENT 
Build future capabilities to meet evolving regulatory requirements, and scientific and 
technological advances.
FINANCIALS/VALUE FOR MONEY 
Build future capabilities to meet evolving regulatory requirements, and scientific and 
technological advances.
Irish Medicines Board
Bord Leigheasra na hÉireann
Kevin O’Malley House 
Earlsfort Centre
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Tel: 353-1-676 4971    
Email: customerservice@imb.ie     
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